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9Chapter 1 
Introduction and Outline
Partly based on ‘Turner syndrome in adulthood: the need of multidisciplinary care’
Kim Freriks1, Catharina CM Beerendonk2, Janneke Timmermans3, Didi DM Braat2, Ad RMM 
Hermus1, Henri JLM Timmers1
Author Affiliations 
Departments of 1Internal Medicine, division of Endocrinology, 2Obstetrics and Gynecology, 
3Cardiology of the Radboud university medical center, Nijmegen
Ned Tijdschr Geneeskd 2007;151(29):1616-22
(Published in Dutch as ‘Het syndroom van Turner op volwassen leeftijd: het belang van 
multidisciplinaire zorg’)
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Turner syndrome
Turner syndrome (TS) is named after Henry Turner, who described the triad of short stature, 
‘sexual infantilism’ and dysmorphic abnormalities in 1938.1 Later on, in 1959, TS was found to 
be the result of the absence of one X-chromosome in women.2 Nowadays, TS is known as a 
common chromosomal disorder, with an incidence in the Netherlands between 1:2000 and 
1:5000 in live born girls.3 The classic phenotype described by Henry Turner is still accurate, 
although it is currently recognized that the clinical picture of TS is highly variable and ranges 
from severe congenital lymphedema and cardiac anomalies to a milder phenotype of secondary 
amenorrhea and/or unexplained infertility as presenting symptoms.
 The diagnosis of TS is confirmed by karyotyping of at least 30 lymphocytes. Based on 
this approach half of the patients are found to have a complete X chromosomal monosomy 
(karyotype 45,X). In 30-40% of the patients a mosaicism of different karyotypes is found, 
for example 45,X/46,XX, 45,X/47,XXX and 45,X/46,XY. In 5-15% of the cases one of the 
X chromosomes has structural anomalies including an isochromosome, ring chromosome 
or a deletion (Figure 1).4-6 In general, patients with a 45,X/46,XX  karyotype have a milder 
phenotype than those with 45,X.4,6,7
 FIGURE 1 
 X-chromosomal abnormalities in Turner syndrome
A normal female karyotype (46,XX)
B complete monosomy (45,X)
C (partial) deletion short arm Xp (46,X,del(Xp))
D (partial) deletion long arm Xq (46,X,del(Xq))
E isochromosome Xq (46,X,i(Xq))
F ring chromosome (46,X,r(X))
Adapted from https://www.radboudumc.nl/Zorg/Ziektebeelden/Documents/1%20Turner.pdf
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Growth and development
The disease spectrum of TS is broad and besides consultation for congenital anomalies, 
recurrent otitis and developmental problems, the cornerstones of childhood care are treatment 
with growth hormone (GH) to increase adult height and estrogen to induce puberty. Short 
stature is the most common characteristic of TS. Untreated TS women in the northern part 
of Europe reach a mean adult height of 147 cm. The main cause of reduced height is the lack of 
the ‘short-stature homeobox-containing gene’  (SHOX-gene) located on the short arm, Xp, of 
the X-chromosome.8-10 Although girls with TS are not GH deficient, supra-physiological doses 
of GH are given resulting in an average adult height gain of 5-12 cm.11-13 Differences in efficacy 
of GH treatment can be explained by age at initiation and duration of therapy, compliance, 
estrogen therapy regimen, and several, partly unknown, genetic factors.11,13,14
 During fetal development the ovaries initially develop normally, but already before birth an 
accelerated regression with apoptosis of the oocytes and fibrosis of the stroma occurs.4 In most 
patients this causes non functional ovaries resulting in absence of spontaneous puberty and 
infertility. Nevertheless 8-9% of the girls with monosomy 45,X and 40-47% of the girls with 
45,X/46,XX develop (temporary) menstrual cycles.15,16 Following the induction of puberty (or 
in case of insufficient estrogen production after a period of spontaneous puberty) hormonal 
replacement therapy (HRT) is indicated. Several HRT regimens are available with different 
formulations and doses of estrogens and different modalities of administration (continuous 
or cyclic / oral or transdermal). In the international guidelines, it is recommended to base the 
choice of HRT on age, personal preferences of the patient, complications of estrogen deficiency 
and additional risk factors for osteoporosis and coronary heart disease.17 In general HRT needs 
to be continued until the normal age of menopause.17
 
Fertility
Spontaneous pregnancies occur in 2-8% of the women, most commonly in those with 
45,X/46,XX.18-20 When spontaneous pregnancy is not achieved, assisted pregnancy with oocyte 
donation, besides adoption and foster care, can be considered. Pregnancy and implantation rates 
after oocyte donation in TS are comparable to the normal population.21 However, pregnancies in 
TS are associated with an increased risk of miscarriage and fetal abnormalities,16,22 although not 
all studies confirm an increased incidence of birth defects.21 Pregnancy in TS, spontaneous or 
assisted, is accompanied by an increased risk of cardiovascular morbidity, so careful counseling 
including cardiac evaluations before and during pregnancy is warranted.23-25
Structural cardiovascular disease
TS patients have an approximately 3-fold increased risk of age-related mortality, mainly due 
to structural cardiovascular anomalies and unfavorable cardiovascular risk factors.26,27 A recent 
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review on cardiovascular disease in TS estimated that of all TS patients up to 70% have some 
form of congenital heart and/or aorta anomaly.28 The most common anomalies are obstructive 
lesions of the left heart including a bicuspid aortic valve (15-30%) and coarctation of the aorta 
(up to 17%).28 Also malformations of the left sided vessels -such as elongation of the transverse 
aortic arch-, abnormal aortic arch vessels and anomalies of the large thoracic veins are more 
common than in the general population.29 Especially at adult age a bicuspid valve can lead to 
aortic valve stenosis and regurgitation.30,31 Furthermore, patients with bicuspid aortic valve and 
(surgically corrected) coarctation are assumed to have an increased risk of aortic dilation and 
dissection.32-34 The incidence of dilation in TS increases with age and dilation can already be 
present in the second decade of life.35,36 Aortic dissection also occurs at an earlier lifespan than in 
the general population: it is reported already from the third decade on with a life-time chance 
of 1-2 percent of the TS women.23,37,38 Regardless of the presence of a cardiac or aortic congenital 
anomaly, follow-up for aortic dilation is essential from childhood on.17 In (induced) pregnancy 
the risk of aortic dissection is assumed to be even higher, so cardiovascular screening before and 
during each pregnancy is strongly advised.24
Non-structural cardiovascular disease 
Additional to the structural abnormalities, the prevalence of atherosclerosis is doubled and the 
risk of ischemic heart disease is increased with a standardized mortality ratio of 3.5.39,40 Coronary 
heart disease in TS is determined by the relatively high prevalence of hypertension, insulin 
resistance and diabetes, dyslipidaemia and estrogen deficiency.28 Hypertension is reported 
in up to half of the adult women with TS and is idiopathic in the majority of the patients.34,36 
Diabetes mellitus type 1 and 2 are respectively 11 and 3-4 times more common in TS than in the 
normal population.41 The prevalence of diabetes type 2 is probably related to body mass index 
(BMI), since Bakalov et al. found a prevalence of diabetes type 2 in 25% of a young American TS 
population (BMI 28.9 ± 7.7 kg/m2), while Landin-Wilhelmsen et al. reported a prevalence of 3% 
in a similar age group around 30 years old (BMI 25.9 ± 5.0 kg/m2).42,43 Independent of BMI, total 
cholesterol, low density lipoprotein cholesterol and triglycerides are elevated in 37-50 percent 
of the TS women.40,44,45 Furthermore, up to 21% of the adult TS women have a prolonged QTc 
interval.46,47
Osteoporosis
Decreased bone mineral density (BMD) is frequently reported in women with TS. Estrogen 
deficiency plays an important role in the etiology, however low BMD despite adequate HRT 
is reported.48,49 Probably, achievement of optimal peak bone mass during adolescence is 
essential,50,51 since it was reported that TS patients with spontaneous menstruation have 
normal BMD.52 Besides estrogen deficiency, a primary defect in bone formation, most likely 
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due to haploinsufficiency of SHOX gene, seems to be an important contributing factor to 
the pathogenesis of osteoporosis as well.53-56 A selectively decreased cortical BMD, rather 
than trabecular BMD, is suggested.48,57,58 However, the exact burden of osteoporosis in the 
TS population is uncertain. The high frequency of osteoporosis, up to 80%, observed in TS 
patients is probably an overestimation, because short stature –especially a height below 150 
cm– causes false low areal BMD measurements.54,59,60 Using volumetric BMD measurements, 
either direct measurements with computed tomography or indirect calculations, instead of 
areal measurements to correct for height, can partly overcome this problem.57-61 Nevertheless, a 
higher fracture risk in TS, varying from 24-32%, has been reported. The fracture risk is elevated 
due to the combination of diminished BMD and a higher incidence of falling.55,62 Especially 
forearm fractures, probably related to frailty of cortical bone, are more common with a relative 
risk of 1.9.62,63
Auto-immunity
Diseases related to autoimmunity are frequently reported in TS and the incidence increases 
with age.64,65 Mortensen et al. found that auto-antibodies (against gliadin, transglutaminase, 
adrenal cortex, intrinsic factor, thyroid peroxidase and glutamic-acid-decarboxylase 65 or a 
combination thereof) are present in 58% of the patients with TS.64 Especially, autoimmunity of 
the thyroid (anti-TPO, 45%) and celiac disease (18%) were present. Concerning clinical disease, 
as many as 16-30% of the TS population develop auto-immune hypothyroidism,64-66 and celiac 
disease is seen in around 5% of the adult TS population.64,67 To a lesser extent, other autoimmune 
diseases like diabetes mellitus type 1 (relative risk 11) and inflammatory bowel disease (relative 
risk 2-3) are mentioned in relation to TS.41 The pathophysiology of these autoimmune 
phenomena is unclear. It is suggested that auto-immunity is more common in patients with an 
isochromosome (46,X,iXq).68 Others found that both TS women and women with premature 
ovarian failure have an increased incidence of Hashimoto’s thyroiditis, suggesting a role for 
estrogen as well.69
Ear and hearing problems
In childhood there is a high prevalence of middle ear infections and related conductive hearing 
loss.70,71 Adult patients often experience sensorineural hearing loss, which starts with a typical 
mid-frequency dip already during adolescence.72,73 Also, progressive sensorineural high-
frequency loss manifests earlier in TS women than in the normal population, especially in 
those patients with a previous mid-frequency dip.74 The need for a hearing aid is frequent with 
a range from 27% in a younger population to 44% in those above 35 years old.72 TS patients with 
monosomy 45,X or isochromosome 46,X,i(Xq) are supposed to be more prone to hearing 
problems than those with mosaicism or other structural X-chromosomal anomalies.75,76 
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This suggests that the locus for hearing impairment in TS may be located on the short arm, 
Xp. Furthermore, due to the presence of estrogen receptors in the human inner ear, estrogen 
deficiency is probably a contributing factor in hearing problems as well.77,78
Psychological problems
Besides the physical aspects, women with TS may report various psychological problems. 
Girls with TS have a distinct neuro-cognitive profile characterized by a normal to high verbal 
intelligence quotient (VIQ) and a decreased performance IQ (PIQ).79,80 Cognitive problems 
commonly persist until adulthood and the diminished performance on non-verbal skills make 
adult women with TS prone to impairments in visual-motor integration, attention, (working) 
memory, executive function and spatial cognition.79,80 In addition, women with TS report 
more social isolation, shyness, social anxiety and problems in relationships. 81-83 Furthermore, 
women with TS have a high rate, estimated at 36%, of lifetime depression and an increased risk 
for developing autism and attention-deficit hyperactivity disorder.84-86
For a schematic overview of TS associated morbidity see Table 1. 
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TABLE 1 
Abnormalities in Turner syndrome (adapted from Gravholt5 and others28,29,33,34,36,40,42,43,45,46,64-67,72,112-115)
Organ system Abnormality Frequency (%)
Reduced adult height 95-100
Gonadal dysgenesis No pubertal development 85
Infertility 98
Chronic estrogen deficiency 95-98
Eyes Epicanthus 20
Nearsightedness 20
Strabismus 15
Ptosis 10
Ears Otitis media ~60
Conductive hearing loss 0-40
Sensorineural hearing loss 4-66
Deformity of the external ear 15
Hearing loss requiring hearing aid 27-44
Mouth Micrognatia 60
High arched palate 35
Neck Low posterior hairline 40
Broad short appearing neck 40
Pterygium colli (webbed neck) 25
Skinfold in the back of the neck of newborns 25
Thorax Broad chest with widely spaced nipples 30
Inverted nipples 5
Skin, nails, hair Increased skin ridge count 30
Lymphedema of hands and feet 25
Multiple pigmented naevi 25
Nail hypoplasia 10
Alopecia 5
Vitiligo 5
Skeleton Bone age retardation 85
Osteoporosis or osteopenia 50-80
Cubitus valgus 50
Short 4th metacarpal bone 35
Genu valgum 35
Congenital hip luxation 20
Scoliosis 10
Madelungs deformity 5
Heart-aorta Heart-aorta deformities (congenital) 22-70
Bicuspid aortic valves 15-30
Coarctatio aortae up to 17
Aortic dilation/aneurysm 3-42
Elongation of the transverse aortic arch ~50
Prolonged QTc interval ~20
Stomach, intestines, liver Chronic inflammatory bowel disease <1
Celiac disease 4-6
Elevated hepatic enzymes 36-80
Kidney Renal anomalies 28-38
Endocrine Autoimmune hypothyroidism 16-30
Diabetes mellitus type 1 0.5-5
Diabetes mellitus type 2 3-25
Glucose intolerance 7-50
Hypertension up to 50
Dyslipidemia 37-50
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Multidisciplinary care in adult TS patients
Since GH treatment and induction of puberty requires strict pediatric follow-up, traditionally 
the care for patients with TS is focused on girls. Many patients were lost to follow-up after 
induction of puberty.45,87-90 However, the need for ongoing care for adult patients is increasingly 
recognized. The mean life expectancy is reduced by 13 years and there is an approximately 3-fold 
increased age-related mortality risk.26,41 This has lead to expert-based international guidelines 
for the care of TS patients, taking into account the broad spectrum of morbidity in adult women, 
warranting vigorous follow-up and treatment.4,17,91 A screening protocol for medical follow-up 
is depicted in Table 2. 
TABLE 2  
Screening protocol for adults with Turner syndrome (adapted from Bondy,17 Saenger91 and Conway116)
Investigation Once Every 1-2 yrsc Every 3-5 yrsc
Height, weight, blood pressure, auscultation of the heart X
Creatinin, blood urea nitrogen, ASAT, gamma-GT, TSH, X
Celiac serologya X
Karyotype X
Renal ultrasound X
Pelvic ultrasound X
Audiogramb X
Cardiac ultrasound and electrocardiogram X
MRI aorta (thoracic and abdominal) X
Bone mineral density measurement (DEXA) X
ASAT=aspartate-aminotransferase; gamma-GT=gamma glutamyl transpeptidase; TSH= thyroid stimulating hormone; 
fT4=free thyroxine; HbA1c=glycated hemoglobin.
a  IgA antibodies to tissue transglutaminase and endomysium; in case of IgA deficiency, IgG antibodies were 
measured  
b repeat at age of 40
c frequencies are increased when abnormalities are found
The morbidities associated with TS in adults lie within the fields of different medical and 
paramedical professions, making multidisciplinary collaboration essential. Proper transition 
from pediatric to adult care is important, considering the fact that TS-related conditions 
diagnosed during childhood require ongoing follow-up. For example congenital anomalies 
of the heart and/or aorta require regular investigations at adult age because of the risk of late 
complications.32,91,92 Collaboration is particularly important during pregnancy. Considering the 
increased risk of aortic dilation and dissection during pregnancy, cardiac evaluations before and 
during pregnancy are called for, especially when congenital heart disease and/or hypertension 
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is present.23-25 Since medical care for TS throughout adult life is advocated, several specialized 
TS clinics have been established in the United States and Europe.4,17,91 Nevertheless, the medical 
care for TS patients needs improvement. A French group reported that only 3.5% of the adult 
population received appropriate medical care and in a Belgian cohort 12.7% of the women 
lacked medical attention despite reported health problems.87,88 It was reported that in the 
United States only one third of the adult TS women had undergone the three examinations 
considered standard care (renal and cardiac ultrasound and audiology).89 Also, an inventory 
in the  Netherlands showed that only a minority of the patients continued to receive adequate 
medical care after discharge from pediatricians’ follow-up.90 In order to provide appropriate 
medical care for TS women, the Radboudumc opened a multidisciplinary Turner clinic in 2005. 
The aim was to ensure an adequate transition from pediatric to adult care, optimize screening 
and treatment of TS related conditions in adults, and to provide optimal HRT and fertility 
counseling.
 In Chapter 2 we describe our study on the effectiveness of an approach to medical care of 
TS women as advocated in published expert opinion based guidelines. The aim of this study 
was to investigate the yield of an initial comprehensive screening for TS-associated morbidity 
in a large group of adult patients in a single Dutch center in order to answer the question if the 
burden of screening is justified by the yield of new diagnoses.
Karyotyping in Turner syndrome
With standard karyotyping of 30 blood lymphocytes a 10% chromosomal mosaicism can be 
identified with a 95% confidence interval.17,93,94 However, standard karyotyping might not be 
sufficient for comprehensive genotyping. Firstly, it does not rule out low-grade mosaicism in 
blood lymphocytes and secondly, it does not rule out tissue mosaicism, i.e. the coexistence of 
different karyotypes across different body tissues. The idea of tissue mosaicism is established by 
the assumption that fetuses with apparent 45,X must have a parallel normal cell line to survive 
to term. This theory is strengthened by the fact that 45,X is much more common in still-born 
fetuses than in live born girls with TS.95,96 Several reports on TS patients confirm the presence 
of tissue specific mosaicism.97-99 Comprehensive karyotyping is important for gaining insight 
in genotype/phenotype correlations, but also appears to be relevant for individual patients 
when it comes to mosaicisms that include a Y chromosome. Y chromosomal material in TS 
is associated with the development of gonadoblastoma in the streak ovaries and when found 
on standard karyotyping, prophylactic gonadectomy is performed, to prevent the development 
into a malignant dysgerminoma.100 The need for gonadectomy when a Y chromosome is found 
in another tissue besides blood lymphocytes has not been established.
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 In chapter 3 we describe our study that was aimed at evaluating whether conventional 
karyotyping of blood lymphocytes is accurate for full understanding of the karyotype. We 
investigated the role of additional cytogenetic investigations using different techniques 
including fluorescent in situ hybridization and real-time polymerase chain reaction in additional 
tissues such as buccal mucosa cells.
Long term effects of oxandrolone treatment
The results of routine GH treatment in TS girls are not always optimal. Therefore, in previous 
studies higher doses of GH have been investigated, as well as the addition of androgens. Given 
the fact that androgens are important mediators of growth, it seems worthwhile to investigate 
the effects of androgen treatments on adult height gain. Oxandrolone (Ox),  a synthetic, non-
aromatizable anabolic androgenic steroid derived from testosterone, has been previously tested 
to enhance growth in TS. Ox has a high anabolic to androgenic ratio (10:1), which means that Ox 
gives less virilizing effects compared to testosterone.101 Nevertheless, in the initial studies on 
Ox in TS, where dosages of 0.1 mg/kg per day or higher were used, the dose had to be frequently 
lowered due to virilization and early bone maturation.102-104 
 More recently three randomized controlled studies on the growth  enhancing effect of lower 
than conventional doses of Ox in addition to GH have been published.105-107 This includes the 
Dutch Turner Oxandrolone Study, a collaborative initiative of ten pediatric endocrine centers 
in the Netherlands. Participants of this randomized double-blind placebo controlled trial were 
recruited between 1991 and 2003.105 In total 133 girls were included and blindly randomized to 
receive Ox in a dose of 0.03 mg/kg/day (Ox 0.03) or 0.06 mg/kg/day (Ox 0.06) or placebo (Pl) 
orally after reaching the age of 8 years. Furthermore the girls were treated with GH (1.33 mg/
m2/day) from baseline and, when spontaneous puberty was absent, with estrogen from the age 
of 12 years. 
 The main results of the pediatric study were that compared to GH+Pl, GH+Ox 0.03 
increased adult height gain –final minus predicted adult height– (9.5 vs. 7.2cm in GH+Pl) at 
the cost of mild deceleration of breast development (Figure 2). At the higher dose, Ox 0.06, no 
significant increase in height gain was found (8.3 vs. 7.2cm in GH+Pl), probably due to faster 
bone maturation and premature discontinuation of Ox because of virilizing side effects. In the 
GH+Ox 0.06 group significantly more girls reported subjective virilization. Findings in both 
Ox groups included a decrease in fat mass, an increase in muscle mass and lowering of the voice 
pitch, which were initially in the higher range, to normal voice frequencies in most cases.108,109 
There were no effects of Ox on behaviour, aggression, romantic and sexual interest, mood, and 
gender role.110 Furthermore no effects on glucose metabolism were established.111
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 FIGURE 2 
  Adult height gain in the intention-to-treat analysis (A) and per-protocol analysis (B). Diamonds represent adult height 
gain of the individual patients; lines represent mean adult height gain per dosage group.
A: Intention-to-treat analysis
B: Per-protocol analysis
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So far, previous studies on Ox in TS were focusing on the short-term effects in children and 
adolescents and long-term follow-up data were lacking. In this part of the thesis we report the 
results of our follow-up investigations in the Dutch Turner Oxandrolone Study cohort. The 
aim of these follow-up studies was to assess the long-term effects of the different treatment 
regimens of the trial (GH and estrogen with or without Ox 0.03 or Ox 0.06). The above 
mentioned beneficial and adverse effects on growth, body proportions, body composition, 
metabolic parameters and psychological items may or may not carry on beyond adolescence. 
The original participants of the Dutch Turner Oxandrolone Study, who have now reached an 
adult age, were investigated. We explored whether beneficial effects of auxiliary treatment with 
Ox are permanent and outweigh adverse effects that may be temporary. A broad spectrum of 
outcome parameters was investigated. In chapter 4 we discuss the long-term effects of Ox 
on height, body proportions and composition, virilization and cardiovascular risk profile. In 
chapter 5 the effects on neurocognition, quality of life and social-emotional functioning are 
discussed. In chapter 6 we focus on the influence of Ox on hearing with additional analyses to 
establish the genetic basis for hearing problems in TS.
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ABSTRACT 
Context 
Besides short stature and gonadal dysgenesis Turner syndrome (TS) is associated with various 
abnormalities. Adults with TS have a reduced life expectancy mainly related to structural 
abnormalities of the heart and aorta, and an increased risk of atherosclerosis. 
Objective 
Our objective was to investigate the yield of an initial standardized multidisciplinary screening 
in adult TS patients. 
Design
This was an observational study at a multidisciplinary care unit for adult women with TS.
Participants
Participants were adult women with TS (n=150). Mean age 31.0±10.4 years, 47% karyotype 45,X.
Interventions
All women were consulted by an endocrinologist, a gynecologist, a cardiologist, an 
otorhinolaryngologist, and when indicated, a psychologist. The screening included magnetic 
resonance imaging of the heart and aorta, echocardiography, electrocardiogram, dual-energy 
x-ray absorptiometry, renal ultrasound, audiogram and laboratory investigations according to 
international expert recommendations. 
Main outcome measures
New diagnoses and prevalences of TS associated morbidity were evaluated.
Results
Thirty percent of patients currently lacked medical follow-up and 15% lacked estrogen 
replacement therapy in the recent last years. The following disorders were newly diagnosed: 
bicuspid aortic valve (n=13), coarctation of the aorta (n=9), elongation of the transverse aortic arch 
(n=27), dilation of the aorta (n=34), osteoporosis (n=8), osteopenia (n=56), renal abnormalities 
(n=7), subclinical hypothyroidism (n=33), celiac disease (n=3), glucose intolerance (n=12), 
dyslipidaemia (n=52), hypertension (n=39), and hearing loss warranting a hearing aid (n=8). 
Psychological consultation was needed in 23 cases.
Conclusions
Standardized multidisciplinary evaluation of adult women with TS as advocated by expert 
opinion is effective and identifies significant morbidity. Girls with TS benefit from a careful 
transition to ongoing adult medical care.
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INTRODUCTION
Turner syndrome (TS) is the result of complete or partial absence of one X chromosome and 
one of the most common sex chromosomal abnormalities with an incidence of approximately 
1:2000 in live born girls.1 Besides short stature, gonadal dysgenesis, and dysmorphic features 
TS is associated with a wide range of abnormalities affecting nearly every organ system. 
Girls with TS are usually treated with growth hormone to increase adult height and with 
oestrogens to induce puberty. Hormone replacement therapy (HRT) has to be started either 
following induction of puberty or when oestrogen production becomes insufficient after initial 
spontaneous puberty.  
 Also in adulthood, TS is associated with significant morbidity. There is a ~3 fold increased 
age related risk of mortality mainly caused by structural cardiovascular anomalies and 
atherosclerosis related to hypertension, diabetes and dyslipidaemia.2 In addition, women with 
TS are prone to develop hypothyroidism, osteoporosis, hearing loss, neurocognitive deficits, and 
emotional problems.3,4 In recent years the enhanced morbidity and mortality in adults with TS 
as well as the ensuing need for regular medical attention are increasingly recognized. Especially 
the transition from pediatric to adult care is a point of concern. Many young women are lost 
to regular medical follow-up after discharge from the pediatric clinic. Several specialized TS 
clinics have been established in the US and Europe to provide a coordinated multidisciplinary 
care service. Based on the experience of these centers, recommendations for standard of care 
and periodic screening have been put forward. 5-7 Despite these efforts, however, adult women 
with TS often lack appropriate medical attention.8-12 In a young French TS population, only 
3.5% received appropriate medical care.8 In an adult US TS population, only one third had 
undergone the three examinations considered standard care for TS women, i.e. cardiac and renal 
ultrasound, and audiology.10 In a Belgian cohort, 12.7% lacked medical attention despite reported 
health problems and 14.5% lacked HRT.9 An inventory among Dutch TS women previously 
followed at a single pediatric clinic showed that appropriate specialist care was continued in 
only a minority.12 
 Our multidisciplinary care unit for TS women was established in 2005 and is the largest 
facility in the Netherlands. Our approach was adapted from international guidelines for care 
in TS patients.5-7 The yield of screening as advocated in these guidelines was not previously 
examined. In light of the question whether the burden of screening is justified by the yield 
of new diagnoses, and whether the approach is cost-effective, the aim of this study was to 
investigate the yield of an initial comprehensive screening for TS associated morbidity in a large 
group of adult patients in a single Dutch center.  
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PATIENTS AND METHODS
Patients
The study included 150 consecutive adult TS patients who underwent an initial evaluation 
between May 2005 and June 2009. Mean age was 31.0 ± 10.4 years. The diagnosis TS was 
established by standard karyotyping of 30 peripheral lymphocytes (Table 1).5 
TABLE 1 
Patients characteristics (n=150)
Physical examination Mean (SD)
Age (yr) 31.0 (10.4) 
Height (cm) 153.2 (7.5) 
Weight (kg) 61.6 (13.6) 
BMI (kg/m2)a 26.2 (5.5) 
Karyotype Percentage
45,X 47%
45,X/46,XXb 12%
45,X/47,XXX 3%
45,X/46,X,i(Xq) 14%
45,X/46,X,del(X) 5%
45,X/46,XY or marker Y 3%
45,X/46,X,r(X) 3%
46,X,i(Xq) 3%
46,X,del(X) 2%
Othersc 5%
Pendingd 3%
Medical care prior to investigation Percentage
Direct transition from pediatric care 17%
Specialist caree 53%
     Gynecologist 36%
     Internist 7%
     Cardiologist 2%
     Combination of more than one specialist 8%
No medical care 30%
BMI= body mass index 
a No difference in patients with and without diabetes 
b Including one patient with mosaicism trisomie 21 as well
c  Four patients with a mosaicism containing more than two cell lines, two patients with a marker chromosome, and 
two patients with a translocation with chromosome 13 
d Patients were diagnosed with TS elsewhere; confirmation in our laboratory is pending
e Of these patients 6 had lacked medical attention during a mean period of 18.5 years earlier in life
CHAPTER 2    Standardized multidisciplinary evaluation yields significant previously  
undiagnosed morbidity in adult women with Turner syndrome
33
Seventy-six percent of the women had received regular pediatric care during childhood and 56% 
of the women had been treated with growth hormone. Of 150 patients, 26 were directly referred 
for transition from pediatric to adult care within our centre. Seventy-nine patients already 
received regular medical care by either a gynecologist, cardiologist, and/or endocrinologist. 
Forty-five patients had lacked medical follow-up by any specialist, with a mean period of 
approximately 12 years before attending the clinic. The patients lacking medical follow-up were 
older than those with medical follow-up (37.5 vs. 28.2 years, P value < 0.01) and mean time since 
diagnosis was longer (26.7 vs. 17.0, P value < 0.01).
Screening 
All patients underwent a standardized medical evaluation adapted from expert opinion 
recommendations,5-7 which consisted of consultation (history and physical) by an 
endocrinologist, gynecologist, cardiologist, otorhinolaryngologist and, in a selected group 
of patients, a psychologist. The work-up included laboratory investigations and imaging, as 
indicated in Table 2. 
TABLE 2 
Screening protocol for adults with Turner syndrome (adapted from Bondy5, Saenger6, Conway7)
Investigation Once Every 1-2 yrsc Every 3-5 yrsc
Height, weight, blood pressure, auscultation of the heart X
Creatinin, blood urea nitrogen, ASAT, gamma-GT, TSH, 
fT4, total cholesterol, low-density cholesterol, high-density 
cholesterol, triglycerides, glucose, HbA1c, urine dipstick 
analysis
X
Celiac serologya X
Karyotype X
Renal ultrasound X
Pelvic ultrasound X
Audiogramb X
Cardiac ultrasound, including electrocardiogram X
MRI aorta (thoracic and abdominal) X
Bone mineral density measurement (DEXA) X
ASAT=aspartate-aminotransferase; gamma-GT=gamma glutamyl transpeptidase; TSH= thyroid stimulating hormone; 
fT4=free thyroxine four; HbA1c=glycated hemoglobin.
a IgA antibodies to tissue transglutaminase and endomysium; in case of IgA deficiency, IgG antibodies were measured 
b repeat at age of 40
c frequencies are increased when abnormalities are found
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MRI scans were performed using Avanto 1.5T (Siemens, Erlangen, Germany). The protocol 
consists of dark blood (TSE db T1) and TRUFI images. Diameters of the aorta were measured at 
the level of the sinuses of Valsalva, the right pulmonary artery, the origin of the left subclavian 
artery, the left atrium, the diaphragm, the kidney arteries, and just above the bifurcation of the 
abdominal aorta. Also, the largest cross sectional diameters of the thoracic and abdominal aorta 
were measured.
 Echocardiographic evaluation was performed according  to the American Society of 
Echocardiography recommendations.13 All examinations were performed by the same clinician 
(J.T.), using the echocardiography machine Vivid 7 or System Five (GE-Vingmed, Horten, 
Norway) connected to a phased-array probe (2.5 and 3.5 MHz). Digitized measurements of the 
aortic root were made in 2-dimensional parasternal long-axis views at end-diastole using the 
leading-edge technique at four aortic levels: the annulus, the sinuses of Valsalva, the supra-
aortic ridge, and the proximal ascending aorta. The largest aortic diameter obtained in these 
views was described. 
 A twelve lead electrocardiogram (ECG) was performed to diagnose conduction or 
repolarization abnormalities.
 Bone mineral density was measured at the lumbar spine (L1-L4) and the right femoral neck 
using a QDR 4500 densitometer (Hologic, Zaventem, Belgium). Bone mineral density was 
expressed as T- and Z-scores based on a normal reference population.  
 Standard renal ultrasound was performed for assessment of morphological abnormalities.  
 Hearing measurements were conducted according to standard audiometric methods (ISO 
389) in a sound proof room. Air conduction thresholds were measured in dB hearing level at 
0.25, 0.5, 1, 2, 4, and 8 kHz and bone conduction thresholds were measured in dB hearing level 
at 0.5, 1, 2, 4, and 8 kHz.
Data Analysis and Statistics
The analysis was restricted to the findings of the initial evaluation. No data of subsequent 
follow-up visits are presented. We recorded all newly identified diagnoses. In case of previous 
diagnoses, relevant changes in treatment were recorded. Case finding definitions are given in 
Table 3. For individual patients TS-related disease burden was calculated as the total number 
of diagnoses among the following principal stigmata (maximum score of fourteen): bicuspid 
aortic valve, coarctation of the aorta, elongation of the transverse aortic arch, dilation of the 
aorta, diabetes, glucose intolerance, hypertension, dyslipidaemia, osteoporosis or osteopenia, 
(subclinical) hypothyroidism, celiac disease, renal anomalies, liver enzyme disturbances and 
hearing loss requiring a hearing aid.14 Results are expressed as mean (standard deviation), unless 
mentioned otherwise. In order to analyze which patients benefit most from the standardized 
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screening, we performed a subgroup analysis and compared the yield of diagnoses between 
patients with different times since initial diagnosis, patients with or without previous care and 
patients with monosomy 45,X versus patients with other karyotypes. For subgroup analyses 
and comparisons of means, Student’s t-test or Chi-square tests were used where appropriate. 
We used Statistical Package for the Social Sciences version 16.0 (SPSS, Inc., Chicago, Illinois).
Data were collected under conditions of regular clinical care, with institutional review board 
approval obtained for the use of these data for scientific reasons.
TABLE 3 
Case finding definitions
Case finding definition
Congenital anomalies of the heart/aorta Bicuspid aortic valve, coarctation of the aorta, elongation of the  
transverse aortic arch
Dilation of the aorta Dilation of the ascending aorta based on BSA corrected values17,40  
and/or local or fusiform dilation of the descending aorta 
Diabetes Diabetes: random glucose > 11,1 mmol/l or Hba1c ≥ 6.5 mmol/l
Impaired glucose tolerance: random glucose between 7.8 mmol/l  
and 11.1 mmol/l or HbA1c between 5.7% and 6.4%41
Hypertension Use of antihypertensive medication or systolic blood pressure > 140 
mmHg and/or a diastolic blood pressure > 90 mmHg
Dyslipidemia Total cholesterol (TC) ≥ 5.50 mmol/l and/or  high density lipoprotein 
cholesterol (HDL-C) ≤ 1.10 mmol/l and/or low density lipoprotein 
(LDL-C)  ≥ 3.50 mmol/l and/or triglycerides (TG) ≥ 2.20 mmol/l  
(random lipid profiles)
Diminished bone mineral density Osteoporosis: T-score below or equal to -2.5 SD. Osteopenia: T-score 
between the -1.0 and -2.5 SD 
Hypothyroidism Hypothyroidism: thyroid stimulating hormone above upper reference 
limit of 4.0 mE/l and free thyroxin below lower reference limit of 8.0 
pmol/l
Subclinical hypothyroidism: thyroid stimulating hormone > 4.0 mE/l  
and free thyroxin within normal range (8.0-22.0 pmol/l)
Structural anomalies of the kidney Horse shoe kidney, duplication of the collecting system, agenesis and 
rotation as TS specific renal malformations
Liver enzyme elevation Gamma-GT > 35 U/l and/or ASAT > 40 U/l
BSA=body surface area; gamma-GT=gamma-glutamyl transpeptidase; ASAT= aspartate-aminotransferase; 
TS=Turner syndrome
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RESULTS
New diagnoses and total prevalence of morbidity are summarized in Table 4 and Figure 1. The 
disease burden in individual patients was 1.2±1.2 diagnoses before screening and 3.5±1.9 diagnoses 
after screening (p<0.01). The mean increase in disease burden was 2.3±1.5. When comparing 
patients with 45,X with those with other karyotypes, the former had a disease burden of  3.7±1.8 
diagnoses after screening and the latter 3.3±2.0. Patients with 45,X had significantly more new 
diagnoses during screening when compared to patients with other karyotypes (2.6±1.5 vs 2.0±1.5). 
Age correlated positively with the disease burden before screening (r 0.485), after screening (r 
0.689) and the number of new diagnosis during screening (r 0.403).
 FIGURE 1 
 Frequencies of TS associated morbidities in 150 TS patients
Anomalies of the Heart and Aorta 
Prior to the current investigations, 81 patients (54%) had undergone cardiac ultrasound and 16 
(10.7%) MRI. Eighteen had a previous diagnosis of structural cardiac and/or aortic anomalies. 
Five had undergone surgery. Re-evaluation yielded additional aortic anomalies in six. Screening 
of 132 patients without previously known cardiac or aortic anomalies consisted of MRI and 
cardiac ultrasound (n=100), MRI only (n=12), and ultrasound only (n=9). MRI results are 
pending in nine. In addition, no MRI was performed in six because of claustrophobia and in five 
because of recent cardiovascular screening including MRI. This yielded one or more congenital 
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anomalies in 40 patients (30.3%). Fifteen of these patients had an additional dilation of the aorta. 
In 15 other patients aortic dilation was an isolated finding. In the group with new discovered 
cardiac and aortic abnormalities (n=55), 25 had previously undergone cardiac screening by 
cardiac ultrasound and MRI in one. In five patients a bicuspid aortic valve was missed by 
previous screening. All other new diagnoses were attributable to screening with an additional
MRI: elongation, mild coarctation and dilation of the aorta. See Figure 2 for images. 
 FIGURE 2 
 MRI and MRA images of anomalies of the heart and aorta: 
 a. coarctation of the aorta 
 b. dilation of the aorta 
 c. bicuspid aortic valve 
 d. elongation of the transverse aortic arch
 Published with permission of the ‘Nederlands Tijdschrift voor Geneeskunde44 
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In women with karyotype 45,X significantly more structural cardiovascular abnormalities were 
diagnosed compared to women with other karyotypes (Supplemental data table A). Furthermore 
the time since the initial diagnosis of TS correlated positively with a higher number of newly 
diagnosed structural cardiovascular abnormalities. (Supplemental data table B)
 An ECG was performed in 134 patients. All patients showed a sinus rhythm, including eight 
patients with sinustachycardia (>100 beats per minute) and one with sinusbradycardia (< 60 
beats per minute). In 53.4% of the patients the ECG was normal, 37.3% showed repolarisation 
abnormalities (STT abnormalities), 17.2% QTc prolongation, 4.5% other conduction 
abnormalities, 3.0% left axis deviation and 0.7% right axis deviation.     
 Concerning the diastolic and systolic function we found that 2.0% of the women (n=3) had 
an impaired cardiac function: one patient had an ejection fraction of 43.8% and two patients had 
a dilated right ventricle: one due to an atrium septum defect and one due to a partial anomalous 
pulmonary venous return. We found one patient with left ventricular hypertrophy secondary 
to a bicuspid aortic valve with stenosis. 15
Atherosclerosis and Risk Factors
Two patients had a history of myocardial infarction at 31 and 44 years of age. Seventeen patients 
(11.3%) were current smokers. Mean BMI was 26.2 ± 5.5 (52.7% had a BMI > 25 kg/m2, 20.7% had 
a BMI > 30 kg/m2). 
 Seven patients were previously diagnosed with diabetes (four insulin dependent) and two 
with impaired glucose intolerance. No new cases of diabetes were encountered. 
 Seventeen patients were known with hypertension, 10 of whom with insufficient blood 
pressure control. An additional 39 patients had an elevated blood pressure based on supine 
office sphygmanometric measurements at time of consultation. In the context of individual 
cardiovascular risk, medication was started in seven.  
 Eight patients were previously diagnosed with dyslipidaemia, three of them were currently 
taking a statin. In the others, lipid profile was abnormal in 36.6%.  
Fertility and Hormone Replacement Therapy
In 36 patients spontaneous menarche had occurred. In the remaining 114 patients, puberty 
was induced by estrogen-therapy in 107. In three patients with 45,X fertility treatment with 
egg donation resulted in one successful pregnancy. Spontaneous pregnancies occurred in two 
patients with mosaicism. Two other patients with mosaicism attempted to become pregnant 
with fertility treatment, one including egg donation, but did not succeed. Five patients were 
known with a (partial) Y chromosome. Prophylactic gonadectomy took place except in two: one 
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refused, in the other the SRY gene was absent. 
 Gynecological ultrasound in 117 patients revealed a uterus subseptus in two, a uterine 
myoma in two, and a polyp in one. 
 At referral, 146 women were below 52 years of age, the median age for menopause. In this 
group, 23 women lacked any form of HRT, including 7 with a spontaneous menstrual cycle and 
1 because of current fertility treatment. 
 The different regimes of the 124 (one above 52 years of age) patients already on HRT were: 
continuous combined (15.3%), sequential combined (54.0%), oral contraceptives (28.2%), and 
estrogen only (2.4%). Eight of them previously lacked HRT for a mean duration of six years. 
In 31 patients the regimen was intensified or otherwise adjusted because of decreased bone 
mineral density (n=5), metrorrhagia, dysmenorrhea, and/or the patient’s preference to switch 
to a non-cyclic regimen (n=26). 
Bone Mineral Density
Forty-six patients (30.7%) had a history of trauma associated fractures. Forty-three patients 
(28.7%) had previously undergone a bone mineral densitometry, yielding osteoporosis in 10 
and osteopenia in 22. Ten of these patients were taking bisphosphonates. Based on 26 repeated 
bone mineral density measurements four patients needed adjustment of therapy. In 118 
patients without a prior diagnosis, 111 bone mineral density measurements were performed. 
In patients with osteoporosis (n=8) or osteopenia (n=56) life style interventions enhancing 
bone health were advocated, i.e. adequate calcium intake, exposure to sunlight, and weight 
bearing exercise. Additionally, in eight HRT was started or intensified, in eight calcium/
vitamin D supplementation was started, in two bisphosphonates were prescribed, and in two a 
combination of calcium/vitamin D supplementation and change in HRT. 
Thyroid Disease 
Seventeen patients had a history of hypothyroidism and were taking thyroid hormone. The 
dose needed adjustment in 11 patients. We found 33 cases of new subclinical hypothyroidism, 
prompting supplementation of thyroid hormone in five symptomatic cases.
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Kidney Malformations
Seventy-two patients (48%) had previously undergone renal ultrasound showing anomalies in 
23 patients. Three patients had undergone surgical interventions.
Of the remaining 78 patients, 70 underwent a renal ultrasound yielding anomalies in seven. 
Renal function was normal in all patients. Isolated erythrocyturia was found in two patients 
without structural anomalies or proteinuria. In eight patients renal ultrasound results are 
pending. 
Hearing Loss
Thirty-one patients already had a hearing aid, including four patients with a bone anchored 
hearing aid. Of 119 without a prior diagnosis, 78 underwent audiology indicating significant 
hearing impairment in 43 patients, with the requirement of a hearing aid in eight.
Psychological problems
Twenty-three patients (mean age 38 yr) consulted the psychologist with the following reasons: 
need for support in accepting TS related limitations in daily life (70%), low self esteem (55%), 
non assertiveness (45%), lack of social support (25%), and infertility related emotional problems 
(10%). 
Abnormalities regarding celiac disease and liver enzyme disturbances are specified in Table 4.
When comparing the women without previous medical care and the women with adult 
specialist care to the women with direct transition from pediatric care we found that a larger 
number of new diagnoses were found in the first group (Table 5). 
TABLE 5 
Impact of previous care on percentage new diagnosis
Direct transition  
from pediatric care
(mean age 19.0±1.5)
Preceding adult  
specialist care
(mean age 31.3±9.1)
No specialist
care
(mean age 37.5±9.2)
Structural cardiovascular abnormalities 34.6% 31.7% 60.0%*
Osteoporosis or osteopenia 53.9% 32.9%* 53.3%
Cardiovascular risk factors 34.6% 51.9% 57.8%*
(Subclinical) Hypothyroidism 15.4% 15.2% 37.8%*
 
* Significant compared to women directly referred from pediatric care
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DISCUSSION 
We investigated the yield of comprehensive screening for TS associated morbidity in a large 
group of adult TS patients in a single Dutch centre. Multidisciplinary evaluation identified 
many patients with previously unknown diagnoses, including cardio-aortic anomalies (40.7%), 
hypertension (26.0%), dyslipidemia (34.7%), impaired glucose tolerance (8.0%), current or 
previous lack of HRT despite oestrogen deficiency (15.3%), osteoporosis (5.3%), osteopenia 
(37.3%), subclinical hypothyroidism (22.0%), and hearing loss requiring a hearing aid (5.3%). 
In individual patients on average two new major TS related diagnoses were found. Patients 
without previous specialist care benefited most from the screening.
 In the majority of patients, 76% in our cohort, TS was diagnosed in childhood triggered 
by dysmorphic features, impaired growth, and/or delayed puberty. Ensuing growth hormone 
treatment and induction of puberty requires strict pediatric follow-up. Many patients are lost 
to follow-up after discharge from pediatric care.8-11 In the present cohort, one third lacked any 
form of ongoing specialist care. Lack of care was most prevalent among older patients. It is 
unclear which patients are prone to lack ongoing medical care. It might be that socio-economic 
factors play a role. We have insufficient data to investigate this. However in the Netherlands 
health insurance is obligatory by law and entitles all patients to identical care.   
 The importance of a well organized transition from pediatric to adult care was stressed 
by the Turner Syndrome Consensus Study Group.5 Besides a well organized transition, a 
multidisciplinary periodic screening of adult women with TS is advocated in international 
expert based guidelines, mainly because many disorders do not present until adult age.5-7 
Our current finding of a significant previously unrecognized morbidity demonstrates the 
effectiveness of such an approach.
 Medical care in adult women with TS is mainly aimed at reduction of the ~3 fold increase in 
age related risk of cardiovascular mortality.2 The necessary screening for structural cardiac and 
aortic anomalies had been omitted in half of our patients. Current screening revealed unknown 
cardiac and/or aortic anomalies in approximately 40% of the patients. Cardio-aortic anomalies 
and hypertension are assumed to increase the risk of aorta dilation and dissection.4,16,17 The 
prevalence of aortic dilation increases with age, but dilation in TS can already be present in the 
second decade of life.18,19 Aortic dissection occurs at relatively young age (third decade) with 
an age dependent incidence of 15-50 cases in 100.000 TS years compared to 6 cases in the 
normal population.20 Considering the fact that aortic abnormalities are usually asymptomatic 
until complications occur, periodic screening of the aortic diameter appears to be justified. 
Cardiac follow-up can be performed using ultrasound and MRI, the latter having the advantage 
of superior imaging of the coarctation site and the distal aorta.16,19 In a recent report Matura 
et al. advise to use aorta size index (aortic diameter/body surface area) instead of absolute 
aortic diameter because of limited availability of reference values for aortic diameters.17 The 
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authors suggest strict follow-up in case of an aorta size index ≥ 2.0 cm/m2 and evaluation for 
prophylactic intervention in case of an aorta size index of ≥ 2.5 cm/m2 in combination with 
an absolute aorta diameter above 3.5 cm. In (induced) pregnancy, the risk of dissection is even 
higher and in one retrospective study the pregnancy related mortality is estimated at two 
percent.21 Cardiovascular screening is strongly advised before and during each pregnancy. 
In fact, pregnancy is discouraged in patients with congenital cardiac and aortic anomalies, 
hypertension and/or an aortic size index (aortic diameter/body surface area) of ≥ 2.0 cm/m2.
22
 Besides structural anomalies, TS in adults is associated with an unfavorable risk profile for 
cardiovascular disease. The prevalence of atherosclerosis is doubled.23 In the present young 
population 37% had hypertension, 40% had an abnormal non-fasting lipid profile, 5% had 
diabetes, and half of the patients were overweight. Prevalence of diabetes type 2 in the TS 
population is increased compared with the general population. Focusing on the age group 
around 30 incidence numbers vary. Bakalov et al. found a prevalence of diabetes type 2 in 25% of 
a young TS population (age 35.4 ± 11.3 years, BMI 28.9 ± 7.7 kg/m2), while Landin-Wilhelmsen 
et al. reported a prevalence of 3% in a similar age group (age 33.7 ± 11 years, mean BMI 25.9 ± 
5.0 kg/m2).24,25 Probably this difference is related to differences in BMI. Nevertheless, the 
clearly unfavorable cardiovascular risk profile at young age suggests that patients benefit from 
screening and careful management. Intervention trials, however, are lacking.
 The pathophysiology of the increased prevalence of autoimmune disease, especially in 
association with Xi(Xq) genotypes, remains unknown. We confirm a high prevalence (38%) of 
hypothyroidism, including subclinical cases. Previous studies have indicated that 16-30% of the 
TS patients have elevated TSH levels and that 27-45% of the TS patients have positive thyroid 
antibody titers.26,27 Furthermore we found 3 patients with proven celiac disease. It has been 
shown that celiac disease is more common in the TS population with a prevalence of 4-6%.28 
Ongoing periodic screening for both hypothyroidism and celiac disease seems reasonable 
because incidences increase with age. Vigilance for additional less common TS-related auto-
immune diseases is essential. 28-30
 Another important issue that needs ongoing medical attention, at least until normal age of 
menopause, is HRT. HRT in estrogen deficient women has a positive effect on bone mineral 
density, prevents vaginal atrophy and was shown to have a favorable impact on cardiovascular 
risk in TS.31 In our cohort 15% lacked HRT, which is similar to observations in other countries.9,32 
In about half of the cases HRT was discontinued by the patient because of self reported side 
effects or unawareness of the reasons for HRT. In others HRT was never started. One reason 
could be that physicians might be unjustly reserved regarding HRT because of the relationship 
with breast cancer in elderly postmenopausal women.33 
 Two thirds of our TS patients were found to have a low bone mineral density correlated with 
older age and lack of HRT. TS is associated with an intrinsic structural bone defect, which is 
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worsened by estrogen deficiency.34 Because short stature can cause false low areal bone mineral 
density, it is possible that the high frequency of osteoporosis observed in TS patients based 
on bone mineral density measurements is in fact an overestimation.35 Nevertheless, a higher 
fracture risk in TS, varying from 24-32%, has been established warranting careful observation 
and treatment of bone health, including optimal HRT.32,36
 During childhood, the vast majority of TS patients suffer from recurrent glue ear, otitis 
media and resulting conductive hearing loss, probably related to an abnormal Eustachian tube.37 
During adulthood, conductive and perceptive hearing loss frequently occurs, the latter often 
with either a mid- or high frequency dip. In our group more than 25% of patients suffered from 
significant hearing impairment warranting the use of a hearing aid, which is similar to previous 
reports. Hultcrantz et al found that 27% of TS patients needed a hearing aid (n=324; age range 
4-68), and as many as 44% when focusing on those aged above 35 years.38 
 Besides physical health issues women with TS often deal with (neuro)psychological 
problems.39 Our study confirms that many TS women experience difficulties in regards to 
acceptance of limitations related to TS and low self esteem. Remarkably, emotional problems 
related to infertility were mentioned by only a small minority. 
 In conclusion, standardized multidisciplinary evaluation of adult women with TS yields 
significant previously undiagnosed morbidity. TS patients are therefore likely to benefit from 
a careful transition from pediatric into adult medical care, consisting of a multidisciplinary 
service with standardized screening for TS associated morbidity. To what level our approach 
improves long-term morbidity, mortality, and health related quality of life remains to be 
investigated. The actual benefit should also be weighed against the costs of screening and the 
risk of medicalisation.
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Supplemental data
TABLE A 
Impact of karyotype on percentage new diagnosis
45,X (n=71) Other karyotypes (n=79)
Structural cardiovascular abnormalities 56.3% 26.6%*
Osteoporosis or osteopenia 40.9% 44.3%
Cardiovascular risk factors 54.9% 46.8%
(Subclinical) Hypothyroidism 26.8% 17.7%
*Significant difference between both groups (significance stated as p<0.05)
TABLE B 
Impact of time since initial diagnosis on percentage new diagnosis
0-10 years
(n=25)
(age 23.6±7.2)
11-20 years
(n=55)
(age 25.9±6.6)
21-30 years
(n=47)
(age 34.5±8.5)
31-40 years
(n=16)
(age 44.0±6.4)
>41 years
(n=6)
(age 49.4±7.0)
Structural cardiovascular abn* 32.0% 34.6% 40.4% 62.5% 83.3%
Osteoporosis or osteopenia 52.0% 38.2% 46.8% 31.3% 33.3%
Cardiovascular risk factors 36.0% 45.5% 57.5% 68.8% 66.7%
(Subclinical) Hypothyroidism 8.0% 20.0% 29.8% 25.0% 33.3%
* Significant difference for structural cardiovascular abnormalities. Total number of patients does not equal 150, due 
to one missing value.
TABLE C 
Impact of age at initial diagnosis on percentage new diagnosis
0-10 years
(n=68)
(age 26.4±8.5)
11-20 years
(n=68)
(age 33.5±9.8)
21-30 years
(n=10)
(age 43.5±8.8)
31-40 years
(n=3)
(age 42.0±9.2)
Structural cardiovascular abnormalities 44.1% 39.7% 40% 0%
Osteoporosis or osteopenia 42.7% 41.2% 50% 33%
Cardiovascular risk factors* 38.2% 55.9% 90% 100%
(Subclinical) Hypothyroidism 27.9% 20.6% 0% 0%
* Significant difference for cardiovascular risk factors. Total number of patients does not equal 150, due to one 
missing value.
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ABSTRACT
Turner syndrome (TS) is the result of (partial) X chromosome monosomy. In general, the 
diagnosis is based on karyotyping of 30 blood lymphocytes. This technique, however, does not 
rule out tissue mosaicism or low grade mosaicism in the blood. Because of the associated risk of 
gonadoblastoma, mosaicism is especially important in case this involves a Y chromosome. We 
investigated different approaches to improve the detection of mosaicisms in 162 adult women 
with TS (mean age 29.9±10.3). Standard karyotyping identified 75 patients (46.3%) with a non-
mosaic monosomy 45,X. Of these 75 patients, 63 underwent additional investigations including 
FISH on buccal cells with X- and Y-specific probes and PCR-Y on blood. FISH analysis of buccal 
cells revealed a mosaicism in 19 of the 63 patients (30.2%). In five patients the additional cell 
lines contained a (derivative) Y chromosome. With sensitive real-time PCR we confirmed the 
presence of this Y chromosome in blood in three of the five cases. Although Y chromosome 
material was established in ovarian tissue in two patients, no gonadoblastoma was found. 
Our results confirm the notion that TS patients with 45,X on conventional karyotyping 
often have tissue specific mosaicisms, some of which include a Y chromosome. Although 
further investigations are needed to estimate the risk of gonadoblastoma in patients with Y 
chromosome material in buccal cells, we conclude that FISH or real-time PCR on buccal cells 
should be considered in TS patients with 45,X on standard karyotyping.
INTRODUCTION
Turner syndrome (TS) is the result of (partial) X chromosome monosomy and one of the most 
common chromosomal disorders with an incidence of approximately 1 in 2000 to 2500 live 
born girls.1 Besides short stature and gonadal dysgenesis, TS is associated with a wide range 
of abnormalities affecting nearly every organ system. The phenotype is highly variable which 
is partly explained by differences in karyotype. Furthermore the presence of tissue mosaicism 
i.e. genetic variability among different body tissues can explain phenotypic variation. Tissue 
mosaicisms may also involve tissue-specific presence of a (derivative) Y chromosome.
 When Y chromosomal material is encountered upon karyotyping in TS, usually a 
prophylactic gonadectomy is recommended because of the increased risk of gonadoblastoma, 
a benign neoplasm of the dysgenetic gonad.2,3 Gonadoblastoma in TS is assumed to develop 
early in life and may develop into malignant tumors such as dysgerminoma.2,4 The incidence of 
gonadoblastoma in TS patients carrying a Y chromosome is estimated at 12%, although higher 
incidences up to 30% have been documented.2-4 However, gonadoblastoma is also reported 
in patients with TS lacking a Y chromosome on conventional cytological analysis.4-6 In these 
studies Y chromosomal material was revealed only after applying additional cytogenetic and/
or molecular techniques.
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 Diagnosis of TS is generally based on cytogenetic analysis of 30 cultured blood lymphocytes, 
by which a 10% chromosomal mosaicism can be identified with a 95% confidence interval.3,7,8 
According to this approach, about half of the patients appear to have a pure monosomy 45,X, 
30 to 40 percent have a mosaicism and yet another 5-15% have a structurally abnormal X 
chromosome. When using conventional karyotyping, approximately 5-6% of the TS patients 
are found to carry a complete or derivative Y chromosome.10 Standard karyotyping of merely 
blood lymphocytes in patients with TS is probably not sufficient in a large number of cases.4-7 
Firstly, it does not rule out tissue mosaicism. The idea of tissue mosaicism is established by the 
assumption that for a fetus to survive to term it is necessary to have a second sex chromosome. 
This implies that most, if not all, live born girls with apparent 45,X have additional cell lines in 
other tissues. This assumption is strengthened by the fact that complete 45,X is more common 
in fetuses who do not survive to term than in live born girls with TS.11,12 Several studies 
confirm the presence of tissue mosaicism in live born patients with TS.13-15 Secondly, a low 
grade mosaicism (<10%) in blood lymphocytes can easily be missed during karyotyping. For 
that reason it is advocated to use additional techniques.4-7,16-19 A meta-analysis of 541 patients 
showed that, when using polymerase chain reaction (PCR) techniques on blood samples of 
patients with apparent 45,X, Y chromosomal sequences can be found in approximately 5%.2 
Alternatively, fluorescent in situ hybridization (FISH) with X- and Y- specific probes is used to 
find mosaicisms of the sex chromosomes or derivatives thereof.5,16,19
 The clinical guideline for TS advises to perform conventional karyotyping of blood 
lymphocytes in patients with clinical suspicion of TS.3 At the moment, additional FISH is 
recommended only when conventional karyotyping reveals a marker chromosome or when 
clinical virilization is present. Another, more recent, guideline advises additional FISH with X- 
and Y-specific probes in all patients with 45,X.7 Although both guidelines suggest cytogenetic 
studies of a second cell line in case of clinical suspicion of TS and a normal female karyotype, 
they do not comment upon the investigation of other tissues besides lymphocytes in patients 
with proven TS, without virilization or marker chromosomes.
 Considering the high percentage of (tissue) mosaicism in TS and the possible clinical 
impact of a Y chromosome or derivatives thereof, we set out this study to determine the 
value of additional genetic studies (FISH, conventional and real-time PCR) and the inclusion 
of a second, easy accessible tissue (buccal cells) in search for mosaicisms in TS patients with 
apparent complete 45,X karyotype on standard lymphocyte karyotyping.
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PATIENTS AND METHODS
Patients
Between 2005 and 2009, 162 adult women (mean age 29.9 ± 10.3) with a previously established 
diagnosis of TS were evaluated at our multidisciplinary facility. Standard postnatal karyotyping 
of 30 blood lymphocytes had identified 75 patients (46.3%) with 45,X in all examined cells 
(Table 1). 
TABLE 1 
Conventional lymphocyte karyotype (n=162)
Karyotype Number (%)
45,X
45,X/46,XY or derivative Y
45,X/46,XX
45,X/47,XXX
45,X/46,Xi(Xq)
45,X/46,X,del(X)
45,X/46,X,r(X)
46,X,i(Xq)
46,X,del(X)
Othersa
75 (46.3)
6 (3.7)
17 (10.5)
5 (3.1)
23 (14.2)
9 (5.6)
7 (4.3)
7 (4.3)
5 (3.1)
8 (4.9)
a Four patients with a mosaicism containing more than two cell lines, two patients with a marker chromosome and 
two patients with a translocation with chromosome 13
In the other 87 patients (53.7%) we found other karyotypes including mosaicisms and structural 
X chromosomal anomalies. In six patients (3.7%) the presence of a (derivative) Y chromosome was 
encountered. Four of the six had previously undergone bilateral gonadectomy. Histological evaluations 
yielded no malignancies in three patients and bilateral gonadoblastoma and unilateral dysgerminoma 
in one patient. In two patients, gonadectomy was omitted; one patient refused surgery and in the other 
patient surgery was not performed because of absence of the part of the Y chromosome that is typically 
associated with gonadoblastoma. This patient had karyotype 45,X/46,X,i(Yq), missing the entire 
short arm of the Y chromosome, where most gonadoblastoma associated genes are located.18
 Of the 75 patients with 45,X, 63 (mean age 29.0 ± 10.4) agreed to participate in additional 
cytogenetic investigations. None of these patients showed signs of virilization.
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Methods
FISH analysis of buccal cells
In all patients, buccal smears were collected from the inner lining of the cheeks. Buccal cells 
were stored in standard culture tissue medium and subsequently centrifuged. The samples 
were incubated at 37 degrees Celsius with 0.075 M kaliumchloride for 10 minutes followed by 
prefixation with 1 ml fixative (3:1 methanol/acetic acid). Fixation was repeated three times. The 
cell suspension was applied on a slide in 2 drops, 15 microliter each. FISH was performed with 
X- and Y-specific centromeric probes (CEP X and CEP Y; Vysis, Abbott, USA) and an additional 
probe of the SRY-region (LSI SRY, Vysis, Abbott, USA). One female and one male sample were 
used to define the intensity of the signals. As an example of FISH on buccal cells with X- and 
Y-probes see figure 1.
 FIGURE 1
 A.  FISH on buccal cell with one Y chromosome specific signal (red), one X chromosome specific signal (green) and 
two chromosome 18 signals (light blue). 
 B. FISH on buccal cells with one X chromosome specific signal (green) and two chromosome 18 signals (light blue).
In patients with Y chromosomal signals in buccal cells additional FISH on interphase blood 
lymphocytes was performed and/or the number of cells for conventional karyotyping was 
extended. When possible we performed standard PCR-Y and/or FISH on ovarian tissue.
PCR-Y of blood lymphocytes
We were able to collect 20cc EDTA –ethylene diamine tetraacetic acid- blood for DNA 
extraction in 56 of the 63 patients with apparent 45,X. To detect Y chromosome sequences DNA 
was amplified after extraction in two separate reactions according to the protocol described by 
Simoni et al.20 After amplification the resulting fragments were separated on a 1.4% agarose gel, 
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and photographed. This method not only detects the presence of the SRY gene on the Yp-arm, 
but also sequences on Yq euchromatin (sY84, sY86, sY127, sY134, sY254 and sY255).
 Besides this conventional PCR to detect Y chromosomal sequences, a more sensitive real-
time PCR protocol was used. This protocol is in essence the same as it is used for the detection 
of fetal Y chromosomal sequences in the plasma of pregnant women, as described by Scheffer 
et al.21 In short, with real time PCR with probes for the SRY gene and a separate assay for the 
multicopy DYS14 marker the concentration of Y chromosome specific sequences was measured 
compared to a control.
Data were collected under conditions of regular clinical care, with ethical committee approval 
obtained for the use of those data for scientific purposes.
RESULTS
FISH analysis of buccal cells
In patients with complete monosomy X (45,X) on conventional lymphocyte karyotyping 
(n=63), FISH analysis of buccal smears revealed second or third cell lines in 19 patients (30.2%) 
(Figure 2). In five patients (7.9%), the additional cell lines included the presence of a (derivative) 
Y chromosome. In 4 of the 5 Y positive cases, prophylactic gonadectomy was performed. FISH 
analysis of ovarian tissue was performed in two patients, revealing Y positive signals in both 
cases (Table 2). Histological evaluation of the ovarian tissue was normal in all cases. In one patient 
(Table 2, patient 5) we performed no gonadectomy because of absence of the gonadoblastoma 
associated region of the Y chromosome.
In the 5 cases with Y positive buccal cells, FISH was also performed on interphase blood 
lymphocytes, revealing Y chromosomal material in one patient only (Table 2, patient 5). 
Repeating the chromosome studies on cultured lymphocytes in this patient revealed a marker 
chromosome (derivative Y) in 6% of the cells.
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 FIGURE 2 
 Karyotype of buccal cells (as interpreted from the FISH signals) in patients with 45,X on conventional karyotyping
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PCR-Y analysis of blood lymphocytes
Conventional PCR-Y analysis of blood lymphocytes was negative in all 56 cases, including 
those in whom FISH in buccal cells had revealed the presence of a Y chromosome (Table 2). Of 
the four patients who underwent prophylactic gonadectomy prompted by buccal FISH results, 
PCR-Y was also performed on ovarian cells in two, yielding one positive result.
Real-time PCR revealed the presence of SRY and DYS14 sequences in blood in 2 of the 5 patients 
with a Y chromosome positive FISH result. In one patient, only a low concentration of the 
DYS14 sequences could be detected (Table 2). This was expected since the Y chromosome was 
incomplete (marker Y). All other patients had a negative real-time PCR result.
DISCUSSION
In this study we show that in patients with a full-blown monosomy 45,X on conventional 
karyotyping of blood lymphocytes, FISH analysis of buccal cells with X and Y chromosome 
specific probes reveals tissue-specific sex-chromosomal mosaicism in 30 percent of the cases. 
This includes the detection of a (derivative) Y chromosome in 8% of the patients. Regular 
PCR-Y using 7 different Y-specific markers failed to identify Y chromosomal derivatives in 
blood samples, including those from patients whose buccal cells were Y positive. However, a 
much more sensitive real-time PCR could confirm the presence of Y chromosomal sequences in 
the blood in three of the five Y positive cases. Our results imply that if a full blown monosomy 
45,X is detected after conventional karyotyping of blood lymphocytes, a second tissue like easy 
accessible buccal cells should be examined for full appreciation of the genotype.
Karyotyping blood cells versus buccal cell FISH
The main limitation of karyotyping blood lymphocytes only, is the fact that low-grade 
mosaicisms and tissue specific mosaicisms, including those with a Y chromosome, are likely to 
be missed.13-15 Conventional karyotyping identifies Y chromosomal mosaicism in approximately 
5-6% of TS patients.9,10 In our group, 3.6% of the patients had a Y chromosome or derivate thereof 
on conventional karyotyping and FISH on buccal cells doubled the number of patients carrying 
Y chromosomal material. A previous study drew the attention to superior results of FISH 
on buccal cells in a group of 12 patients with Y chromosome material found by conventional 
karyotyping. Concerning the level of Y positive cells, FISH on buccal cells showed significant 
differences compared with FISH on lymphocytes in half of the cases, while gonadal karyotypes 
were better reflected by buccal FISH results than by regular lymphocyte karyotyping.15 Another 
study of 21 patients with apparent 45,X and negative PCR-Y (DYZ and DYZ3) reported that 
FISH on buccal cells revealed an extra cell line in 6 patients. Only 3 of these additional cell lines 
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could be confirmed by FISH on blood lymphocytes.13 The additional value of performing FISH 
in patients with an already established chromosomal mosaicism or structural abnormality on 
regular karyotyping is limited. We performed FISH on buccal cells of 13 patients with TS and 
various X chromosomal mosaicisms and found that all mosaicisms were confirmed in buccal 
cells, although proportions of the different cell lines varied between lymphocytes and buccal 
cells and additional cell lines were encountered (data not shown). No additional Y chromosomal 
signals were detected which in fact was what we anticipated.
Molecular analysis (PCR-Y)
Tissue-specific and low-grade mosaicisms, in particular of Y chromosomal sequences, can also 
be detected by molecular techniques like a PCR-Y. One study showed that in 35% of 20 patients 
with apparent 45,X, PCR-Y (SRY and DYZ3) could reveal Y chromosome sequences in at least 
one tissue. PCR-Y results varied between different tissues, i.e. blood, buccal cells and hair roots.14 
A meta-analysis of 541 patients with TS who did not show Y chromosomal material on regular 
cytogenetic analysis, revealed that 5% had a Y chromosome containing cell line when using PCR-Y 
on lymphocyte extracted DNA.2 It is therefore tempting to apply such a PCR-Y on DNA extracted 
from blood cells in order to detect low frequencies of a Y chromosome. However, in our cohort 
regular PCR-Y on blood DNA did not identify any additional patients carrying Y chromosomal 
material, which has also been reported by others.13,22-24 The most probable explanation is that 
the standard PCR-Y that we used has a too low sensitivity, since we know it is difficult to detect 
mosaicisms below 10%. Even in one patient with a marker chromosome, the standard PCR-Y was 
not able to detect the proven low grade Y chromosomal mosaicism. Therefore, we decided to set 
up another, much more sensitive, real time PCR technique to analyze the blood DNA and in this 
way we were able to detect Y chromosome specific sequences in three of the five patients with Y 
chromosome material earlier found with FISH on buccal cells, while no additional patients were 
encountered using this technique. These results implicate that this appears to be a very promising 
technique to use on other tissues as well and it is perfectly conceivable that applying real-time PCR 
on DNA extracted from buccal cells is even more sensitive to detect a (derivative) Y chromosome 
than FISH, since in blood lymphocytes the real-time PCR revealed Y chromosomal sequences 
while FISH did not (Table 2). Our negative real time PCR-Y results in the remaining two patients 
with a Y chromosome detected by FISH in buccal cells, is most likely caused by a complete 
absence of Y chromosome material in the blood or an extremely low frequency. This assumption 
is strengthened by the fact that extended FISH studies on blood lymphocytes, metaphases as 
well as interphases, also failed to detect Y chromosomal sequences in all but one patient (Table 2). 
Further improving the search for Y chromosome derivatives in blood by performing a nested PCR 
does not seem to be a very promising approach regarding the high rate of false positive results.25,26
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Y chromosomal mosaicism and gonadoblastoma
In several studies positive PCR-Y in patients with apparent 45,X was associated with 
gonadoblastoma.4-6,14,18 Out of 161 patients with Y negative results on conventional karyotyping, 
four had a (derivative) Y chromosome when using a PCR with SRY and DYZ3 markers, while 
two of them had a gonadoblastoma.4 In another study, 107 TS patients with apparent 45,X 
were investigated and 2 gonadoblastomas were detected in 10 PCR-Y (SRY, ZFY, Yc, Yq, PABY 
markers) positive patients.6 Furthermore, in a group of 78 non-selected TS patients it was 
shown that 18.5% had a positive PCR-Y (SRY, TSPY and DYZ3), while 2 of them had a bilateral 
gonadoblastoma.18 Others combined FISH and PCR-Y and in two out of 50 patients lacking a Y 
chromosome on conventional karyotyping positive results and gonadoblastoma were found.5
 Regardless the technique used, Y chromosomal material in patients with dysgenetic gonads 
is associated with a risk of gonadoblastoma. It is generally accepted that the finding of a Y 
chromosome on conventional karyotyping urges for gonadectomy to prevent the development 
of a gonadoblastoma and the associated malignant dysgerminoma.2 The need for gonadectomy 
when a Y chromosome is found in another tissue or with another technique than conventional 
karyotyping on blood lymphocytes is not yet fully established. The incidence of gonadoblastoma 
in patients with TS and a (derivative) Y chromosome in blood is estimated at 12%.2 However, 
the risk of developing gonadoblastoma and the associated dysgerminoma is uncertain since not 
all patients with a Y chromosome revealed by other techniques than conventional karyotyping 
consistently underwent gonadectomy. Furthermore, gonadectomy is performed mostly 
prophylactically i.e. before a gonadoblastoma and especially dysgerminoma actually develops 
in the dysgenetic gonad. We performed gonadectomy in 4 patients with apparent monosomy 
45,X and Y chromosomal material present in buccal cells, and found no gonadoblastoma. 
Cytogenetic analysis of the ovarian tissue was performed in two and revealed Y chromosome 
material in both samples. This suggests that the streak ovaries were indeed prone to developing 
gonadoblastoma. Nevertheless, the beneficial effects of gonadectomy should be weighed against 
potential negative consequences. Although a high percentage of women with TS are infertile 
and already need lifelong hormone replacement therapy, gonadectomy induces early oestrogen 
deficiency. In this context it is not established whether gonadectomy is necessary when Y 
chromosomal material is found with a more sensitive technique than conventional karyotyping 
or identified in another tissue besides blood lymphocytes, including buccal mucosa. However, 
increased vigilance towards the development of gonadoblastoma would at least warrant careful 
gynecological follow-up, for example with (transvaginal) ultrasound of the gonads.
 In conclusion our results confirm that TS patients with apparent 45,X on conventional 
karyotyping of blood lymphocytes often have various tissue specific mosaicisms, which may 
include the presence of a (derivative) Y chromosome. These mosaicisms can rather quickly be 
detected with high sensitivity by applying FISH with X- and Y-specific probes on non-invasively 
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obtainable buccal cells. The results of this approach seem to correlate well with the karyotype of 
ovarian tissue and could as such serve as a predictor of the risk of developing gonadoblastoma. 
Buccal FISH studies, or alternatively real-time PCR on DNA extracted form buccal cells, should 
therefore be considered as an additional routine investigation in TS patients with a 45,X karyotype 
in blood lymphocytes. Further investigations are needed to estimate the exact risk of developing 
gonadoblastoma in patients with Y chromosomal material in buccal cells. 
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ABSTRACT
Objective 
Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by 
growth hormone (GH) treatment. We have previously reported the results of a trial on the effect 
of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg/day (Ox 0.03) significantly 
increased adult height gain, whereas Ox 0.06 did not, at the cost of deceleration of breast 
development and mild virilization. The aim of this follow-up study in adult participants of the 
pediatric trial was to investigate the long-term effects of previous Ox treatment.
Design and methods 
During the previous randomized controlled trial, 133 girls were treated with GH combined with 
either placebo (Pl), Ox 0.03, or Ox 0.06 from 8 years of age and estrogen from 12 years. Sixty-
eight women (Pl n=23, Ox 0.03 n=27, Ox 0.06 n=18) participated in the double-blind follow-up 
study (mean age 24.0 years, mean time since stopping GH 8.7 years, mean time of Ox/Pl use 4.9 
years). We assessed height, body proportions, breast size, virilization and body composition.
Results 
Height gain (final minus predicted adult height) was maintained at follow-up (Ox 0.03 
10.2±4.9cm, Ox 0.06 9.7±4.4cm vs. Pl 8.0±4.6cm). Breast size, Tanner breast stage and body 
composition were not different between groups. Ox-treated women reported more subjective 
virilization and had a lower voice frequency.
Conclusion 
Ox 0.03 mg/kg/day has a beneficial effect on adult height gain in TS patients. Despite 
previously reported deceleration of breast development during Ox 0.03 treatment, adult breast 
size is not affected. Mild virilization persists in only a small minority of the patients. The long-
term evaluation indicates that Ox 0.03 treatment is effective and safe.
INTRODUCTION
Turner syndrome (TS) has an incidence of approximately 1 in 2000 live born girls and is the 
result of complete or partial absence of one X chromosome.1 Short stature, together with 
ovarian failure and dysmorphic features, is one of the most prominent aspects. Without growth 
hormone (GH) treatment, adult women with TS are on average 20 cm shorter than women 
without TS.2 Although TS is not associated with GH deficiency, supraphysiological GH doses 
increase adult height by 5-12 cm.3-5 Differences in efficacy of GH treatment can be explained 
by age at initiation and duration of therapy, compliance, estrogen therapy regimen and several, 
partly unknown, genetic factors.4,6,7
 Oxandrolone (Ox) is a synthetic non-aromatizable anabolic steroid with weak virilizing 
effects compared with testosterone. Ox has been shown to increase adult height and growth 
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velocity in TS.8-14 Some of the initial studies used Ox dosages of 0.1 mg/kg/day or higher which 
were subsequently lowered due to virilization and early bone maturation.9-11
 We have previously reported the results of a randomized placebo-controlled double blind 
trial on the effect of the addition of Ox in lower dosages to standard GH and estrogen treatment 
in girls with TS.12 Intention to treat analysis showed that compared to GH+placebo (Pl), GH+Ox 
in a dose of 0.03 mg/kg/day (Ox 0.03) increased adult height gain –final minus predicted 
adult height- (9.5 vs. 7.2cm in Pl) at the cost of mild deceleration of breast development. At a 
higher dose of 0.06 mg/kg/day (Ox 0.06), no significant increase in height gain was found 
(8.3 vs. 7.2cm in Pl), probably due to faster bone maturation and premature discontinuation 
of Ox because of virilizing side effects. In the Ox 0.06 group significantly more girls reported 
subjective virilization. Findings in both Ox groups included a decrease in fat mass, an increase 
in muscle mass and lowering of the voice pitch, which were initially in the higher range, to 
normal voice frequencies in most cases.15,16 To assess whether these effects were transient or 
definitive, we conducted this follow-up study. We investigated the long term side effects of Ox 
in the two different dosages (0.03 and 0.06 mg/kg/day) compared to Pl in GH and estrogen 
treated TS women several years after discontinuation of GH and Ox therapy. We examined 
height, body proportion and composition, virilization (including voice frequency) and breast 
development.
SUBJECTS AND METHODS
Participants and previous treatment
Participants of the initial pediatric randomized double-blind placebo controlled trial were 
recruited between 1991 and 2003 in ten pediatric endocrine centers in the Netherlands.12 
Inclusion criteria were a TS compatible karyotype (except for cytogenetical evidence of 
Y-chromosomal material), a calendar age between 2.00 and 15.99 years, and a bone age younger 
than 12.00 years. Exclusion criteria were growth failure due to other causes, use of medication 
that could interfere with study medication and previous GH or sex steroid therapy.
 In total 133 girls were included and assigned to age group 1 (2.00-7.99), 2 (8.00-11.99), or 3 (12.00-
15.99 years). After stratification for calendar age and height standard deviation score (SDS), they were 
randomized and blindly assigned to receive Ox 0.03, Ox 0.06 or Pl orally at bedtime after reaching 
the age of 8 years. Furthermore the girls were treated with GH (1.33 mg/m2/day) from baseline and, 
when spontaneous puberty was absent, with estrogen from the age of 12 years. 17-ß-Estradiol was 
prescribed in age groups 1 and 2 and ethinyl-estradiol in age group 3 (5 and 0.05 μg/kg/day orally, 
increasing to 10 and 0.1 μg/kg/day after two years, respectively). When ethinyl-estradiol became 
unavailable in 2002, 17-ß-estradiol was also prescribed in age group 3. For more detailed participant 
information, randomization and treatment modalities see Menke et al.12
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 All participants in the original trial were eligible for inclusion in the current follow-up study, 
provided that they had been off GH treatment at least six months prior to the investigation. 
Additional exclusion criteria for the follow-up study were participation in another drug study 
within two months of entry, malignancy, severely disabling disease, psychiatric illness and 
current pregnancy or fertility treatment.
Investigations
Participants and investigators were blinded to the treatment arms, so data were collected in a 
double-blind fashion. Participants were invited for a one-day visit in the out-patient department 
of the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. We used a 
questionnaire, including an extensive medical history and questions about possible side effects, 
which was completed at home. All examinations were performed by a single researcher (KF), 
except for the gynecological examinations, which were done by a gynecologist (MAFT).
Height
Height was measured using an electronic stadiometer. Adult height gain was calculated as the 
mean of three height measurements minus the predicted adult height. Predicted adult height 
was calculated using the modified projected adult height (mPAH): 146.95 + 6.37 * (-0.2 + 0.836 
* height SDS at baseline).12,17 Height SDS for untreated Northern European girls with TS at adult 
age was calculated by: (adult height – 146.95)/ 6.37.2
Body composition and proportions
Sitting height was measured using an electronic stadiometer and a sitting height table. Subischial 
leg length was calculated by height minus sitting height. Biacromial and biiliacal distance 
and hand and foot length were measured using a Harpenden anthropometer. Skinfolds were 
measured with a Harpenden skinfold caliper at the biceps, triceps, subscapular and suprailiacal 
level. We measured the arm span and circumferences of the head, left arm, waist, hip and thigh 
with a conventional measuring tape. All measurements were performed according to Gerver 
et al.18 Body weight was measured on a scale, with the patient in underwear and barefoot. 
Body mass index (BMI) was calculated by dividing weight (kg) by squared height (m). Upper 
arm muscle area (UAMA) was calculated according to Frisancho: UAMA = (mid upper arm 
circumference - (π x triceps skinfold thickness))2/4π.19 Total body fat percentage was calculated 
using the sum of four skinfolds and c and m values according to Durnin and Womersley.20 Total 
body fat percentage was calculated by (4.95/( c – (m* log sum of skinfolds)))-4.5)*100. A total 
body dual-energy X-ray absorptiometry (DXA) (Hologic QDR 4500 densitometer, Zaventem, 
Belgie) was performed to estimate body composition including percentages of total body fat 
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and lean body mass. To asses ‘android’ fat percentage, a region of interest spanning from the 
pelvis cut (lower boundary) to a line defined as 20% of the distance between the pelvis and neck 
cuts (upper boundary) was used, as defined by the manufacturer.
Breast size and sexual maturation
Breast size was estimated by subtraction of the widest chest circumference (at the level of the 
nipples) minus the smallest chest circumference (under the breasts) with the patient in supine 
position. Pubertal stage was estimated according to Tanner for breast development and pubic 
hair.21
Subjective virilization
Subjective virilization was scored by the following questions: Do you experience excessive hair 
growth (yes/no)? Do you suffer from acne (yes/no)? Do you experience a greasy skin (yes/no)? 
How do you consider your clitoral size (too small/small/normal/large/too large)? How do you 
consider your voice (low/normal/high)?
Objective virilization 
The Ferriman and Gallwey score was used to assess hirsutism. A score of six or higher was 
considered as hirsutism.22 The existence of acne, greasy hair and/or skin was scored. The 
gynecologist measured clitoral size (large/normal/small/absent, a clitoris size above 1 cm was 
considered large). To assess voice frequencies recordings were performed in a quiet room. The 
voice recording consisted of a backward count from 10 to 0 and five standardized sentences. 
Both measurements were at a comfortable pitch and loudness. Fundamental voice frequency 
was assessed using a multidimensional voice program (Kay Elemetrics Corp., Lincoln Park, 
New Yersey, USA). Based on Traunmüller et al. we considered a fundamental voice frequency 
below 201 Hz as abnormally low.23
Laboratory investigations
To assess long-term safety and to identify possible confounders of outcome measures, venous 
blood samples were assayed for lipid spectrum, kidney- and liver function, glucose metabolism 
(fasting glucose and insulin levels, glycosylated haemoglobin),  insulin like growth factor-I 
(IGF-I), androgen levels (dehydroepiandrosterone, androstenedione and testosterone) and 
thyroid function. The homeostatic model assessment (HOMA) index for insulin resistance was 
calculated according to the formula: (insulin mU/l * glucose mmol/l)/ 22.5.24
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Statistical analyses
Differences in patient characteristics between the participants and non-participants of the 
follow-up study were assessed using student’s T test. Differences in outcome between dosage 
groups were tested by linear regression using two dummies (for GH+Ox 0.03 and GH+Ox 0.06) 
for continuous variables, and by Pearson Chi Square test for nominal data. We performed an 
intention to treat analysis for height related items (primary endpoint) and, in order to prevent 
underestimation of the side-effects of Ox, a modified intention to treat analysis, i.e. including 
only those patients who took at least one dose of the study medication, for the secondary 
endpoints (Figure 1). A P value <0.05 was considered significant. We used Statistical Package for 
the Social Sciences version 16.0 (SPSS, Inc., Chicago, Illinois).
This follow-up study was conducted in accordance with the guidelines of the Declaration of 
Helsinki and was approved by the ethics committee of the Radboud University Nijmegen 
Medical Centre. Written informed consent was obtained for each participant.
RESULTS
Recruitment
Of the 133 original participants in the trial, 68 were eligible for inclusion in the follow-up study 
(Pl n=23, Ox 0.03 n=27, Ox 0.06 n=18). Their data are shown in Figure 1 and Table 1. Besides lost 
to follow-up (n=9), excluded (n=7) and deceased (n=2), 47 women refused to participate. Causes 
of death in the two deceased patients were severe pneumonia at the age of 15 years and colorectal 
carcinoma at the age of 28 years. The main reasons for declining to participate were the burden 
of a full day of examination besides regular medical follow-up (at the cost of work or study) and 
travel distance. Table 2 compares the 68 participants in the follow-up study with the 65 non-
participants. The participants used Ox for a longer period and had a higher height gain at the end 
of the pediatric study compared to the non-participants. The main results for the participants 
are summarized in Table 3. The mean age was 24.0±3.8 years and the mean interval since the 
end of GH treatment was 8.7±3.3 years.
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TABLE 2 
Characteristics of participants versus non-participants in the follow-up study
Participants (n=68) Non-participants (=65) P value
Age at start GH 9.2±3.6 7.9±4.2 0.061
Age at start Ox 10.3±2.2 10.3±2.4 0.947
Height SDS (ref TS) start 0.6±0.9 0.3±1.0 0.064
Duration of GH usea 6.2±2.9 6.9±3.5 0.258
Duration of Ox useab 5.0±1.4 4.3±1.8 0.040
Height SDS (ref TS) last pediatric visita 1.7±0.9 1.2±1.0 0.002
Height gain last pediatric visita 9.4±4.6 7.5±4.3 0.017
% 45,X 47.1% 53.9% 0.434
GH=growth hormone; Ox=oxandrolone; SDS=standard deviation score; TS=Turner syndrome
a  Five patients in the non-participant group were still on GH treatment and four were lost to follow-up. These nine 
were excluded for these comparisons. 
b 6 patients in the non-participant group and 2 patients in the participant group never started Ox.
 FIGURE 1 
 Follow-up of original study participants and inclusion to the current study 
* Exclusion in the Pl group due to current GH treatment (n=2) and multiple handicaps (n=1), in the Ox 0.03 group due to 
current GH treatment (n=2) and in the Ox 0.06 group due to current GH treatment (n=1) and psychiatric illness (n=1). 
  Pl=placebo; GH=growth hormone; Ox=oxandrolone
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Height gain
For the total group mean adult height gain was 9.2±4.7 cm as compared to 9.1±4.8 cm at the 
last visit of the pediatric trial. Differences in adult height gain between both Ox treated groups 
and the Pl group were comparable with the data of the pediatric trial. Duration of Ox use was 
positively correlated to adult height gain (P value 0.011).
Body composition and proportions
Weight, BMI and percentage lean body mass/fat mass were equal across the three treatment 
modalities. Regarding body proportions, sitting height-to-height ratio was higher in the 
GH+Ox 0.06 group. Biiliacal distance was not different between the Pl and Ox groups nor 
was biacromial distance. Hand and foot lengths were similar in all groups, but the foot length/
height ratio was slightly lower, indicating relatively smaller foot length, in the GH+Ox 0.03 
group. Head circumference was higher in both Ox treated groups. No differences in left arm, 
waist, hip and left thigh circumferences were found.
Breast size and sexual maturation
Four patients underwent breast surgery: one patient underwent a breast reduction (GH+Ox 
0.06), one patient a breast enlargement (GH+Ox 0.06) and two patients a breast reconstruction 
because of shape (one in the GH+Ox 0.03 group, one in the GH+Ox 0.06 group). Two 
additional patients did not want to have their breast size measured. These six patients were 
excluded from the breast size analysis. Breast size and Tanner stages did not differ between the 
different treatment modalities. Fifty percent of the women reported a subjective delay of breast 
development in puberty as compared to peers, with equal distributions across groups. At the 
time of reassessment, five patients regarded breast size as being too small (one in the GH+Pl 
group, three in the GH+Ox 0.03 group and one in the GH+Ox 0.06 group).
Subjective virilization
Hirsutism was reported by 19 women (GH+Pl n=0, GH+Ox 0.03 n=9, GH+Ox 0.06 n=10). The 
frequency was significantly higher in both Ox groups as compared to Pl (Table 3). Acne was 
reported by five women (GH+Pl n=0, GH+Ox 0.03 n=4, GH+Ox 0.06 n=1) and greasy skin by 
five (GH+Pl n=0, GH+Ox 0.03 n=3, GH+Ox 0.06 n=2). A low voice was reported by 15 women 
(GH+Pl n=6, GH+Ox 0.03 n=4, GH+Ox 0.06 n=5) and clitoromegaly by two (GH+Pl n=2, 
GH+Ox 0.03 n=0, GH+Ox 0.06 n=0). Women treated with Ox 0.03 or 0.06 had a relative risk 
of 1.4 (P = 0.342) and 2.4 (P = 0.004), respectively, to report one or more virilizing effects.
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Objective virilization
Hirsutism, defined as a Ferriman and Gallweyscore above six, was confirmed objectively in three 
women (GH+Pl n=0, GH+Ox 0.03 n=2, GH+Ox 0.06 n=1). None of them had elevated androgen 
levels. Women in both Ox groups had a lower mean voice frequency compared to the Pl group. 
Nine women had a voice frequency below the reference values for both counting backwards and 
reading standardized sentences (GH+Pl n=2, GH+Ox 0.03 n=5, GH+Ox 0.06 n=2, mean voice 
frequency 189.1±6.9). Three (GH+Ox 0.03 n=1, GH+Ox 0.06 n=2) had objective evidence of mild 
clitoromegaly (clitoral size just over 1 cm). Four patients had more than one sign of virilization: 
two in the GH+Ox 0.03 group (one patient with a greasy skin, acne, hirsutism and a low voice, and 
one patient with acne, hirsutism and a low voice) and two in the GH+Ox 0.06 group (one patient 
with clitoromegaly and low voice, and one with greasy skin, acne and hirsutism).
Correlation between subjective and objective virilization
Virilization was objectively confirmed in a minority of the patients with subjective symptoms. 
The proportions of objective virilization in patients with subjective symptoms were as follows: 
hirsutism 3/19, greasy skin 3/5, acne 5/5, clitoromegaly 0/2 and low voice 4/15. Patients who 
reported a low voice were confirmed to have a lower mean voice frequency than those who 
reported a normal or high voice (205.5 Hz vs. 219.5 Hz, P = 0.016). Vice versa, actual virilization 
was recognized in most cases, except for clitoromegaly. The proportions of patients with 
subjective symptoms in cases of objective virilization were as follows: hirsutism 3/3, greasy 
skin 3/3, acne 5/8, clitoromegaly 0/3 and low voice 4/9.
Laboratory investigations
The lipid spectrum was equal in all groups, except for high density lipoprotein cholesterol 
(HDL) which was lower in both Ox groups compared to placebo (Table 3). Ten patients, equally 
distributed in the treatment modalities, had a HDL below the 1.10 mmol/l. Thyroid function, 
after exclusion of 11 levothyroxine users, was similar between groups. Glucose metabolism 
did not differ between the treatment groups. There was one patient with type 2 diabetes in the 
GH+Ox 0.03 group. All patients had a creatinine level within the reference values. Ten patients 
had one or more liver enzymes above twice the upper reference limit: three in the Pl group 
(13.0%), four in the GH+Ox 0.03 group (16.0%) and three in the GH+Ox 0.06 group (16.7%).
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DISCUSSION
We present the long-term outcome of a Dutch multi-center trial on the effects of Ox (besides 
GH and estrogen) in girls with TS. We have shown that the positive effect of Ox in a dosage of 
0.03 mg/kg/day on adult height gain found in the pediatric study has been maintained. The 
initial study showed a mild deceleration of breast development, mild subjective virilization 
and a lower voice frequency due to Ox. Our current findings indicate that the deceleration of 
breast development during Ox treatment is transient. In the long-term study final breast size 
and Tanner stage were similar between the Ox and Pl groups. The Ox treated adult women still 
reported more subjective virilization, but actual virilization was only confirmed objectively in 
a few cases.
 Besides our study, two placebo controlled trials have confirmed an increase in height gain 
with Ox.8,12,14 The mechanism by which Ox influences growth is unclear. A positive effect on the 
growth plate as well as effects via other growth factors such as IGF-I have been suggested.25,26 
Data of our original study and the US study point towards a dose dependent effect of Ox on 
bone maturation.8,12 However, others could not confirm a faster bone maturation during Ox 
treatment when using a dosage of 0.05 mg/kg/day, with a maximum Ox dose of 2.5 mg daily.14
 Previous studies in TS girls using Ox dosages of ~ 1 mg/kg/day found that these dosages 
frequently needed to be lowered due to virilization.9-11 In our study as well as in the US study 
virilization was more frequently seen in girls treated with Ox than placebo, particularly with 
Ox 0.06.8,12 Gynecological examination revealed three patients with mild clitoromegaly, and 
although the numbers are too small to allow conclusions, it is noteworthy that all three patients 
had been treated with Ox. Furthermore, there were three other Ox treated women, all of 
Mediterranean origin, with overt (though mild) hirsutism. We speculate that this hirsutism 
was mainly related to ethnicity but we cannot rule out an effect of Ox. Even in the cases without 
hirsutism, we still found a small yet significant, dose-dependent effect of Ox on androgen 
dependent body hair. This is in line with increased subjective scores of hair growth. The lower 
voice frequency observed in girls treated with Ox in our pediatric study confirmed the data of 
a cross-sectional study on Ox from Sweden.27 As expected the voice changes were irreversible 
and we confirmed the dose dependent lower mean voice frequencies in the Ox 0.06 treated 
group. However, mean voice frequencies of both Ox treated groups are normal. Remarkably, no 
virilizing effects were found in the UK study of 106 TS girls treated with Ox in a dosage of 0.05 
mg/kg/day with a maximum of 2.5 mg/day.14 A possible reason for this discrepancy with our 
study might be the use of a maximum Ox dose, and also the lack of systematic assessments of 
virilization in that study.
 Although pubertal induction with low-dose estrogens starting at 12 years of age seems to be 
appropriate, half of the patients reported delayed breast development. Consequently, a further 
delay of breast development due to Ox (observed in the US study as well as in our pediatric 
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study, while not specifically assessed in the UK study) is undesirable.8,12,14 Theoretically, Ox 
inhibits the estrogen effect on breast development.28 Our follow-up study, however, showed no 
differences in subjective breast development between the treatment groups. Furthermore final 
breast size and Tanner stage were similar in both Ox and Pl groups, indicating that the effect of 
Ox on breast development is transient. This is in line with the improvement of breast stage SDS 
after discontinuation of Ox seen in our pediatric study.12
 Theoretically, Ox could affect body composition in a beneficial way. In general women with 
TS tend to have an increase in BMI and fat mass including visceral fat.29-31 In a pilot study in adult 
women with TS, androgen treatment increased lean body mass and decreased fat mass.32 In our 
pediatric study we also showed a reduction in fat mass and an increment in muscle mass during Ox 
treatment.15 In our current study, however, we did not find any differences in body composition. 
We found a small reduction of high density lipoprotein cholesterol in the Ox treated groups. This 
is in line with a recent study on the use of methyltestosterone in adult women with TS, although 
in that study the decrease of HDL during treatment was accompanied by a reduction of total 
cholesterol and triglycerides resulting in a more favourable lipid profile.32 Also in the US study the 
decrease in HDL was accompanied by a decrease in triglycerides.8 Since women with TS in general 
have an unfavorable cardiovascular risk profile, this may be an important issue.33
 Regarding body proportions, TS women have relatively shorter legs, larger hands and feet, 
and broader shoulders and pelvis.34 GH treatment has a beneficial effect on the disproportion 
between total height and sitting height.34,35 Ox, however, seemed to negatively influence this 
disproportionality. In the pediatric study, we found a significant increase in sitting height/height 
ratio in the Ox treated groups, which was confirmed for the Ox 0.06 group at long-term follow-
up. Furthermore the notion that Ox increases biacromial distance and decreases biiliacal distance 
is confirmed in our adult population, although the numbers did not reach statistical significance.
 An important limitation of the current study is that only half of the original participants 
could be included for follow-up. We cannot rule out that certain differences between the 
treatment groups remained undetected due to lack of power. For example, the difference in 
height gain favoring Ox 0.03 observed in the full cohort failed to reach statistical significance 
(p=0.094) in the follow-up study. The number of drop-outs were equally distributed among 
the treatment arms, suggesting that the sample remains representative of the cohort. However, 
the participants of the follow-up study had a larger height gain at last pediatric follow-up as 
well as a longer duration of Ox treatment than the non-participants. This may have affected the 
outcome. Also, we cannot rule out that possible differences in spontaneous puberty, although 
not significant, have impacted long-term effects.
 Our study is the first long-term follow-up study on the effects of Ox in TS patients. Based 
on our previous and current findings we conclude that Ox 0.06 mg/kg/day should not be 
used in girls with TS since there is no significant effect on adult height and it results in (non-
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reversible) virilizing effects. Ox 0.03 mg/kg/day in addition to growth hormone and estrogen 
treatment has a beneficial effect on adult height gain in TS patients. Despite previously reported 
deceleration of breast development during Ox 0.03 treatment, eventual adult breast size is 
not affected. We conclude that Ox in this dosage can be safely used in girls with TS, although 
usually mild virilization can persist in a minority of patients. We therefore recommend careful 
counseling before the start of Ox. Currently Ox is not universally available in Europe. Our study 
might contribute to the reintroduction of Ox. Long-term follow-up, including assessment of 
cardiovascular and uterine status, is necessary to assess effects of Ox even on the longer term.
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ERRATUM
In the discussion section we incorrectly stated that the use of a maximum Ox dose in the UK study 
could explain the differences in virilization frequency: ‘A possible reason for this discrepancy with 
our study might be the use of a maximum dose, and also the lack of systematic assessments of 
virilization in that study.’ The correct phrase should be: ‘A possible reason for this discrepancy with 
our study might be the use of a lower maximum Ox dose (2.5 mg in the UK study, versus 3.75 mg in 
the US and Dutch study), and also the lack of systematic assessments of virilization in that study.’
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Long-term effects of oxandrolone treatment in 
childhood on neurocognition, quality of life and 
social-emotional functioning in young adults with 
Turner syndrome
Kim Freriks1, Chris M Verhaak2, Theo CJ Sas3,4, Leonie A Menke5, Jan M Wit5, Barto J Otten6, 
Sabine MPF de Muinck Keizer- Schrama3, Dominique FCM Smeets7, Romana T Netea-Maier1, 
Ad RMM Hermus1, Roy PC Kessels2,8,9, Henri JLM Timmers1
Author affiliations
1Radboud university medical center, Nijmegen, Department of Internal Medicine, Division 
of Endocrinology, 2Radboud university medical center, Nijmegen, Department of Medical 
Psychology, 3Erasmus Medical Centre, Rotterdam, Department of Pediatrics, 4Albert 
Schweitzer Hospital, Dordrecht, Department of Pediatrics, 5Leiden University Medical Center, 
Leiden, Department of Pediatrics, 6Radboud university medical center, Nijmegen, Department 
of Pediatrics, 7Radboud university medical center, Nijmegen, Department of Human Genetics, 
8Vincent van Gogh Institute for Psychiatry, Venray, Centre of Excellence for Korsakoff and 
Alcohol-Related Cognitive Disorders, 9Radboud university medical center, Nijmegen, Donders 
Institute for Brain, Cognition and Behaviour
Hormones and behavior, accepted
86
ABSTRACT
Turner syndrome (TS) is the result of (partial) absence of one X-chromosome. Besides short 
stature, gonadal dysgenesis and other physical aspects, TS women have typical psychological 
features. Since psychological effects of androgen exposure in childhood probably are long-
lasting, we explored long-term psychological functioning after oxandrolone (Ox) therapy 
during childhood in adults with TS in terms of neurocognition, quality of life and social-
emotional functioning. During the initial study, girls were treated with growth hormone (GH) 
combined with placebo (Pl), Ox 0.03 mg/kg/day, or Ox 0.06 mg/kg/day from the age of eight, 
and estrogen from the age of twelve. Sixty-eight women participated in the current double-
blinded follow-up study (mean age 24.0y, mean time since stopping GH/Ox 8.7y). We found 
no effects on neurocognition. Concerning quality of life women treated with Ox had higher 
anxiety levels (STAI 37.4±8.4 vs 31.8±5.0, p0.002) and higher scores on the depression subscale 
of the SCL-90-R (25.7±10.7 vs 20.5±4.7, p0.01). Regarding social-emotional functioning, 
emotion perception for fearful faces was lower in the Ox-treated patients, without effect on 
interpersonal behavior. Our exploratory study is the first to suggest that androgen treatment 
in adolescence possibly has long-term effects on adult quality of life and social-emotional 
functioning. However, differences are small and clinical implications of our results seem 
limited. Therefore we would not recommend against the use of Ox in light of psychological 
consequences.
INTRODUCTION
Turner syndrome (TS) is the result of total or partial absence of one X chromosome and has 
an incidence of approximately 1:2000 in live born girls.1 In addition to short stature, gonadal 
dysgenesis -with infertility in the majority of the women-, and dysmorphic features, TS is 
associated with a wide range of abnormalities affecting nearly every organ system. Apart 
from these physical aspects, psychological problems including neurocognitive dysfunction, 
diminished quality of life and social-emotional deficits have been reported.
 Regarding neurocognition, women with TS have a distinct profile characterized by a 
normal to high verbal intelligence quotient (VIQ) and a decreased performance IQ (PIQ).2,3 
Cognitive problems commonly persist into adulthood and adult women with TS are prone to 
impairments in visual-motor integration, attention, (working) memory, executive function and 
spatial cognition.2,3
 Quality of life in TS is generally considered to be unaffected, although some studies reported 
diminished scores on especially physical functioning subscales.4-7 Sexual functioning may be 
impacted and women with TS have a higher rate of lifetime depression.6,8 Furthermore, women 
with TS report more social isolation, shyness, social anxiety and problems in relationships.4,9,10 
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Infertility may be one of the main contributing factors, since similar problems have been reported 
in women with premature ovarian failure.6,8,10 In addition to health-related problems, social 
interaction is probably influenced by difficulties in interpreting non-verbal communication, 
that is, recognizing facial expression of certain emotions (especially fear).11-13
 In general, girls with TS are treated with growth hormone (GH) to increase adult height.14 In 
order to improve the growth-enhancing effect of GH in TS, the addition of the weak synthetic 
androgen oxandrolone (Ox) has recently been investigated in three placebo (Pl) controlled 
trials, including ours.15-17 We investigated the additional growth-enhancing effect of Ox in two 
different dosages.16 Compared with GH+Pl, GH+Ox in a dose of 0.03 mg/kg/day (Ox 0.03) 
significantly increased adult height gain (9.5 vs. 7.2 cm in Pl) at the cost of mild deceleration of 
breast development. At a higher dose of 0.06 mg/kg/day (GH+Ox 0.06), no significant increase 
in height gain was found and significantly more girls reported virilization.16 In the Ox groups a 
decrease in fat mass, an increase in muscle mass and lowering of the voice was found.18,19 During 
the same study a psychological survey (testing emotional and behavioral problems, sexual 
aspects of quality of life and gender role) revealed no differences between the Ox and Pl treated 
groups.20
 Others found that during methyltestosterone treatment in TS quality of life, including 
general health, and sexual desire improved.21 In the same study androgen treatment was 
associated with neuro-cognitive functioning in terms of improved selective attention and 
verbal episodic memory, and a decline in some of the executive functions including working 
memory.21 Strikingly, other researchers treated TS girls with Ox for 2 years and found significant 
improvement of working memory and measures of immediate recall, but no effects on verbal 
abilities, spatial cognition, and executive function.22 Four years of Ox treatment resulted in 
slight improvement of mathematical learning disabilities, but no effect was found on reading 
learning disability.23 
 Conventionally, the effects of androgens on psychological functioning are divided into 
activational (temporary, during exposure) and organizational (permanent).24  While research 
on organizational effects has primarily focused on the prenatal and neonatal period, the 
timeframe in which cerebral function can be permanently influenced by external hormonal 
influences possibly last into puberty.25 
 Taking together the susceptibility to (neuro)psychological problems in TS and the 
potentially permanent psychological effects of exposure to exogenous androgens during 
childhood and adolescence, this raises important questions regarding the safety of growth-
enhancing treatment with Ox in these patients. The aim of this exploratory follow-up study 
was to determine the long-term effects of Ox on neuro-cognitive functioning (i.e., ‘traditional’ 
cognitive functions related to information processing), quality of life and social-emotional 
functioning.
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METHODS
Participants and previous treatment
The current study is a follow-up evaluation of the pediatric multi-center randomized, placebo-
controlled, double-blind Turner Oxandrolone Study. The initial study started in 1991. In this 
study 133 girls with TS were treated with GH (1.33 mg/m2 body surface/day) from baseline 
combined with Pl, Ox 0.03, or Ox 0.06 mg/kg body weight/day from the age of eight 
and estrogen from the age of twelve. More detailed participant information and treatment 
modalities, including inclusion and exclusion criteria, were reported previously.16
 For the current study all patients and investigators remained blinded for the study 
medication and the patients who discontinued GH treatment at least six months before entry 
were invited. Additional exclusion criteria of this study were participation in another drug 
study within two months of entry, malignant or severely disabling disease, suspicion of major 
psychiatric disorder and pregnancy or current fertility treatment.
Assessments
All neuropsychological tests and psychological questionnaires were performed during a 
whole-day program, which included medical assessments as well. The questionnaires were 
computerized and set out in a quiet room without any company. All neuropsychological tests 
were performed by two well-trained assistant psychologists. 
Neurocognition and intelligence
Intelligence (total IQ, verbal and performal IQ) was assessed using the abbreviated version 
of the Wechsler Adult Intelligence Scale (WAIS-III), consisting of the 7 subtests Arithmetic, 
Information, Digit Span, Similarities, Picture Completion, Block Design and Symbol 
Substitution.26 Executive function was measured using the Brixton Spatial Anticipation Test 
(Brixton) as an index of rule detection and concept shifting and the Zoo Map subtest of the 
Behavioral Assessment of the Dysexecutive Syndrome (BADS) as a test for visuospatial 
planning.27 Visuospatial working memory was addressed with the Box Task, a computerized 
paradigm to assess visuospatial efficiency and working memory.28 The Box Task consists of 
different trials with increasing difficulty (4, 6, 8 and 10 boxes). Outcome measures are within-
search errors (errors within a single search reflecting the ability to keep visuospatial information 
active), between-search errors (errors between several search trials, reflecting the ability to 
maintain visuospatial information over longer periods of time) and a strategy score (reflecting 
search efficiency).28
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Quality of life
Health-related quality of life was assessed with the RAND 36 adapted from the MOS 36-item 
short-form health survey.29 The original RAND consists of 8 subscales: Physical Functioning, Social 
Functioning, Limitations due to Physical Problems, Limitations due to Emotional Problems, Mental 
Health, Vitality, Bodily pain and General health. A ninth subscale ‘Health change’ was added.
 The Dutch revised version of the Symptom Checklist (SCL-90-R) was performed to 
estimate general psychological, somatic and cognitive wellbeing.30 The test consists of 90 
items that have to be rated on a five-point scale. Eight subscales are defined as Agoraphobia, 
Somatization, Anger-Hostility, Depression, Interpersonal Sensitivity and Paranoid Ideation, 
Anxiety, Cognitive Performance Difficulty, and Sleep Disturbance. 
 More detailed information about depression and anxiety was collected by two additional 
questionnaires. The level of depressive symptoms was measured using the Beck Depression 
Inventory-2nd Edition (Dutch version, BDI-II-NL).31,32 The scores for the 21 items range from 0-3 
and are divided into three categories: Cognitive, Somatic and Affective. We considered a score 
above 16 as indicative for depression. Anxiety was measured using the Spielberger State Trait 
Anxiety Inventory (Dutch version, STAI).33 The STAI measures the Trait Anxiety (a general 
tendency of an individual to be anxious) and the State Anxiety (the level of anxiety on a certain 
moment). Both measures include 20 items which scores range from 1-4. 
 To examine women’s evaluation of the impact of TS in their life (cognitive coping), the 
Illness Cognition Questionnaire (ICQ) was used.34 A score was computed for each of the three 
subscales: Helplessness, Acceptance and Disease Benefits. 
 Five items of the Inventory Social Involvement (ISI)- the social dimension of the Arthritis 
Impact Measurement Scales- were used to assess the participant’s own perception of social 
support in the past six months.35,36
 To assess the thoughts and emotions concerning sexuality we used the Dutch version 
adapted from the Women’s Sexual Self-Concept Scale (WSSCS).37 The three different subscales 
of the WSSCS are defined as Agentic Sexuality (women’s interest and active role in sexuality), 
Negative Associations (sexual coercion, negative emotions and concerns about sexuality) and 
Reserved Approach (responsibility, carefulness and faithfulness).37
Social and emotional functioning
We assessed three different aspects of social-emotional functioning: understanding of 
emotions, interpersonal distress, and recognition of emotions. 
 To assess the ability to understand and process emotions the Bermond-Vorst Alexithymia 
Questionnaire (BVAQ) was administered.38 The five sub-scales differentiate between 
cognitive (Identifying, Verbalizing and Analyzing) and affective (Emotionalizing, Fantasizing) 
dimensions of alexithymia. 
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 As an index for social behavior and the associated experience of stress, the Scale for 
Interpersonal Behaviour (SIB) was administered.39 The SIB consists of two different scales (50 
items): one for the frequency of engagement in a specific social situation (SIB-F) and one for the 
degree of experienced discomfort (SIB-G). The index provides four subscales named Negative 
Assertion (disclosure of negative feelings), Insecurity (expression of and dealing with personal 
limitations), Initiating Assertiveness (social assertiveness and expressing one’s own opinion) 
and Positive Assertion (praising others and the ability to deal with compliments). 
 To examine the ability to perceive and label emotional expressions the short form of the 
Emotion Recognition Test (ERT) was administered.40 This is a computerized test for the 
recognition of the six basic facial emotional expressions: anger, disgust, fear, happiness, sadness 
and surprise. The emotions are mimicked by two male and two female actors. Morphed video 
clips show a neutral face gradually changing into different emotions at different levels of 
intensities (40, 60, 80 en 100%). After each video clip, the participant is asked to make a forced 
choice between the six emotional expressions. Each emotion in each intensity is presented four 
times, each by a different actor.
Statistical analyses
We performed a ‘modified intention to treat analysis’ including only those patients who took 
at least one dose of the study medication (Pl or Ox). For comparison between the three groups 
(Pl, Ox 0.03, Ox 0.06) ANOVA or Chi-square test were used where appropriate. Only in the 
case of significant main effects post-hoc comparisons were performed. ERT and Box Task were 
analyzed using a general linear model repeated-measures analysis. For comparison between 
Pl and the total Ox group (Ox 0.03 and Ox 0.06 together) we used ANOVA and unpaired 
T-tests. To correct for multiple testing, alpha was set at 0.01 for comparison of the three 
treatment modalities. We used Statistical Package for the Social Sciences version 16.0 (SPSS, 
Inc., Chicago, Illinois). Effect sizes have been calculated using the Effect Size Calculator (www.
cognitiveflexibility.org/effectsize/).
The study was performed in accordance with the declaration of Helsinki and approved by the 
ethics committee of the Radboud university medical center. Written informed consent was 
obtained from all participants.
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RESULTS
Recruitment
Of the original 133 patients, 68 patients participated in the follow up study. For recruitment 
and participation details see Figure 1. Between the three groups there were no differences 
in education level, employment and living situation. One patient in the Ox 0.06 group was 
excluded because of a serious psychiatric disorder. Three patients were under regular care of a 
psychiatrist and/or psychologist, all three had been treated with Ox 0.03.
 FIGURE 1 
 Flow chart of patient inclusion
n.p.e.=neuropsychological examination; p.a.=psychological assessment
a exclusion due to current GH treatment (n=5), multiple handicaps (n=1) or psychiatric illness (n=1). The patient with 
psychiatric illness was in the Ox 0.06 group. 
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Two patients did not complete the psychological questionnaires because their parents considered 
them incapable (IQ 63 and 74, respectively) and another patient because of anxiety to fail. The 
fourth patient was excluded because of too many missing values. Three other patients did not 
undergo neuropsychological examination: one patient refused to participate and in two patients 
data could not be collected due to logistic reasons. According to the modified intention to treat 
analysis, two patients were excluded in the Ox 0.03 group because they had never started Ox.
Table 1 summarizes the main patient characteristics and physical outcome measures. More 
detailed information about growth, body composition and virilization has been reported in a 
previous paper.41 The mean time±SD interval since the end of GH/Ox was 8.7±3.3 years. The 
timing and duration of GH/Ox was not different between the three treatment modalities. 
Estrogen therapy was equal in all groups. 
TABLE 1 
Patient characteristics modified intention to treat (n=66)
GH+Pl 
(n=23)
GH+Ox 0.03 
(n=25)
GH+Ox 0.03 
vs GH+Pl P 
value
GH+Ox 0.06 
(n=18)
GH+Ox 0.06 
vs GH+Pl P 
value
Age 24.6±4.2 24.2±3.4 0.707 23.6±3.4 0.414
Percentage 45,X 14/23=60.9% 8/25=31.0% 0.045 8/18=44.4% 0.295
Age at start Ox/Pl 10.7±2.5 10.4±2.2 0.593 9.7±1.7 0.140
Duration of Ox/Pl 
therapy
5.1±1.6 4.7±1.5 0.315 5.0±1.3 0.709
Adult height (cm) 156.7±4.7 159.0±6.7 0.171 157.9±5.2 0.531
Adult height gain (cm) 8.0±4.6 10.0±4.9 0.144 9.7±4.4 0.258
BMI (kg/m2) 26.9±5.2 28.0±6.9 0.487 26.6±4.2 0.879
Breast size (cm)a 13.5±3.6 13.9±4.3 0.730 12.7±3.1 0.518
Tanner breast stage 4.5±0.7 4.6±0.5 0.619 4.7±0.4 0.398
Ferriman & Gallwey 
scoreb
0.09±0.3 3.5±8.8 0.039 1.7±2.2 0.372
One or more virilizing 
complaintsc
8/23=34.8% 13/25=52.0% 0.230 15/18=83.3% 0.002
a  Breast size was estimated by subtraction of the widest chest circumference (at the level of the nipples) minus the 
smallest chest circumference (under the breasts) with the patient in supine position. Six patients were excluded for 
breast size measurements: two patients refused measurement without underwear and four had a history of breast 
surgery.
b Ferriman & Gallwey score is a score for excessive, androgen dependent, body hair
c Excessive hair growth, acne, greasy skin, large clitoral size and/or lowering of the voice
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Neurocognition and Intelligence
All neurocognitive results are summarized in Table 2. We found no main effect of treatment 
modality on intellectual ability (TIQ, PIQ, VIQ: all F values < 0.8).  No differences between 
the treatment groups were found on visuospatial planning (Zoo Map: all F values < 1.9) and rule 
detection and concept shifting (Brixton: F2,62 = 1.8). Repeated-measures analyses revealed no 
effect of Ox on visuospatial working memory (Box task between-search errors). No strategy 
differences were observed on this task either (all F values < 2.0).
Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life   CHAPTER 5
 and social-emotional functioning in young adults with Turner syndrome   
94
TA
BL
E 
2 
N
eu
ro
co
gn
iti
on
 a
nd
 in
te
llig
en
ce P
la
ce
bo
 
(n
=2
3)
  
M
ea
n±
SD
O
x 
0.
03
 
(n
=2
3)
M
ea
n±
SD
Ef
fe
ct
 si
ze
 
O
x 
0.
03
Co
he
n’
s d
O
x 
0.
06
 
(n
=1
7)
M
ea
n±
SD
Ef
fe
ct
 si
ze
O
x 
0.
06
Co
he
n’
s d
To
ta
l O
x 
gr
ou
p 
(n
=4
0)
M
ea
n±
SD
Ef
fe
ct
 si
ze
To
ta
l O
x 
gr
ou
p
Co
he
n’
s d
W
AI
S 
III
   
 To
ta
l I
Q
87
.1
±1
2.
0
90
.5
±1
3.
6
-0
.2
7
86
.7
±1
0.
6 
0.
04
88
.9
±1
2.
4
-0
.1
5
   
 V
er
ba
l I
Q
91
.7
±1
2.
6
95
.0
±1
4.
5
-0
.2
4
91
.8
±1
4.
2
-0
.0
1
93
.7
±1
4.
3
-0
.1
5
   
 P
er
fo
rm
al 
IQ
83
.3
±1
2.
2
86
.6
±1
2.
5 
-0
.2
7
82
.5
±8
.7
 
0.
08
84
.9
±1
1.
1
-0
.1
4
Br
ix
to
n
11
.1
±4
.2
13
.0
±5
.6
 
-0
.3
9
14
.2
±6
.1
-0
.6
0
13
.5
±5
.8
-0
.4
8
Zo
o 
M
ap
 (B
AD
S)
Sc
or
e 
(co
nd
iti
on
 1
)
3.
5±
4.
9
3.
7±
4.
4 
-0
.0
4
2.
9±
5.
3
0.
12
3.
4±
4.
8
0.
02
Pl
an
ni
ng
 ti
m
e 
(se
c)
11
1.
6±
16
3.
1
79
.5
±6
4.
1
0.
28
11
0.
2±
11
9.
6 
0.
01
92
.6
±9
1.
8
0.
15
To
ta
l t
im
e 
(se
c)
20
9.
4±
15
3.
1
18
6.
0±
85
.4
0.
20
25
2.
3±
16
2.
5 
-0
.2
7
21
4.
2±
12
6.
7
-0
.0
3
Sc
or
e 
(co
nd
iti
on
 2
)
7.
4±
1.
8
6.
6±
2.
2
0.
40
7.
6±
1.
2
-0
.1
3
7.
0±
1.
9
0.
22
Pl
an
ni
ng
 ti
m
e 
(se
c)
10
.3
±1
0.
2
15
.2
±2
5.
2
-0
.2
8
14
.2
±1
9.
6 
-0
.2
6
14
.8
±2
2.
7
-0
.2
7
To
ta
l t
im
e 
(se
c)
63
.8
±2
4.
1
69
.4
±2
8.
9
-0
.2
1
72
.2
±3
1.
5 
-0
.3
0
70
.6
±2
9.
7
-0
.2
5
Bo
x 
Ta
sk
Be
tw
ee
n 
se
ar
ch
 e
rro
r
   
  4
 b
ox
es
0.
2±
0.
3
0.
2±
0.
3
0.
00
0.
3±
0.
4
-0
.2
9
0.
2±
0.
4
0.
00
   
  6
 b
ox
es
0.
8±
1.
0
0.
8±
1.
2
0.
00
0.
4±
0.
7
0.
47
0.
7±
1.
0
0.
10
   
  8
 b
ox
es
3.
6±
3.
9
3.
2±
2.
5
0.
13
4.
0±
3.
6
-0
.1
1
3.
5±
3.
0
0.
03
   
  1
0 
bo
xe
s
10
.0
±4
.3
10
.0
±4
.4
0.
00
9.
2±
3.
5
0.
21
9.
7±
4.
0
0.
07
St
ra
te
gy
 sc
or
e
   
  4
 b
ox
es
1.
9±
0.
7
1.
8±
0.
6
0.
15
2.
1±
0.
6
-0
.3
1
1.
9±
0.
5
0.
00
   
  6
 b
ox
es
3.
2±
1.
1
3.
4±
0.
7
-0
.2
2
3.
5±
1.
0
-0
.2
9
3.
5±
0.
8
-0
.3
2
   
  8
 b
ox
es
4.
4±
1.
3
4.
7±
1.
1
-0
.2
5
4.
6±
1.
0
-0
.1
7
4.
7±
1.
1
-0
.2
5
   
  1
0 
bo
xe
s
6.
5±
2.
0
6.
7±
1.
1
-0
.1
3
6.
8±
1.
6
-0
.1
7
6.
7±
1.
3
-0
.1
2
W
AI
S=
W
ec
hs
le
r A
du
lt 
In
te
lli
ge
nc
e 
Sc
al
e;
 IQ
=i
nt
el
lig
en
ce
 q
uo
tie
nt
; B
AD
S=
Be
ha
vio
ra
l A
ss
es
sm
en
t o
f t
he
 D
ys
ex
ec
ut
ive
 S
yn
dr
om
e;
 S
D=
st
an
da
rd
 d
ev
iat
io
n.
 H
ig
he
r s
co
re
s o
n 
th
e 
W
A
IS
 in
d
ic
at
e 
a 
hi
g
he
r 
IQ
. M
o
re
 e
rr
o
rs
 f
o
r 
th
e 
B
ri
xt
o
n 
re
fle
ct
 m
o
re
 p
ro
b
le
m
s 
in
 e
xe
cu
ti
ve
 f
un
ct
io
n.
 F
o
r 
th
e 
Zo
o
 M
ap
 h
ig
he
r 
sc
o
re
s 
co
rr
el
at
e 
w
it
h 
b
et
te
r 
vi
su
o
sp
at
ia
l p
la
nn
in
g
. 
C
o
nc
er
ni
ng
 t
he
 B
o
x 
Ta
sk
 a
n 
in
cr
ea
si
ng
 n
um
b
er
 o
f 
er
ro
rs
 r
efl
ec
ts
 p
ro
b
le
m
s 
in
 v
is
uo
sp
at
ia
l e
ffi
ci
en
cy
 a
nd
 w
o
rk
in
g
 m
em
o
ry
, w
he
re
 a
 lo
w
er
 s
co
re
 o
n 
st
ra
te
g
y 
in
d
ic
at
es
 m
o
re
 e
ffi
ci
en
t 
us
e 
of
 st
ra
te
gy
.
CHAPTER 5    Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life  
and social-emotional functioning in young adults with Turner syndrome
95
Quality of life
All results are summarized in Table 3.
 Concerning quality of life the RAND-36 showed no main effect of Ox (all F-values < 2.7). 
When comparing the Pl group with both Ox treated groups taken together no significant 
differences on the subscales were found. In addition, the SCL-90-R subscales did not reveal 
any significant differences when comparing the Ox 0.03 and Ox 0.06 groups with Pl separately 
(all F-values <2.4). When combining the two Ox groups, the patients using Ox reported 
significantly more complaints compared to Pl on the subscale Depression (25.7 vs 20.5, p = 0.01). 
None of the other subscales showed a treatment effect. 
 Focusing on depression and anxiety, no main effect of the study medication was found 
on the different subscales of the BDI-II (all F-values < 1.4). Mean values in all three groups 
indicate low levels of depressive symptoms. When comparing the Pl group with the Ox treated 
groups together no significant differences were found. Eight patients had a total score > 16: one 
in the Pl group, four in the Ox 0.03 group and three in the Ox 0.06 group, but no significant 
differences were found in frequency of occurrence across the three groups. Testing anxiety with 
the STAI, we demonstrated no main effect of Ox compared to Pl for both current anxiety and 
anxiety predisposition. When combining the Ox treated groups for both subscales a significant 
effect was found when compared to Pl: current anxiety (37.4 vs 31.8, p = 0.002) and anxiety 
predisposition (40.2 vs 33.4, p = 0.002), indicating higher levels of anxiety in the Ox treated 
groups.
 Testing cognitive coping, no significant main effect of treatment condition on the ICQ was 
found (all three F values < 1.5). A comparison between the Pl group and both Ox groups together 
showed no significant differences as well.
 We found no main effect for Ox on the total ISI score (F2,61 = 2.41, p = 0.1), meaning that self 
reported social support is comparable between the treatment modalities. Comparing the Ox 
groups together revealed no differences with Pl.
 Concerning psychosexual wellbeing mean scores of the WSSCS subscales were 4.3±1.1 
for Agentic Sexuality, 2.1±0.7 for Negative Associations and 5.4±1.2 for Reserved Approach, 
without any differences between the treatment modalities.
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Social and emotional functioning
Table 3 shows the results of the various tests. Concerning alexithymia, we found a main effect 
of Ox on the BVAQ subscale Emotionalizing (F2,61 = 6.29, p = 0.003). Post-hoc analysis however, 
showed no significant differences between the three treatment modalities. 
Scores on the SIB did not differ between the different treatment modalities on both SIB-F (all F 
values < 1.4) and SIB-G (all F values < 1.3). Comparing combined Ox groups with Pl revealed no 
significant differences for social behavior and associated stress.
 Figure 2 shows the results of the ERT for the three treatment groups. Main effects for emotion 
type (F5,300 = 103.5, p < 0.0001) and intensity (F3,180 = 68.1, p < 0.0001) were found. ERT revealed 
no main effect of Ox (F2,60 = 0.56, p = 0.57). We found an interaction between treatment group 
and intensity (F6,180 = 3.3, p = 0.004). Subsequent analyses revealed a main effect of treatment 
condition only on intensity 40% (F2,60 = 6.3, p = 0.003). Combining both Ox groups, Ox treated 
patients performed worse on fear (0.83 vs 1.61, p = 0.001) for the 40% intensity trials.
Correlation physical aspects and quality of life
No significant correlations between adult height, adult height gain, Ferriman and Gallwey 
score, BMI, breast size and Tanner breast stage and quality of life were found (all Pearson 
correlation (r) ≤ 0.2). When comparing women with subjective virilization to women without 
subjective virilization no difference in quality of life was found (mean RAND score 77.6±14.3 
and 82.5±14.9 respectively). Furthermore, no difference in quality of life was found when 
comparing women satisfied with adult height to women who were not satisfied (mean RAND 
score 80.3±15.1 and 77.9±13.2 respectively).  
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 FIGURE 2 
 Emotion recognition task performance
Mean performance of the three different treatment modalities (Pl, Ox 0.03 and Ox 0.06) for the six emotions and the 
four intensities (percentage emotional expression 40, 60, 80 and 100 percent respectively).
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DISCUSSION
We present the psychological and neuropsychological long-term follow-up data of the Dutch 
randomized double blind placebo controlled study on Ox in GH treated girls with TS at a mean 
of 8.7 years after discontinuation of Ox. Our exploratory study shows that women previously 
treated with Ox may have more feelings of anxiety and depression compared to those who had 
received Pl, although an overall effect on quality of life was not found. We found no long-term 
effect of Ox on neurocognition (i.e. intelligence, working memory and executive function). 
Regarding social-emotional functioning, only emotion perception for fearful faces was lower 
in the Ox groups, without affecting social functioning in daily life. 
 Our study is the first to explore quality of life using a follow-up assessment after 
discontinuation of Ox. We observed a trend towards lower quality of life in the Ox treated 
groups, which is likely related to the higher frequency of depressive complaints and the 
higher anxiety levels in the Ox groups. With respect to anxiety, the Ox treated groups taken 
together reported higher levels of anxiety (measured with the STAI) with a large effect size 
and a moderate, yet statistically not significant, effect on the anxiety subscale of the SCL-90-R. 
Considering depressive symptoms we observed a moderate significant effect on the depression 
subscale of the SCL-90-R, but depression measured with the BDI was not more common.
 Studies on quality of life in relation to androgen use in TS are scarce. One previous 
study showed that during testosterone treatment in adult women with TS the quality of life 
improved.21 Also in other patient groups androgen substitution has positive effects on well-
being: for example in postmenopausal women after oophorectomy transdermal testosterone 
resulted in an improvement of well-being.42 However, it is yet unclear if testosterone and Ox 
have comparable effects, since Ox is nonaromatizable.43 Moreover, we do not know the exact 
effect of Ox on quality of life during treatment in our pediatric study, since quality of life was 
not measured in childhood. We cannot rule out that previous Ox treatment changed some 
aspects of quality of life with permanent effects years after treatment. A long-lasting effect of 
Ox on the endogenous androgen production is unlikely, because androgen levels during this 
follow-up were similar between the three treatment modalities (data not shown). 
 Additionally, we found no correlation between quality of life and certain physical effects of 
androgen treatment. First of all, objective and subjective virilizing effects were more frequently 
found in the Ox treated women.41 We did neither find any differences in quality of life when 
comparing women with and without subjective virilization, nor a correlation between quality 
of life and the Ferriman and Gallwey score for hirsutism. Secondly, in our pediatric study 
we found that breast development was decelerated in the Ox treated groups.16 One could 
hypothesize a negative effect of this experience on quality of life. However, the follow-up study 
after several years of treatment with adult estrogen dosages, did not reveal any differences in 
breast size. The current breast size did not correlate with quality of life and the women who 
CHAPTER 5    Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life  
and social-emotional functioning in young adults with Turner syndrome
101
reported a subjective delay of breast development during puberty as compared to peers were 
equally distributed over the Pl and Ox groups. Thirdly, we speculated about a positive effect 
of height (gain) on quality of life, but in our study height was not correlated with quality of 
life. This is in line with previous studies in TS showing no positive effects of GH treatment 
and/or increased height on quality of life.4,44,45 Previously Bannink et al. reported that patient 
satisfaction with adult height correlated positively with quality of life.46 We could not confirm 
this observation, since we found no differences in quality of life between patients with and 
without satisfaction with their adult height.
 In this study, we found that Ox treated women only performed worse on the perception and 
labeling of fearful faces at low intensity with a large effect size for both the Ox 0.03 and 0.06 
group. Previous studies showed that a typical female and male emotion perception profile can 
be defined: females typically recognized the emotions happiness, fear and sadness more easily, 
where male participants were more accurate in recognizing anger.47 Although the effects of Ox 
in our study were small (besides the effect on the emotion fear, only a non-significant trend 
for the emotions sadness and disgust), Ox may induce a slight shift towards a less ‘feminine’ 
emotion perception.47 An alternative explanation for the difference in emotion perception 
could be the higher levels of anxious and depressive symptoms in the Ox treated groups, since 
it is known that these factors negatively influence the emotion perception.48 However, the 
differences in emotion perception found in the current study are small and these outcomes did 
not affect the interpersonal behavior as assessed with the SIB. Still, future studies using larger 
samples should include measure of emotion perception to examine these hypotheses in more 
detail.
 In this follow-up study we found no effect on PIQ, nor on VIQ and TIQ. Furthermore, we 
found no effect on executive function and working memory, constructs that show conceptual 
overlap with performance intelligence tests that assess fluid intelligence.49 Probably the effect 
of Ox and other androgens on fluid intelligence tasks is only apparent during treatment, since 
others found differences during or directly after treatment.21-23
A higher frequency of sexual problems in adult TS women was previously reported.50 In 
this study, we found no differences in sexual self-concept between the treatment groups. 
Consequently, Ox treatment during childhood does not seem to have a long-lasting effect on 
sexuality in adulthood.
 A limitation of this study is the relatively small sample of patients, since not all participants 
of the original study participated in the follow-up study. In this light, selection bias might have 
occurred towards ‘psychologically better performing’ women. However, loss to follow-up did 
not differ between the treatment groups. 
 This is the first study to explore the long-term (neuro)psychological effects of Ox treatment 
in childhood and the effects seem to be limited. Our findings suggest that during late childhood 
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and adolescence androgen treatment may influence cerebral function in an organizational way. 
Although even small differences may be of greatest interest from a scientific point of view, their 
clinical relevance is probably limited. As a result, we certainly would not advice against the 
use of Ox -in low doses- in clinical practice. However, awareness of potential psychological 
consequences of androgen use in girls with TS is encouraged. Future studies in larger cohorts 
should include evaluation of quality of life and social-emotional functioning. These studies will 
hopefully also shed light on the differential effects on aspects of quality of life in TS.
 In conclusion, our exploratory data show that treatment with Ox in childhood and 
adolescence has only limited long-term effects on feelings of anxiety and depression, and 
emotion perception of fearful faces. No late effects on overall quality of life or neurocognition 
were present. Therefore, we would not advise against the use of Ox in girls with TS as a growth-
enhancing drug. Future research during and after androgen treatment in larger samples is 
necessary to establish the exact effect of Ox and to improve the understanding of the underlying 
pathofysiology. 
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ABSTRACT
Objective 
To evaluate karyotype-specific ear- and hearing problems in young adult patients with Turner 
syndrome (TS) and assess the effects of previous treatment with oxandrolone (Ox).
Study design 
Double-blind follow-up study. 
Setting 
University hospital.
Patients 
Sixty-five TS patients (mean age 24.3y) previously treated with growth hormone combined 
with placebo, Ox 0.03 mg/kg/day, or Ox 0.06 mg/kg/day from the age of eight and estrogen 
from the age of twelve years.
Intervention 
Ear examination was performed according to standard clinical practice. Air- and bone 
conduction (AC and BC) thresholds were measured in dB hearing level (db HL).
Main outcome measures 
We compared patients with total monosomy of the short arm of the X-chromosome (Xp) 
-monosomy 45,X and isochromosome 46,X,i(Xq)- to patients with a partial monosomy Xp 
-mosaicism or other structural X-chromosomal anomalies-. We assessed the effect of previous 
Ox treatment.
Results 
Sixty-six percent of the patients had a history of recurrent otitis media. We found hearing 
loss in 66% of the ears including pure sensorineural hearing loss in 32%. Hearing thresholds in 
patients with a complete monosomy Xp were about 10 db worse compared to patients with a 
partial monosomy Xp.  AC- and BC thresholds were not different between the placebo and Ox 
treatment groups.
Conclusions 
Young-adult TS individuals frequently have structural ear pathology and many suffer from 
hearing loss. This indicates that careful follow-up to detect ear and hearing problems is 
necessary, especially for those with a monosomy 45,X or isochromosome 46,X,i(Xq). Ox does 
not seem to have an effect on hearing.
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INTRODUCTION
Turner syndrome (TS), a chromosomal disorder with a prevalence of approximately 1 
in 2000 live born girls, is caused by complete or partial absence of one X-chromosome. 
Prominent features are short stature, estrogen deficiency and dysmorphic abnormalities.1 
Monosomy 45,X, characterized by the presence of a single X-chromosome in all cells, is the 
most frequent karyotype. Other patients have a karyotype with a duplication of the long 
arm of the X-chromosome (isochromosome, 46,X,i(Xq)), mosaicism or another structural 
X-chromosomal anomaly. In general, women with monosomy 45,X have a higher disease 
burden than those with a mosaicism.2,3
Ear and hearing problems are frequently reported in TS. In childhood, middle ear infections resulting 
in conductive hearing loss are common.4,5 Abnormal craniofacial morphology and Eustachian tube 
dysfunction are thought to be the main contributing factors. TS patients are also prone to develop 
sensorineural hearing loss.6,7 A typical sensorineural mid-frequency dip is often already seen in 
adolescence. Progressive sensorineural high-frequency loss manifests earlier in TS women than in 
healthy women, especially in those patients already having a mid-frequency dip.8
TS patients with monosomy 45,X or isochromosome 46,X,i(Xq), i.e. those with monosomy of the 
complete short arm of the X-chromosome (Xp), are supposed to be more prone to hearing problems 
than those with mosaicism or other structural X-chromosomal anomalies, in which monosomy of 
Xp is only partial.9,10 This suggests that the locus for hearing impairment may be located on Xp. 
Furthermore, estrogen deficiency is suggested to be a contributing factor in hearing problems.7,11,12
While growth hormone (GH) has been shown to improve final height, such treatment can 
only partially overcome the growth failure observed in TS. It is for this reason that adjunctive 
therapy has been tried, notably with oxandrolone (Ox), a synthetic anabolic steroid derived from 
dihydrotestosterone. In previous studies, we investigated the growth-enhancing effect of Ox, a 
weak androgen, in addition to GH in TS girls.13 We, and others found that low-dose treatment of Ox 
increases growth velocity and adult height.13-15 The effect of Ox on hearing has not been previously 
investigated. Theoretically, Ox may also positively affect the growth and development of the 
mastoid bone and middle ear. This in turn could lead to prevention of recurrent otitis media and 
conductive hearing loss. In addition, Ox could also positively affect inner ear function through a 
suspected decrease in sex hormone binding globulin and the resulting higher free estrogen levels.16 
However, negative effects of androgens on hearing are suggested as well.17,18  
We recently carried out a follow-up study to determine the long-term effects of previous Ox 
treatment on growth and body composition in young adult women with TS.19 This provided 
the unique opportunity to analyze the otologic and audiologic features of a well-characterized 
TS population. In addition to the evaluation of karyotype-specific ear- and hearing problems, 
the aim of the study was to investigate whether hearing is influenced by previous Ox treatment. 
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MATERIALS AND METHODS
Patients
All of the 133 participants of the original randomized double-blind placebo controlled trial were 
invited for a medical assessment including otologic and audiologic examination. Participants 
of the original trial were recruited between 1991 and 2003 in ten pediatric endocrine centers in 
the Netherlands and randomized to receive Ox in a dosage of 0.03 mg/kg/day (Ox 0.03), 0.06 
mg/kg/day (Ox 0.06) or placebo (Pl) after reaching the age of 8 years.13 Furthermore, girls were 
treated with GH (1.33 mg/m2/day) from baseline and, when spontaneous puberty was absent, 
with estrogen from the age of twelve years. For more details see Menke et al. 13 and Freriks et al.19
This follow-up study was conducted in accordance with the guidelines of the Declaration of 
Helsinki and was approved by the ethics committee of the Radboud University Nijmegen 
Medical Centre. Written informed consent was obtained for each participant. The study is 
registered at www.trialregister.nl (NTR1934).
Otologic and audiologic examination
All ears were macroscopically and micro-otoscopically examined according to standard clinical 
practice. Medical history was taken focusing on ear and hearing problems including questions 
about confounding factors such as meningitis, head injury and problems related to birth. Pure 
tone hearing thresholds were measured according to standard audiometric methods (ISO 389) 
in a sound proof room. Air conduction (AC) thresholds and bone conduction (BC) thresholds 
were measured in dB hearing level (db HL) at (0.25,) 0.5, 1, 2, 4, and 8 kHz. 
We defined the following audiometric categories: 
Normal hearing
The AC thresholds were equal to or better than 20 dB HL across the frequency range of 0.25-8 kHz. 
Mild conductive hearing loss
The AC thresholds were never worse than 20 dB HL, though there was an air bone gap (ABG) of 
at least 10 dB at more than one frequency within normal range. By this classification we include 
these relevant ABGs in the analyses.
Conductive hearing loss (CHL)
AC thresholds were worse than 20 dB HL at one or more frequencies in the range of 0.25-8 kHz. 
There was an ABG of at least 10 dB at one or more frequencies at which the AC threshold was 
worse than 20 dB HL. BC thresholds were better than 20 dB HL at any frequency.
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Mixed hearing loss (MHL)
The BC thresholds were worse than 20 dB HL at one or more frequencies in the range of 0.25-8 
kHz and there was an ABG of at least 10 dB at one or more frequencies at which the BC threshold 
was worse than 20 dB HL.
Pure sensorineural hearing loss (SNHL)
The AC thresholds were worse than 20 dB HL at one or more frequencies in the range of 0.25-8 
kHz and there was no ABG at the frequencies at which the AC threshold was worse than 20 dB 
HL. 
Based on the BC thresholds of the MHL- and SNHL groups, we categorized the following 
subgroups:
Sensorineural mid-frequency dip
Audiograms showing a typical sensorineural mid-frequency dip at 1 and/or 2 kHz. The dip 
was defined as BC thresholds being at least 10 dB HL worse than all of the lower and higher 
frequencies.
Sensorineural mid- and high-frequency loss
Audiograms showing the typical sensorineural mid-frequency dip at 1 and/or 2 kHz in 
combination with a dip at 8 kHz. The dip at 8 kHz was only scored when worse or not more 
than 10 db better, as the maximum of the mid-frequency dip. 
Sensorineural high-frequency loss
High-frequency SNHL was defined as BC thresholds worse than 20 dB HL at 4 kHz or higher 
frequencies or BC thresholds worse than 20 dB HL at frequencies below 4 kHz with an increasing 
loss with increasing frequency (down sloping).
Statistical analysis
We tested the hypothesis that patients with monosomy 45,X or isochromosome 46,X,i(Xq) 
karyotype (complete monosomy Xp) have a higher prevalence of hearing problems compared 
to those with a mosaicism or other structural X-chromosomal anomaly (partial monosomy 
Xp). Linear regression was used to analyze the influence of age and karyotype on hearing. 
An F test was used to compare between regression lines. Testing on the slopes between the 
regression lines was performed first and testing between the ‘elevations’ (measure that pertains 
to the group’s ‘offset’ threshold) was only performed if there was no significant difference in 
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slope. The total effect of all frequencies was considered significant when the p value was <0.11 
at three or more frequencies. Concerning the influence of previous Ox treatment we tested the 
differences in mean hearing thresholds between different dosage groups and placebo by testing 
linear regression using two dummies (for Ox 0.03 and Ox 0.06). We performed a modified 
intention to treat analysis, i.e. including only those patients who took at least one dose of the 
study medication. We used the Statistical Package for the Social Sciences version 16.0 (SPSS, 
Inc., Chicago, Illinois) and the Prism program (GraphPad, San Diego) where applicable.
RESULTS
Patients
Of the 133 original participants in the trial, 68 could be included in the general follow-up 
study. Besides lost to follow-up (n=9), excluded (n=7) and deceased (n=2), 47 women refused 
to participate. Main reasons for refusal were the burden of the investigations besides regular 
medical follow-up and travel distance. For the specific ear and hearing analyses we excluded 
one extra patient because of an age just under 18 years. Furthermore, in two patients no ear and 
hearing evaluation took place for logistic reasons. Table 1 shows the karyotype differentiation of 
the 65 patients who participated in the study (Pl n=22, Ox 0.03 n=26, Ox 0.06 n=17). The mean 
age was 24.3±3.6 years (range 18-32 years). One patient did not undergo otoscopic examination. 
For the analysis of the effects of previous Ox use, we excluded two more patients, who did not 
take any dose of the study medication.
Ear, Nose and Throat history
Data concerning history are presented in Table 1. Many patients had suffered from otologic 
disease. Two out of the five patients with previous surgery for cholesteatoma suffered from 
cholesteatoma in both ears. Recurrent cholesteatoma occurred in five ears and surgery finally 
resulted in a modified radical cavity in five out of seven ears.
External ear findings
Forty-two of the 65 patients (65%) had one or more external ear anomalies including dysmorphic 
auricles, posteriorly rotated ears, low set ears and/or abnormally protruding ears varying from 
only mild to more severe forms.
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Eardrum and middle ear findings
Myringosclerosis and tympanic membrane retraction were the most common findings, 
occurring in 42/128 (33%) and 16/128 (13%) of the ears, respectively. An overview of all eardrum 
and middle ear findings is shown in Table 1.  Some ears showed multiple pathology.
Audiologic examination
Normal hearing was present in 44/130 (34%) ears. The other ears could be classified in one of 
the categories of abnormal audiometric results (Table 1).  CHL was found in 10/130 (8%) ears. 
Figure 1A shows the hearing thresholds of the ears in which the mean AC was worse than 25 
dB, counting 5/130 (4%) ears. The other 5 ears showed CHL at one or more frequencies, though 
the mean hearing threshold of all frequencies was better than 25 dB. MHL was present in 31/130 
(24%) ears (Figure 1B). Pure SNHL was found in 42/130 (32%) ears (Figure 1C). Figure 1C only 
shows the ears in which the mean AC threshold was worse than 25 dB, counting 15/130 (12%) 
ears. 
Concerning only the BC thresholds of the MHL-and SNHL group, the following audiogram 
configurations were seen (Figure 1D-E-F): a typical sensorineural mid-frequency dip (19/130 
ears, 15%), a combined mid-and high-frequency sensorineural hearing loss (14/130 ears, 11%) 
and high-frequency sensorineural hearing loss (27/130 ears, 21%). The remaining 13/130 (10%) 
ears showed BC-threshold configurations that could not be classified in one of these categories.
Audiometric findings in relation to karyotype
Linear regression showed no significant deterioration in mean BC thresholds with increasing 
age of each patient, for both the patients with a complete monosomy Xp and those with a partial 
monosomy Xp. Furthermore, there was no significant difference in slopes between both groups. 
However, there was a significant difference in elevation indicating a substantial difference 
in hearing thresholds, being about 10 dB worse for patients with a complete monosomy Xp 
compared to those with a partial monosomy Xp. Figure 2 shows an example at 2 kHz.
Regression analysis for AC thresholds showed no progression with age. The differences in AC 
thresholds were similar, being about 10 dB worse in the patients with complete monosomy Xp 
compared to those with a partial monosomy Xp. Figure 3 shows an example at 1 kHz. 
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 FIGURE 1 
 -O- : Air conduction, -X- : Bone conduction
A  Mean air conduction (AC) and bone conduction (BC) threshold for the conductive hearing loss (CHL) group, only 
showing the ears with a mean AC threshold worse than 25 dB (n = 5 ears). 
B Mean AC and BC threshold for the mixed hearing loss (MHL) group (n = 31 ears).
C  Mean AC threshold for the sensorineural hearing loss (SNHL) group, only showing the ears with a mean AC 
threshold worse than 25 dB (n = 15 ears). Six audiograms of the SNHL group had an ABG of 10-20 dB at more than 
one frequency at which the BC was within normal range.
D Mean BC threshold for the sensorineural mid-frequency dip group (n = 19 ears).
E  Mean BC threshold for the group showing combined mid-and high-frequency sensorineural hearing loss (n=14 ears).
F Mean BC threshold for the group with high-frequency sensorineural hearing loss (n=27 ears). 
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 FIGURE 2 
  Mean bone conduction (BC) thresholds at 2 kHz plotted as a function of age for the patients with a monosomy/
isochromosome ( --- and ○), and those with a mosaicism/structural anomaly (  and ●) (n = 65 patients). Linear 
regression analysis shows a significant difference in elevation between both groups.
 FIGURE 3 
  Mean air conduction (AC) thresholds at 1 kHz plotted as a function of age for the patients with a monosomy/
isochromosome ( --- and ○), and those with a mosaicism/structural anomaly (  and ●) (n =65 patients). Linear 
regression analysis shows a significant difference in elevation between both groups. 
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Oxandrolone and hearing
Regarding the influence of Ox on hearing we found that mean AC- and BC thresholds were 
not significantly different in the three treatment groups (Pl, Ox 0.03 and Ox 0.06, see Table 2). 
All p-values were >0.11 at all frequencies. We found no relevant correlation with height, adult 
height gain and duration of Ox use (data not shown).   
TABLE 2 
Mean hearing thresholds related to oxandrolone use (n=63)a
GH+Pl (n=22) GH+Ox 0.03 (n=24) GH+Ox 0.06 (n=17)
Air conductionb
0.25 kHz 18.3±10.3 18.6±12.7 20.3±21.9
0.5 kHz 17.7±10.3 20.1±11.6 22.5±22.1
1.0 kHz 19.0±15.0 24.3±16.7 25.3±25.3
2.0 kHz 21.6±19.8 20.0±14.7 23.7±28.3
4.0 kHz 18.6±16.5 17.8±17.3 22.5±23.3
8.0 kHz 28.4±20.7 28.5±21.9 29.7±24.3
Bone conductionb
0.5 kHz 12.2±9.4 14.0±9.7 12.6±11.4
1.0 kHz 12.7±13.6 18.8±14.9 15.9±15.1
2.0 kHz 19.7±18.0 17.2±13.5 18.2±18.7
4.0 kHz 11.8±13.4 8.5±14.0 10.9±11.3
8.0 kHz 21.9±16.8 23.8±21.7 22.6±17.2
a Excluding those two patients who never took any dose of the study medication.
b  All P values for the comparison of GH+Ox 0.03 and GH+Ox 0.06 to Placebo are > 0.1.
GH=growth hormone; Pl=placebo; Ox 0.03=oxandrolone 0.03 mg/kg/day; Ox 0.06=oxandrolone 0.06 mg/kg/day
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DISCUSSION
Middle ear disease
The prevalence of a history of recurrent otitis media of 66% is consistent with previous reports 
on TS.4,6,9,10,20-25 Ventilation tubes were placed in 60% of the patients. Other studies showed 
lower percentages varying from 32 to 57.4,6,21,26,27
 Middle ear infections in TS are thought to be related to an abnormal craniofacial morphology, 
including a high arched palate and an abnormal orientation of the Eustachian tube. Rizell et al. 
showed that TS patients have a short posterior and flattened cranial base, retrognathy, short and 
posteriorly rotated maxilla and mandible, increased ramus height, and relatively shorter posterior 
facial height.28 These abnormalities are probably the result of a prolonged cell cycle in the brachial 
arches and neck region and a lack of transacting growth-regulating genes, such as the SHOX–gene.29 
A subnormal immune response could also be a contributing factor in recurrent infections.4,20
Audiometric findings
Normal hearing was found in only 34% of the ears. CHL was found in 8% of the ears. In other 
TS populations percentages of CHL vary between 0 and 44, depending on the age group 
included.4,5,9,20,21,23,25,27,30,31 In our previous report on TS children (age 4.1-21.1 years) CHL was 
more common with a percentage of 33.10 The relatively low percentage of CHL found in the 
current adult group might be explained by the lower prevalence of middle ear pathology at 
increasing age. Others found no pure CHL in an adult population.23
 MHL was present in 24% of the ears, which is more common than in our pediatric cohort 
(14%).10 The range of MHL described in literature varies from 3 to 23%.5,20,21,23,24,27,30-32
 We found a high percentage of pure SNHL in 32% of the ears. The percentages of SNHL 
described in literature are highly variable in a range of 4 to 66.5,9,10,20,21,25,27,30-33 The prevalence of 
pure SNHL was much higher than the four percent in our pediatric population.10 
 Regarding the bone conduction thresholds of the MHL- and SNHL group we found typical 
audiograms with a mid-frequency dip (15%), combined mid-and high-frequency loss (11%) and 
high-frequency loss (21%). In literature, percentages of a mid-frequency dip vary between 8 and 
88.4,6,8-10,21,24,31-33 This wide range might be caused by different definitions and age categories.6,24 
Our previous study on TS children showed a mid-frequency dip in 17% of the ears. The mean 
depth of the dip in the current adult patients is 38.7 dB, which is more pronounced compared to 
25 dB reported in TS children.10 The dip maximum exceeded 20 dB in all adult cases in contrast 
with the findings in TS children where the dip maximum was within normal range as well.4,6,10 
In the present study, 11% of the ears showed a combined mid-and high-frequency loss, which 
is more than was found in TS children (6%).10 It is likely that the high-frequency loss develops 
after the dip in the same individual.23 A high-frequency loss was the most common finding in 
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21% of the ears of the adult TS patients. Our study on TS children showed a high-frequency loss 
in 4% of the ears. This confirms that sensorineural hearing levels in TS decrease with age, as we 
and others demonstrated previously.6,8,10,23 
 The cause of SNHL in TS is not clear. Specific cochlear malformations have not yet been 
revealed.21,34,35 In two TS patients with SNHL hypoplastic lateral semicircular canals were 
found.36 Furthermore, the cell cycle delay hypothesis might be an explanation for SNHL.29 In 
general, the middle turn of the cochlea has the highest hair cell density,37 and this is where the 
cell cycle needs to be up-regulated the most during development to acquire a sufficient number 
of sensory hair cells for signal analysis. In TS it is speculated that this middle part of the cochlear 
duct is most prone to growth disturbances due to a delayed cell cycle which might cause a mid-
frequency dip.29 The early onset of the high-frequency hearing loss in TS is also suggested to be 
the result of a reduced number of sensory hair cells.29 
 Low estrogen levels in TS women could be a possible contributing factor to SNHL, since 
in women without TS more rapid hearing deterioration occurs after the menopause when 
circulating levels of endogenous estrogen drop rapidly.38 Estrogen receptors have been shown 
to exist in human inner ear.12 However, since almost all women used adequate estrogen 
replacement therapy at moment of audiometric measurement, this could not be an explanation 
for the differences found in this study. 
Oxandrolone and hearing
We and others have shown that, when given at a low dose, the weak androgen steroid Ox has a 
growth-enhancing effect in girls with TS.13-15 This is the first study to investigate whether there 
is an association between previous Ox use and hearing. We hypothesized that Ox would have 
a beneficial impact on hearing. 
 First, along with the growth stimulating effect of Ox on body height, Ox may also enhance 
the growth and development of the mastoid bone, middle ear cavity, eardrum and outer ear 
canal. This might occur through increase in insulin like growth factor 1 (IGF-1) observed in TS 
patients treated with Ox.13,16,39 Low IGF-1 levels are associated with hearing loss.40 Both middle 
ear infections and sensorineural hearing loss were related to low IGF-1 levels in TS.29 Subtle 
improvement in growth and development of the ear resulting in a more physiological anatomy 
could to some extent prevent recurrent otitis media and hearing loss. Our current findings 
indicate, however, that there were no differences in mean hearing thresholds between the 
groups treated with Pl, Ox 0.03 and Ox 0.06. Unfortunately, audiologic examinations were not 
performed during treatment, so effects may have been transient.  
 Second, Ox could also positively influence hearing through estrogen-mediated effects on the 
inner ear. Estrogen deficiency may have deleterious effects on hearing, which was suggested to 
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be caused by lack of stimulation of the estrogen receptors ER- α and ER-α, which are abundantly 
present in the inner ear.7,11,12 Ox treatment is expected to decrease estrogen protein binding and in 
turn increase free active estrogen levels, which could positively affect inner ear function. In our 
study, however, we did not discern any differences in hearing thresholds between the treatment 
groups. This might be related to the fact that all patients received proper estrogen replacement 
therapy, with no additional effects of Ox on the availability of estrogen in the ear. 
 In theory, beneficial effects might also be counterbalanced by disadvantageous effects of 
androgens. Previous studies suggested that prenatal exposure to androgens negatively influences 
the auditory system by weakening of the cochlear mechanisms that underlie the production 
of otoacoustic emissions.17 In addition, there is some evidence that circulating androgen levels 
postnatally might negatively influence otoacoustic emissions as well.41,42 In men higher levels 
of circulating testosterone were found to be associated with smaller click-evoked otoacoustic 
emission amplitudes42 and male monkeys produced click-evoked otoacoustic emissions of lower 
amplitude during the breeding season, when testosterone levels are higher.41 In human females, 
data are controversial. One study reported that females with polycystic ovary syndrome (PCOS) 
-having higher androgen levels- showed significantly more high frequency hearing loss compared 
to women without PCOS.18 On the other hand, a recent study in women with PCOS showed that 
hyperandrogenism did not seem to influence otoacoustic emission levels in adult female subjects.43 
Audiometric findings in relation to karyotype
We found that hearing thresholds in general were about 10 dB worse in adults with a complete 
monosomy Xp compared to those with a partial monosomy Xp. This agrees with previous 
findings in TS children and adults.9,10 These results support the hypothesis that genes located 
on the short arm of the X-chromosome (Xp), are of importance in hearing.  
Otologic surgery
Cholesteatoma was found in as many as 8% of the patients (5 patients, 7 ears). A canal wall 
down procedure was necessary in 5 out of 7 ears. This can be problematic in the hearing aid 
dependent TS patient with a tendency to develop recurrent ear infections. In those patients 
a bone anchored hearing aid may offer a solution. A previous study in young adults reported 
cholesteatoma in 2.3%.21 Previous studies in TS children showed percentages ranging from three 
to five percent.10,34 Abnormal craniofacial morphology and Eustachian tube dysfunction could 
be contributing factors in developing cholesteatoma. Early insertion of ventilation tubes should 
be considered in TS patients who suffer from middle ear disease.
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CONCLUSION
This systematic otologic and audiologic evaluation in a well-described young-adult TS 
population treated with Ox or placebo in addition to GH in childhood shows that TS women 
frequently have eardrum- and middle ear pathology and that many of them suffer from hearing 
loss. Sensorineural hearing loss, in contrast to conductive hearing loss, is more pronounced in 
young-adult TS women than in TS children. Hearing thresholds in patients with a monosomy 
45,X or isochromosome 46,X,i(Xq) (complete monosomy Xp) are significantly worse 
compared with those having a mosaicism or other structural X-chromosomal anomaly (partial 
monosomy Xp). These findings indicate that careful follow-up is necessary to detect ear and 
hearing problems, especially for those with monosomy 45,X or isochromosome 46,X,i(Xq). 
Ox, which at a low dose has a positive effect on growth, has no long-term effects on hearing.
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Summary
This thesis focuses on several aspects of health care in adult women with Turner syndrome (TS), 
dealing with diagnostic strategies and the long-term effects of oxandrolone (Ox) treatment.
 In chapter 2 we report the yield of an initial standardized multidisciplinary screening in adult 
TS patients in our multidisciplinary care unit. All 150 adult women with a mean age of 31 years 
old (47% karyotype 45,X) were consulted by an endocrinologist, a gynecologist, a cardiologist, 
an otorhinolaryngologist, and when indicated, a psychologist. The screening included magnetic 
resonance imaging of the heart and aorta, echocardiography, electrocardiography, dual-energy 
x-ray absorptiometry, renal ultrasound, audiogram, and laboratory investigations. We showed 
that medical care according to international expert opinion based guidelines yields significant 
morbidity. Furthermore we found that 30% of the patients currently lacked medical follow-up, 
and 15% lacked estrogen replacement therapy in recent years. We concluded that standardized 
multidisciplinary evaluation of adult women with TS as advocated by expert opinion is effective 
and that girls with TS probably benefit from a careful transition to ongoing adult medical care.
 Chapter 3 describes the results of genetic analysis of a second cell line in TS. In general, the 
diagnosis is based on karyotyping of 30 blood lymphocytes. This technique, however, does not 
rule out tissue mosaicism or low grade mosaicism in the blood. Because of the associated risk 
of gonadoblastoma, mosaicism is especially important in case this involves a Y chromosome. 
We investigated different approaches to improve the detection of mosaicisms in 162 adult 
women with TS (mean age 29.9±10.3). Standard karyotyping identified 75 patients (46.3%) with 
a non-mosaic monosomy 45,X. Of these 75 patients, 63 underwent additional investigations 
including FISH on buccal cells with X- and Y-specific probes and PCR-Y on blood. FISH analysis 
of buccal cells revealed a mosaicism in almost one third of the patients. In five patients the 
additional cell lines contained a (derivative) Y chromosome. With sensitive real-time PCR we 
confirmed the presence of this Y chromosome in blood in three of the five cases. Although Y 
chromosome material was established in ovarian tissue in two patients, no gonadoblastoma 
was found. Our results confirm the notion that TS patients with 45,X on conventional 
karyotyping often have tissue specific mosaicisms, some of which include a Y chromosome. 
Although further investigations are needed to estimate the risk of gonadoblastoma in patients 
with Y chromosome material in buccal cells, we conclude that FISH or realtime PCR on buccal 
cells should be considered in TS patients with 45,X on standard karyotyping.
 In chapter 4, 5 and 6 we discuss the long-term effects of Ox in a population of young adult 
TS patients. During the pediatric randomized controlled trial, 133 girls were treated with GH 
combined with placebo (Pl), Ox in a dose of 0.03 mg/kg/day (Ox 0.03), or Ox in a dose of 
0.06 mg/kg/day (Ox 0.06) from 8 years of age and estrogen from 12 years. The pediatric study 
showed that Ox 0.03 significantly increased adult height gain, whereas Ox 0.06 did not, at the 
cost of deceleration of breast development and mild virilization. Sixty-eight women (Pl, n=23; 
CHAPTER 7   Summary and perspective
127
Ox 0.03, n=27; and Ox 0.06, n=18) participated in the double-blind follow-up study (mean age, 
24.0 years; mean time since stopping GH, 8.7 years; and mean time of Ox/Pl use,4.9 years). 
In chapter 4 we assessed height, body proportions, breast size, virilization and body 
composition. We found that height gain (final minus predicted adult height) was maintained 
at follow-up (Ox 0.03 10.2±4.9 cm, Ox 0.06 9.7±4.4 cm vs Pl 8.0±4.6 cm). Breast size, Tanner 
breast stage, and body composition were not different between groups. Ox-treated women 
reported more subjective virilization and had a lower voice frequency. 
In chapter 5 neurocognition, quality of life and social-emotional functioning were assessed. 
We found no effects on neurocognition. Concerning quality of life women treated with Ox 
had higher anxiety levels when measured with the STAI and higher scores on the depression 
subscale of the SCL-90-R, without differences in actual depression measured with the BDI. 
We found no effect on overall quality of life. Regarding social-emotional functioning, only 
emotion perception for fearful faces was lower in the Ox-treated patients, without effect on 
interpersonal behavior. In chapter 6 we describe ear examination according to standard clinical 
practice and air- and bone conduction (AC and BC) thresholds in dB hearing level (db HL). For 
the total group we showed that 66% of the patients had a history of recurrent otitis media. We 
found hearing loss in 66% of the ears including pure sensorineural hearing loss in 32%. Hearing 
thresholds in patients with a complete monosomy Xp were about 10 db worse compared to 
patients with a partial monosomy Xp. Concerning ear and hearing we found no effect of Ox. 
 In conclusion, based on the results of chapter 4, 5 and 6, we show that Ox 0.03 mg/kg/
day has a beneficial effect on adult height gain in TS patients. Despite previously reported 
deceleration of breast development during Ox 0.03 treatment, adult breast Tanner score and 
breast size are not affected. Mild virilization (including lower voice frequency) persists in only 
a small minority of patients. Our exploratory data on Ox suggest that androgen treatment in 
adolescence has long-term effects on certain aspects of adult quality of life and social-emotional 
functioning, although differences are small and clinical impact probably limited. Ox does not 
seem to have an effect on hearing. We conclude that the use of Ox in a dosage of 0.03 mg/kg/
day is effective and safe.
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Perspective
Diagnostic strategy
Adult women with TS potentially deal with a wide range of morbidities. This has been 
increasingly recognized and for several years now, devoted multidisciplinary care units are 
being advocated, as well as the use of expert opinion based guidelines.1 We have evaluated the 
implementation of a standardized diagnostic screening, as advocated in these guidelines, and 
we have shown that the initial visits to our multidisciplinary unit yield significant previously 
undiagnosed morbidity.2 TS patients are therefore likely to benefit from a careful transition 
from pediatric into adult medical care and a screening program similar to ours has now been 
implemented in the recent guidelines of the Dutch-Flemish Turner platform.3 Beyond optimal 
and timely diagnosis of TS related morbidities, the ultimate goal of health care in TS patients is 
to improve long-term outcome, improve health related quality of life and reduce mortality. The 
approach should be cost-effective and outweigh the benefits of medical screening against the 
burden of repetitive examinations in individual patients. 
 Since we have moved into the era of personalized medicine, the need for an individualized 
approach to the patient is increasingly recognized. This seems particularly important in 
disorders with highly variable phenotypes, such as TS. For example, genotype and age are 
factors that likely need to be taken into account for tailor-made personalized care in TS. It 
has been well established that complete monosomy 45,X results in a higher disease burden 
than 45,X/46,XX mosaicism.4,5 For example, in our study we have shown that the chance 
for structural cardiovascular abnormalities is higher in the 45,X group than in patients with 
mosaicism.2 Furthermore, women with 45,X are more prone to infertility given the fact 
that only 8-9% develops (temporary) menstrual cycles compared to 40-47% of the girls in 
the group with 45,X/46,XX.6,7 Also, patients with isochromosome Xq have a distinctive 
profile with a higher prevalence of diabetes mellitus and probably a higher frequency of auto-
immune diseases and increased levels of anti-TPO and anti-GAD antibodies.8-10 Additionally, 
it is shown that patients with a total loss of one of the short arms of the X-chromosome are 
more likely to develop hearing loss.11-13 Taking these genotype-specific differences into account 
could result in a more personalized health care for TS patients. Besides genotype, age appears 
to be an important determinant of TS associated morbidity. The frequency of aortic dilation, 
autoimmune disease, cardiovascular risk factors and hearing loss increases with age.2,9, 13-15 This 
suggests that the attention for these health issues should be intensified with increasing age as a 
step towards more personalized medicine.
 Another issue that needs to be resolved in the diagnostic strategy in TS patients is the lack 
of disease-specific reference values for several physical parameters. We know that the reference 
values for bone mineral density and aortic diameters of the general population are not directly 
applicable in TS patients. This lack of TS specific values hampers decision making in clinical 
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practice. Although the actual frequency of osteoporosis in TS is not well established, fracture 
risk in adult women with TS is assumed to be increased, which makes adequate measurement 
of bone mineral density important.16 We know that conventional two-dimensional ‘dual-
energy X-ray absorptiometry’ (DEXA) measurements underestimate the bone mineral density 
in smaller persons, especially in persons shorter than 150 cm.17 It is therefore recommended to 
use volumetric instead of areal bone mineral density.17,18 However in clinical practice reference 
values for volumetric bone mineral density are currently lacking. 
 For aortic diameters current opinion is to  use aorta size index (aortic diameter/body surface 
are) instead of aortic diameters. Stricter follow-up is necessary in case of an aorta size index ≥ 
2.0 cm/m2 and evaluation for prophylactic intervention is advised when the aorta size index 
exceeds 2.5 cm/m2 in combination with an absolute aorta diameter above 3.5 cm.19 However, 
aortic diameters probably need to be put in the context of other risk factors for aortic dilation and 
dissection. A nice example of individualized medicine is the use of a dynamic predictive model 
based on subsequent MRI images of the aorta and other characteristics such as the presence of 
a bicuspid aortic valve and/or coarctation, diastolic blood pressure, age, body surface area and 
the use of antihypertensive medication (http://www.biostat.au.dk/MERL/Aorta_Prediction_
model.htm).20 Although not yet validated, this model seems more reliable in identifying high 
risk patients than static data alone and enables a more specified follow-up. 
Treatment
The decreased life expectancy of TS patients is largely determined by excess cardiovascular 
morbidity related to structural anomalies and cardiovascular risk factors.21,22 Therefore, a TS 
specific approach to cardiovascular risk management is probably warranted. Unfortunately, 
there is a lack of randomized controlled trials regarding optimal timing of surgical interventions 
of the aorta and the management of hypertension, hypercholesterolemia and diabetes. It 
is unknown whether the guidelines for the general population are applicable. Considering 
hypertension no uniform treatment goals are defined and it is assumed that TS is an additional 
risk factor in the cardiovascular risk assessment, as is for example diabetes.23 Additional 
cardiovascular abnormalities urge for stricter antihypertensive treatment. Regarding optimal 
drug treatment for hypertension in the context of TS related anomalies of the thoracic vessels (i.e. 
bicuspid aortic valve, coarctation of the aorta, aortic dilation) many uncertainties exist. Because 
of the lack of randomized controlled trials in TS, currently the use of betablockers, in line with 
Marfan syndrome, is advocated.1 However, it is not unlikely that other antihypertensive drugs, 
especially ACE inhibitors, are superior in this context.23 
 Also for optimal hormone replacement therapy (HRT) in adult women with TS no 
randomized controlled trials comparing different regimens exist. For induction of puberty 
transdermal applied estrogens have shown a physiological response with the possibility of 
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achieving a diurnal rhythm.24,25 Omitting the first-pass effect of the liver will result in less effect 
on liver proteins. However, large trials comparing oral and transdermal applications are lacking. 
Small studies suggest that transdermal patches result in more physiological estrogen levels 
with faster bone accrual, increased uterine growth and probably increased lean body mass.26-
28 However, transdermal low-dose patches for induction of puberty are lacking. But also in 
adulthood, although theoretically superior, transdermal estrogens are not used as frequent as 
expected. The guideline advocates to personalize hormone replacement therapy and generally 
continue HRT till normal age of menopause.1 
 Optimal fertility treatment and counseling is a subject of debate as well. Since only 
approximately 2-5 percent of the TS have spontaneous pregnancies,29,30 assisted pregnancy is 
frequently discussed. Until recently, assisted pregnancy with oocyte donation was the only option 
for TS women with infertility and still, possibilities of having a child of their own are limited. 
Since most of the TS women have developed ovarian failure at the time of family planning in 
vitro fertilization is often not possible. Preservation of oocytes and ovarian tissue in adolescence 
is therefore upcoming, but harbors many medical and ethical challenges. In the international 
literature it is suggested that ovarian tissue preservation could be considered in patients older 
than 14 years with spontaneous puberty, a follicle stimulating hormone (FSH) below 40 IU/l, 
a measurable anti mullerian hormone, a normal cardiac status in combination with informed 
consent and research ethics approval.31 And although clinical practice in some Scandinavian 
countries, in the Netherlands cryopreservation of oocytes and ovarian tissue of TS women is still 
considered experimental.3 A survey in the dedicated TS clinics in the Netherlands revealed that 
three academic centers offer such a procedure to adult (at least older than 16) mosaic TS women 
with regular menstrual cycles. Regardless of the technique used, pregnancies in TS women are 
considered high risk and preconceptive cardiovascular screening is necessary.
Impact of novel karyotyping
The approach to karyotyping in TS and its implications are a subject of ongoing debate. The 
diagnosis of TS is based on cytogenetic analysis of 30 cultured blood lymphocytes.1,32,33 Currently, 
the international guidelines do not comment upon the investigation of other tissues besides 
lymphocytes in patients with proven TS without clinical virilization or marker chromosomes. 
Our study is one among others that shows that tissue mosaicisms in patients with apparent 
45,X are rather common.34-37 This is in line with the theory that for a TS fetus to survive to 
term an additional cell line besides 45,X is needed.38,39 The question remains which technique 
is superior to detect additional cell lines in different tissues. Several studies, including ours, 
showed that FISH is very helpful in identifying additional cell lines in tissues different from 
lymphocytes,34,36,37 while others advocate the use of PCR.35 Finding additional cell lines is 
especially important when it involves a (derivative) Y chromosome, since a Y chromosome in 
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patients with gonadal dysgenesis is linked to an increased risk of gonadoblastoma and associated 
malignant dysgerminoma.40 The exact risk is difficult to estimate and dependent on the 
existence of undifferentiated gonadal tissue, but likely lower than 15%, especially when no signs 
of virilization are present.41 The tumor risk associated with a Y chromosome found with other 
techniques than conventional karyotyping and in other tissues besides lymphocytes should be 
a focus for future research. At this moment, we see no reason to assume that Y chromosomal 
derivates found in other tissues than lymphocytes, harbor another chance for Y chromosomal 
tissue in the gonads than Y chromosome derivates found with conventional karyotyping of 
lymphocytes only. However, even when the risk is small, gonadectomy seems appropriate in 
light of non functional gonads in most of the women with TS and relatively low operation risks. 
Therefore, in TS patients with apparent 45,X we would recommend routine screening for tissue 
mosaicisms by karyotyping an additional tissue, such as easy obtainable buccal mucosa cells. 
It is of importance to investigate the incidence of gonadoblastoma in case of the finding of a Y 
chromosome in any tissue in large groups of patients in order to improve the knowledge about 
Y chromosome material in women with TS and to prevent the development of gonadoblastoma 
on the one hand and prevent unnecessary gonadectomies on the other hand.
Treatment with oxandrolone in growth hormone and estrogens treated girls: 
long-term effects
Short stature is one of the most prominent features of TS and related to haploinsufficiency of 
the ‘short-stature homeobox-containing’ (SHOX) gene.42 Although patients with TS are not 
GH deficient, suprafysiological GH doses increase adult height by 5-12cm.43-45 The effect of GH 
treatment on adult height in TS girls is not always satisfying. Differences in outcome can be 
explained by age at initiation and duration of therapy, compliance, estrogen therapy regimen, 
and several, partly unknown, genetic factors.44,46,47 In order to improve adult height alternative 
therapies were suggested, and besides higher doses of GH the addition of oxandrolone (Ox) 
was investigated. Initial studies on Ox were not controlled and did not report on long-term 
effects of Ox.48-51 Our studies on Ox are among two other randomized controlled trials on the 
growth-enhancing effect of Ox. Our initial study in the Netherlands investigated the effect of 
Ox in a low dose of 0.03 mg/kg/day (Ox 0.03) and a previously conventional dose of 0.06 mg/
kg/day (Ox 0.06) compared to placebo (Pl) in standard growth hormone and estrogen treated 
girls.52 The second study is from the US and addressed the effect of Ox at a dosage of 0.06 mg/
kg/day in addition to GH. The third study from the UK investigated Ox in a dosage of 0.05 mg/
kg/day.53,54 
 Although outcome measures differed, taking these three randomized controlled trials 
together, the average effect of Ox on adult height gain is between the 2.3 en 4.6 cm.55 Differences 
in the effect of Ox probably are explained by differences in patient characteristics and dosage 
  Summary and perspective   CHAPTER 7
132
regimens. For study characteristics and an overview of the main results of the three different 
studies see Table 1 and 2 respectively. In our pediatric study we found that compared with Pl, Ox 
0.03 significantly increased adult height gain (9.5 vs. 7.2cm in Pl).52 At a higher dose (Ox 0.06) 
no significant increase in height gain was found.52 In our follow-up study at young adult age we 
see that the differences in adult height gain are maintained.56
TABLE 1 
Characteristics of three placebo-controlled studies on the effect of oxandrolone in girls with Turner syndrome  
treated with growth hormone 1.33 - 1.43 mg/m2/d. Adapted from Sas et al.55
Dutch study
Menke et al.,2010
US study
Zeger et al.,2011
UK study
Gault et al.,2011
Inclusion criteria
  Karyotype Karyotype associated  
with TS except Y  
chromosomal material
Karyotype associated  
with TS except Y  
chromosomal material
Karyotype associated 
with TS
  Age (yr) 2-16 10-15 7-13
  Bone age (yr) < 12 ≤ 12 Open epiphysis
Exclusion criteria
  Previous treatment No Ox, No E2, No GH No Ox,No  E2
No prior GH
exceeding 12 months or in 
the preceding 3 months
No Ox, No E2, No GH  
or only GH range 8.3-
11.7 mg/m2/week
Study design
  Pl/Ox dose (mg/kg/d)
  Maximal Ox dose (mg/d)
  Minimum age of starting Ox (yr)
  GH dose 
Pl vs 0.03 vs 0.06
3.75
8
1.33 mg/m2/d 
at 1 m2 ~ 0.046 
mg/kg/d
Pl vs 0.06
3.75
10
0.05 mg/kg/d
Pl vs 0.05
2.5
9
1.43 mg/m2/d=
10mg/m2/week~
0.049 mg/kg/d
‘Discontinuation’ criteria
GH+Ox/Pl were  
stopped when height  
velocity < 1 cm in  
previous 6 months or  
because patients  
were satisfied with  
their height.
Near-adult height  
defined as height  
obtained when bone  
age was ≥ 13.5 years.
Treatment until adult  
height was reached.  
Final height defined  
as height velocity < 1  
cm/yr and bone age  
≥ 15.5 years
Start estrogen therapy
From the age of 12  
years onwards
After 2 yrs (12-17 yr) of 
treatment with Ox
Randomized to  
starting at 12 yr 
or 14 yr 
Estrogen therapy (oral)
17 ß estradiol :   
1stand 2ndyrs 5  
ug/kg/d; 3rd  yr 10  
ug/kg/d or 
ethinylestradiol :
1st and 2ndyrs 50; 3rd  
100 ng/kg/d
Ethinyl estradiol : 
50 ng/kg/d , during  
year 3 and 100  
ng/kg/d, during year  
4.
Ethinyl estradiol: 
year 1: 2 μg/d; 
year 2, 4 μg/d; 
year 3, 4 months  
each of 6, 8, and 10 
μg/d
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TABLE 2 
Results of 3 placebo-controlled studies on the effect of oxandrolone in girls with Turner syndrome treated with 
growth hormone 1.33 - 1.43 mg/m2/d. Adapted from Sas et al.55
Dutch study
Menke et al., 2010
US study
Zeger et al., 2011
UK study
Gault et al., 2011
Pl/ Ox Number of patients
Pl          
n=42    
0.03
n=42
0.06
n=36
Pl              
n=20         
0.06 
n=21
Pl 
n=43
0.05
n=39
Mean age of starting GH (yr) 9.4    8.5   9.1 12.0 11.9 7.1 7.2
Mean age of starting Ox (yr) 10.9  10.2    10.2 12.0 11.9 10.6 10.8
Height SDS at start GH (Turner ref) 0.5a   0.3a   0.5a 0.1b 0.0b NA NA
Height SDS at start GH (healthy ref)c -3.0  -3.0  -2.9 -2.9 -3.1 NA NA
Mean ending oxandrolone after dose  
adjustments (mg/kg/d)i
Pl 0.030 0.059   Pl 0.049 Pl 0.040
Adult height (cm) 155.6 156.7 156.5 150.5d 152.6d 149.6 154.2
Adult height SDS (Turner ref) 1.4a  1.5a 1.5a 2.2b,e 2.4b,e 1.0b 1.7b
Adult height SDS (healthy ref) -2.3 -2.1 -2.2 -1.6e -1.4e -2.3 -1.6
Delta height SDS (Turner ref) 0.8a 1.2a 1.0a 1.6b,e 2.3b,e NA NA
Delta height SDS (healthy ref) 0.7 0.9  0.7 1.2e 1.8e -0.1 0.4
Height increase from baseline  (cm) 25.5 29.3 28.3 22.2 26.2 23.6 26.1
Adult height minus predicted 
adult height (cm)
7.2f     9.5f 8.3f 6.9g  9.9g   NA NA
Differences in height gain vs Pl (cm)j               2.3  1.1                       3 NA NA
Note that height at enrolment, rather than height at start of GH, were recorded in the UK study, so that data are not 
available for the latter.
a Turner specific references – Dutch Swedish Danish data 
b Turner specific references – Lyon data
c healthy references: using reference data of healthy children of their own country
d near adult height
e height SDS using actual chronological age rather than 20 or 21 year of age
f Teunenbroek modified projected adult height
g Bayley-Pinneau method
i    Ox dose adjustments: in Dutch study ceiling dose of 3.75 mg, in UK study ceiling dose of 3.75 mg, in US study 
ceiling dose of 3.75 mg and dose reduction in case of virilization.
j  (near) adult height minus predicted adult height 
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 Besides efficacy, of course safety parameters were an important subject of investigation 
in our follow-up study. First of all, when using an androgen like Ox, virilizing effects such as 
hirsutism, acne, excessive muscular development, deepening of the voice, and clitoromegaly 
are of concern.48-50 Although all three studies used dosages not higher than 0.06 mg/kg/day 
both dose reduction and premature discontinuation of Ox due to virilization were reported in 
two out of the three studies.52,53 In our pediatric Dutch study one girl in the Ox 0.03 (2.4%) and 
seven in the Ox 0.06 group (19.4%) discontinued Ox due to virilization.52 In the US study dose 
reduction was effected in 40% of the women.53 During follow-up, we report that even years 
after treatment patients treated with Ox have more subjective virilization, although objective 
virilization is mild.56 We found that objective virilization is only present in a small minority of 
the patients. Furthermore we observed that hirsutism and acne regress while clitoromegaly and 
voice deepening, most of the time to a normal voice pitch, appear to be irreversible. Secondly, 
besides virilizing effects, two out of the three placebo controlled studies reported a delay in 
breast development during treatment with Ox.52,53 Our pediatric study showed a catch-up in 
breast development after discontinuation of Ox which was confirmed in our follow-up study 
with equal breast sizes in both the Pl and Ox treated groups. A third concern is the possible 
increased cardiovascular risk with disturbances in glucose metabolism and cholesterol levels. 
Taking the three studies together we see a modest effect on cholesterol levels with a lowering 
of HDL-cholesterol. No effect on glucose metabolism was found. Fourth, during treatment 
no psychological problems due to the androgen treatment itself or related to physical aspects 
were reported. The US study found a positive side effect with a small decrease in frequency of 
severe arithmetic learning disability after four years of treatment.57 In our pediatric study we 
found no differences in total and internalizing problem behavior. Our follow-up study suggests 
that Ox has long-term effects on feelings of depression and anxiety. However, we found no 
effect on overall quality of life. Fifth, Ox could negatively influence hearing. Previous studies 
suggest that prenatal exposure to androgens negatively influences the auditory system.58 Also, 
postnatal androgen levels might negatively influence otoacoustic emissions.59,60 Nevertheless, 
we found no long-term effect of previous androgen use during childhood and adolescence 
on hearing. The sixth matter of importance is the effect on bone mineral density (BMD). We 
know that in non-TS women androgen levels during adolescence predict peak bone mass.61 In 
the TS population we see that girls with spontaneous menstruation, probably with coinciding 
physiological androgen levels, have a normal BMD.62 The US study showed no effect of Ox on 
the BMD of the wrist and spine after four years of treatment with Ox 0.06 mg/kg/day versus 
Pl.53 Zuckerman-Levin et al showed that subjects who received oral methyl testosterone for 1 
year had a significant increment of BMD and bone mineral content.63 Our own preliminary data 
during treatment suggest an improvement of BMD during Ox treatment.64 Preliminary data of 
our follow-up study show that especially the women treated with Ox 0.06 have higher BMD, 
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even years after treatment (unpublished results).
 Although the three randomized controlled trials add valuable information on the use of Ox 
in TS, two main questions still have to be further addressed: the exact optimal dose of Ox and 
the timing of use. Based on the results of the three randomized controlled trials we know that 
lower than previously used conventional dosages are efficient. And although Ox 0.06 increases 
height during therapy and shortens the duration of GH therapy, we would not recommend 
this dose since it does not lead to increased adult height gain and has several adverse effects. 
However the other way around, it is not unthinkable that even lower doses than Ox 0.03 are 
effective with a better safety profile. Based on the currently available data, we would advise 
to use Ox in a dose of 0.03-0.05 mg/kg/d with a pragmatic ceiling dose of 2.5 mg per day to 
prevent overdosing. Under ideal circumstances the Ox dose should probably be adjusted to the 
individual (pretreatment) androgen levels. Concerning the timing, Ox appears to be effective 
in the age range of 8-16 years. The findings of our pediatric study, showing no differences in 
the effect of Ox between the three age groups (age group 1 started at age 8, age group 2 started 
at age 8-11 and age group 3 started at age 12-16), suggest that starting Ox before the age of 8 is 
not better than starting in the early pubertal age range. One could hypothesize that Ox has the 
most optimal effect from the age of 10 to 13 when natural androgen values are lower in untreated 
TS girls compared to healthy controls.65 Postponing the use of androgen until after the start 
of puberty (or start of estrogen treatment) could be of benefit to prevent the delay in breast 
development. 
 Concerning cost-effectiveness, we know that the costs of five years of Ox treatment 
at a maximum dose of 2.5mg are estimated at 6,000-7,000 US dollars (~ 4800 euro). Our 
pediatric study showed that Ox shortens the duration of GH treatment and with that the GH 
related costs.52 The reduction of GH related costs was only significant for the Ox 0.06 group 
(-13.500±6.300 euro – total cumulative costs of GH use in the Pl group 161.200±59.500 euro). 
For the Ox 0.03 group a non-significant reduction of 10.100±6.100 euro was found. 
 In conclusion, low dose Ox has a growth-enhancing effect in GH treated TS girls with a 
good benefit to risk ratio. We would advise adjunctive treatment with Ox at a dosage of  0.03 to 
0.05 mg/kg/day from the age of 8-10 years onwards. When using Ox prescribers are advised 
to monitor subjective and objective signs of virilization, breast development, and blood lipids. 
We hope that the recent publications of the randomized controlled trials and the results of 
the follow-up study help to re-implement Ox, since at current time Ox is not available in the 
Netherlands. It is an important option in the treatment for girls with TS, especially in those 
anticipated a very short adult stature or in whom the growth rate is modest despite good 
compliance with GH.
  Summary and perspective   CHAPTER 7
136
Reference list
1.  Bondy CA. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study 
Group. The Journal of clinical endocrinology and metabolism 2007;92:10-25.
2.  Freriks K, Timmermans J, Beerendonk CC, et al. Standardized multidisciplinary evaluation yields 
significant previously undiagnosed morbidity in adult women with Turner syndrome. The Journal of 
clinical endocrinology and metabolism 2011;96:E1517-26.
3.  Van den Akker EL, van Alfen AA, Sas T, Kerstens M, Cools M, Lambalk CB. Clinical guideline ‘Turner 
syndrome’. Ned Tijdschr Geneeskd 2014;158:A7375
4.  El-Mansoury M, Barrenas ML, Bryman I, et al. Chromosomal mosaicism mitigates stigmata and 
cardiovascular risk factors in Turner syndrome. Clinical endocrinology 2007;66:744-51.
5.  Elsheikh M, Dunger DB, Conway GS, Wass JA. Turner’s syndrome in adulthood. Endocrine reviews 
2002;23:120-40.
6.  Ostberg JE, Conway GS. Adulthood in women with Turner syndrome. Hormone research 2003;59:211-21.
7.  Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous pubertal development in 
Turner’s syndrome. Italian Study Group for Turner’s Syndrome. The Journal of clinical endocrinology 
and metabolism 1997;82:1810-3.
8.  Elsheikh M, Wass JA, Conway GS. Autoimmune thyroid syndrome in women with Turner’s 
syndrome--the association with karyotype. Clinical endocrinology 2001;55:223-6.
9.  Mortensen KH, Cleemann L, Hjerrild BE, et al. Increased prevalence of autoimmunity in Turner 
syndrome--influence of age. Clinical and experimental immunology 2009;156:205-10.
10.  Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in 
Turner syndrome. The Journal of clinical endocrinology and metabolism 2009;94:3289-96.
11.  Verver EJ, Freriks K, Thomeer HG, et al. Ear and hearing problems in relation to karyotype in children 
with Turner syndrome. Hear Res 2011;275:81-8.
12.  Barrenas ML, Nylen O, Hanson C. The influence of karyotype on the auricle, otitis media and hearing 
in Turner syndrome. Hear Res 1999;138:163-70.
13.  Verver EJ, Freriks K, Sas TC, et al. Karyotype-Specific Ear and Hearing Problems in Young Adults With 
Turner Syndrome and the Effect of Oxandrolone Treatment. Otology & neurotology : official publication 
of the American Otological Society, American Neurotology Society [and] European Academy of Otology 
and Neurotology 2014.
14.  Hjerrild BE, Mortensen KH, Sorensen KE, et al. Thoracic aortopathy in Turner syndrome and the 
influence of bicuspid aortic valves and blood pressure: a CMR study. J Cardiovasc Magn Reson 2010;12:12.
15.  Hederstierna C, Hultcrantz M, Rosenhall U. A longitudinal study of hearing decline in women with 
Turner syndrome. Acta oto-laryngologica 2009;129:1434-41.
16.  Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K, Christiansen JS. Increased fracture 
rates in Turner’s syndrome: a nationwide questionnaire survey. Clinical endocrinology 2003;59:89-96.
17.  Bakalov VK, Chen ML, Baron J, et al. Bone mineral density and fractures in Turner syndrome. The 
American journal of medicine 2003;115:259-64.
18.  Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked 
disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic 
hormones in adult turner syndrome: a cross-sectional study. The Journal of clinical endocrinology and 
metabolism 2002;87:2798-808.
19.  Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. 
Circulation 2007;116:1663-70.
20.  Mortensen KH, Erlandsen M, Andersen NH, Gravholt CH. Prediction of aortic dilation in Turner 
CHAPTER 7   Summary and perspective
137
syndrome - enhancing the use of serial cardiovascular magnetic resonance. J Cardiovasc Magn Reson 
2013;15:47.
21.  Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in women with turner 
syndrome in Great Britain: a national cohort study. The Journal of clinical endocrinology and 
metabolism 2008;93:4735-42.
22.  Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. Journal of clinical 
epidemiology 1998;51:147-58.
23.  Turtle EJ, Sule AA, Bath LE, et al. Assessing and addressing cardiovascular risk in adults with Turner 
syndrome. Clinical endocrinology 2013;78:639-45.
24.  Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal 
estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous 
puberty in girls. The Journal of clinical endocrinology and metabolism 2001;86:3039-44.
25.  Piippo S, Lenko H, Kainulainen P, Sipila I. Use of percutaneous estrogen gel for induction of puberty in 
girls with Turner syndrome. The Journal of clinical endocrinology and metabolism 2004;89:3241-7.
26.  Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal 
estrogen replacement in girls with Turner syndrome: a pilot comparative study. The Journal of clinical 
endocrinology and metabolism 2009;94:2009-14.
27.  Alves ST, Gallichio CT, Guimaraes MM. Insulin resistance and body composition in Turner syndrome: 
Effect of sequential change in the route of estrogen administration. Gynecol Endocrinol 2006;22:590-4.
28.  Taboada M, Santen R, Lima J, et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 
17beta estradiol in girls with Turner syndrome. The Journal of clinical endocrinology and metabolism 
2011;96:3502-10.
29.  Hadnott TN, Gould HN, Gharib AM, Bondy CA. Outcomes of spontaneous and assisted pregnancies in 
Turner syndrome: the U.S. National Institutes of Health experience. Fertility and sterility 2011;95:2251-
6.
30.  Bryman I, Sylven L, Berntorp K, et al. Pregnancy rate and outcome in Swedish women with Turner 
syndrome. Fertility and sterility 2011;95:2507-10.
31.  Hewitt JK, Jayasinghe Y, Amor DJ, et al. Fertility in Turner syndrome. Clinical endocrinology 
2013;79:606-14.
32.  Wolff DJ, Van Dyke DL, Powell CM. Laboratory guideline for Turner syndrome. Genet Med 2010;12:52-5.
33.  Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and 
comments on use. Am J Hum Genet 1977;29:94-7.
34.  Nazarenko SA, Timoshevsky VA, Sukhanova NN. High frequency of tissue-specific mosaicism in 
Turner syndrome patients. Clinical genetics 1999;56:59-65.
35.  Bianco B, Lipay MV, Melaragno MI, Guedes AD, Verreschi IT. Detection of hidden Y mosaicism in 
Turner’s syndrome: importance in the prevention of gonadoblastoma. J Pediatr Endocrinol Metab 
2006;19:1113-7.
36.  Hanson L, Bryman I, Janson PO, Jakobsen AM, Hanson C. Fluorescence in situ hybridisation analysis 
and ovarian histology of women with Turner syndrome presenting with Y-chromosomal material: a 
correlation between oral epithelial cells, lymphocytes and ovarian tissue. Hereditas 2002;137:1-6.
37.  Freriks K, Timmers HJ, Netea-Maier RT, et al. Buccal cell FISH and blood PCR-Y detect high rates of X 
chromosomal mosaicism and Y chromosomal derivatives in patients with Turner syndrome. European 
journal of medical genetics 2013;56:497-501.
38.  Hook EB, Warburton D. The distribution of chromosomal genotypes associated with Turner’s 
syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in 
genotypes associated with structural X abnormalities or mosaicism. Hum Genet 1983;64:24-7.
  Summary and perspective   CHAPTER 7
138
39.  Held KR, Kerber S, Kaminsky E, et al. Mosaicism in 45,X Turner syndrome: does survival in early 
pregnancy depend on the presence of two sex chromosomes? Hum Genet 1992;88:288-94.
40.  Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH. Germ cell tumors in the intersex 
gonad: old paths, new directions, moving frontiers. Endocrine reviews 2006;27:468-84.
41.  Cools M, Pleskacova J, Stoop H, et al. Gonadal pathology and tumor risk in relation to clinical 
characteristics in patients with 45,X/46,XY mosaicism. The Journal of clinical endocrinology and 
metabolism 2011;96:E1171-80.
42.  Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene 
cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54-63.
43.  Stephure DK. Impact of growth hormone supplementation on adult height in turner syndrome: results 
of the Canadian randomized controlled trial. The Journal of clinical endocrinology and metabolism 
2005;90:3360-6.
44.  Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner 
syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. The 
Journal of clinical endocrinology and metabolism 2003;88:1119-25.
45.  Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner 
syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. 
The Journal of clinical endocrinology and metabolism 1999;84:4607-12.
46.  Hamelin CE, Anglin G, Quigley CA, Deal CL. Genomic imprinting in Turner syndrome: effects 
on response to growth hormone and on risk of sensorineural hearing loss. The Journal of clinical 
endocrinology and metabolism 2006;91:3002-10.
47.  Binder G, Trebar B, Baur F, Schweizer R, Ranke MB. Homozygosity of the d3-growth hormone 
receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls 
with Turner syndrome. Clinical endocrinology 2008;68:567-72.
48.  Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner’s syndrome: beneficial 
effect on adult height. The Journal of pediatrics 1998;132:319-24.
49.  Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner’s syndrome 
treated with growth hormone and oxandrolone. The Journal of clinical endocrinology and metabolism 
1996;81:635-40.
50.  Stahnke N, Keller E, Landy H. Favorable final height outcome in girls with Ullrich-Turner syndrome 
treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 
years of age. J Pediatr Endocrinol Metab 2002;15:129-38.
51.  Haeusler G, Schmitt K, Blumel P, Plochl E, Waldhor T, Frisch H. Growth hormone in combination 
with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. 
Acta Paediatr 1996;85:1408-14.
52.  Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth 
hormone-treated girls with turner syndrome. The Journal of clinical endocrinology and metabolism 
2010;95:1151-60.
53.  Zeger MP, Shah K, Kowal K, Cutler GB, Jr., Kushner H, Ross JL. Prospective study confirms 
oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with 
Turner syndrome. Hormone research in paediatrics 2011;75:38-46.
54.  Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height 
in Turner’s syndrome: randomised, double blind, placebo controlled trial. BMJ (Clinical research ed 
2011;342:d1980.
55.  Sas TC, Gault EJ, Zeger Bardsley M, et al. Safety and Efficacy of Oxandrolone in Growth Hormone-
Treated Girls with Turner Syndrome: Evidence from Recent Studies and Recommendations for Use. 
CHAPTER 7   Summary and perspective
139
Hormone research in paediatrics 2014:289-97.
56.  Freriks K, Sas TC, Traas MA, et al. Long-term effects of previous oxandrolone treatment in adult 
women with Turner syndrome. European journal of endocrinology / European Federation of 
Endocrine Societies 2013;168:91-9.
57.  Ross JL, Mazzocco MM, Kushner H, Kowal K, Cutler GB, Jr., Roeltgen D. Effects of treatment with 
oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner 
syndrome. The Journal of pediatrics 2009;155:714-20.
58.  McFadden D. Masculinization of the mammalian cochlea. Hear Res 2009;252:37-48.
59.  McFadden D, Pasanen EG, Raper J, Lange HS, Wallen K. Sex differences in otoacoustic emissions 
measured in rhesus monkeys (Macaca mulatta). Hormones and behavior 2006;50:274-84.
60.  Snihur AW, Hampson E. Click-evoked otoacoustic emissions: response amplitude is associated with 
circulating testosterone levels in men. Behavioral neuroscience 2012;126:325-31.
61.  Buchanan JR, Myers C, Lloyd T, Leuenberger P, Demers LM. Determinants of peak trabecular bone 
density in women: the role of androgens, estrogen, and exercise. J Bone Miner Res 1988;3:673-80.
62.  Carrascosa A, Gussinye M, Terradas P, Yeste D, Audi L, Vicens-Calvet E. Spontaneous, but not 
induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. J 
Bone Miner Res 2000;15:2005-10.
63.  Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen 
replacement therapy in Turner syndrome: a pilot study. The Journal of clinical endocrinology and 
metabolism 2009;94:4820-7.
64.  Van Koningsbrugge SHL, Menke LA, Sas TCJ, van Rijn RR, Wit JM. The effect of oxandrolone 
combined with growth hormone and low-dose oestrogens on bone mineral density in Turner girls 
aged 12 years or older. Intern report, Dutch Growth foundation, Rotterdam 2007.
65.  Apter D, Lenko HL, Perheentupa J, Soderholm A, Vihko R. Subnormal pubertal increases of serum 
androgens in Turner’s syndrome. Hormone research 1982;16:164-73.
  Summary and perspective   CHAPTER 7
140
141
Nederlandse samenvatting
Syndroom van Turner
Het syndroom van Turner (SvT) is het gevolg van complete of partiële afwezigheid van een 
X-chromosoom. In Nederland is de prevalentie onder levend geboren meisjes 1:2000-5000.1 
Tot de klassieke symptomen van dit syndroom behoren een gestoorde lichaamsgroei, gonadale 
dysgenesie –meestal leidend tot onvruchtbaarheid- en uiterlijke dysmorfieën. Echter, het 
fenotype is sterk wisselend en varieert van een presentatie met ernstige congenitale (hart)
afwijkingen tot een milder fenotype gekenmerkt door secundaire amenorroe of onverklaarde 
infertiliteit op volwassen leeftijd.
De aandoening wordt vastgesteld door middel van karyotypering van minimaal 30 lymfocyten. 
Gebruikmakend van deze methode heeft ongeveer de helft van de patiënten een complete 
monosomie 45,X en 30-40% een mozaïcisme van verschillende karyotypen. De overige 5-15% 
van de patiënten heeft structurele afwijkingen aan één van beide X-chromosomen.2-4 
De belangrijkste kindergeneeskundige aspecten van het SvT zijn, naast de opsporing van 
congenitale afwijkingen, groeistimulatie met groeihormoon en puberteitsinductie met 
oestrogenen. Zonder behandeling met groeihormoon worden vrouwen met het SvT in 
Noord-Europa gemiddeld 147 cm lang. Behandeling met groeihormoon geeft een lengtewinst 
van gemiddeld 5-12 cm.5-7 Als gevolg van versnelde regressie van de ovaria komen de meeste 
meisjes met het SvT niet spontaan in de puberteit en heeft slechts 8-9% van de meisjes met 
monosomie 45,X en 40-47% van de meisjes met 45,X/46,XX, al dan niet tijdelijke, menstruele 
cycli.8,9 Derhalve wordt een aanzienlijk deel van de meisjes bij het ontbreken van secundaire 
geslachtskenmerken behandeld met oestrogenen. 
Ter voorkoming van oestrogeendeficiëntie op volwassen leeftijd is er na de inductie van de 
puberteit, of later bij het wegvallen van de spontane menstruele cyclus, een indicatie voor 
hormoonsuppletietherapie. Deze moet in principe gecontinueerd worden tot de normale 
leeftijd van de menopauze (gemiddeld 51 jaar).10 Spontane zwangerschappen bij vrouwen met 
het SvT zijn zeer zeldzaam en vrijwel alleen beschreven bij vrouwen met 45,X/46,XX.11-13 Bij 
een kinderwens zijn geassisteerde voortplanting, naast adoptie en pleegzorg, dan de enige 
optie. Zowel spontane als geïnduceerde zwangerschappen bij het SvT behoren tot de hoog-
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risico zwangerschappen en het in kaart brengen van met name cardiovasculaire problemen 
vóór de zwangerschap is essentieel.14-16 Andere kenmerken van het SvT op volwassen leeftijd 
zijn divers. Structurele hart- en vaatafwijkingen en een ongunstig cardiovasculair risicoprofiel 
-als gevolg van een hogere incidentie van hypertensie, hypercholesterolemie en diabetes- 
komen vaker voor dan in de algemene populatie.17-19 Andere belangrijke kenmerken zijn 
een verminderde botdichtheid en daaraan gekoppeld een verhoogd fractuurrisico,20,21 auto-
immuunziekten waaronder hypothyreoïdie en coeliakie,22-24 gehoorsverlies25-27 en problemen 
op het psychologische vlak.28-30 
Multidisciplinaire zorg bij vrouwen met het syndroom van Turner
Jarenlang werden patiënten met het SvT alleen op de kinderleeftijd behandeld door 
een medisch specialist. De kinderarts(-endocrinoloog) richtte zich met name op de 
groeihormoonbehandeling en puberteitsinductie, en coördineerde de controles bij eventuele 
andere behandelaars. Veel vrouwen werden na het bereiken van de volwassen leeftijd en 
ontslag uit de kindergeneeskundige controles niet meer regulier gecontroleerd.31-35 De laatste 
jaren wordt de ernst van de morbiditeit van het SvT op volwassen leeftijd steeds duidelijker 
en zijn er richtlijnen gepubliceerd.2,10,36 Vooral op volwassen leeftijd vereist de zorg voor 
vrouwen met het SvT expertise uit verschillende vakgebieden. Samenwerking tussen deze 
verschillende disciplines is van belang in de dagelijkse zorg, maar zeker ook in het geval van een 
zwangerschapwens.14-16 Sinds de invoering van richtlijnen is de zorg voor volwassen vrouwen 
met het SvT verbeterd en zijn speciale Turnerklinieken voor volwassen vrouwen opgericht.2,10,36 
In 2005 opende het Radboud universitair medisch centrum een multidisciplinaire poli voor 
volwassen vrouwen met het SvT. Binnen dit centrum wordt gestreefd naar een vloeiende 
transitie van de kindergeneeskundige naar de volwassen zorg, naar tijdige onderkenning 
en gecoördineerde behandeling van aandoeningen behorend tot het SvT en naar optimale 
hormoonsuppletietherapie en fertiliteitscounseling. In hoofdstuk 2 van dit proefschrift 
beschrijven we onze studie naar de effectiviteit van het eerste bezoek aan de multidisciplinaire 
polikliniek. Het doel van deze studie was om vast te stellen welke morbiditeit bij een eerste 
screening volgens internationale richtlijnen wordt aangetoond. Alle 150 vrouwen (met een 
gemiddelde leeftijd van 31 jaar oud, 47% 45,X) werden gezien door een endocrinoloog, een 
gynaecoloog, een cardioloog, een KNO-arts en wanneer nodig een psycholoog.  De screening 
bestond uit anamnese, lichamelijk onderzoek en laboratoriumonderzoek aangevuld met een 
MRI van het hart en de aorta, echocardiografie, electrocardiogram, botdensitometrie (DEXA), 
echo van de nieren en een gehoorstest. Wij stelden de volgende nieuwe diagnosen vast: bicuspide 
aortaklep (n=13), coarctatie van de aorta (n=9), elongatie van het transversale deel van de aorta 
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(n=27), dilatatie van de aorta (n=34), osteoporose (n=8), osteopenie (n=56), nierafwijkingen 
(n=7), subklinische hypothyreoïdie (n=33), coeliakie (n=3), glucose intolerantie (n=12), 
hypercholesterolemie (n=52), hypertensie (n=39), en gehoorsverlies met een indicatie voor 
een gehoorapparaat (n=8). Drieëntwintig patiënten werden verwezen voor een psychologisch 
consult. Naast deze nieuwe morbiditeit lieten we zien dat dertig procent van de vrouwen op 
het moment van bezoek en de jaren daarvoor geen medische zorg had genoten. Vijftien procent 
had op het moment van eerste screening geen enkele vorm van hormoonsuppletietherapie. Wij 
concluderen op basis van deze gegevens dat een initiële screening een belangrijke hoeveelheid 
nieuwe morbiditeit aantoont. Het lijkt er dan ook op dat vrouwen met het SvT belang hebben 
bij een adequate transitie. In hoeverre een goede transitie en daaropvolgende controles ook 
daadwerkelijk de kwaliteit van leven verbeteren en mortaliteit verminderen, is niet duidelijk. 
Een belangrijk discussiepunt blijft dan ook of de zorg zoals nu voorgesteld in de richtlijnen 
kosteneffectief is en of de medische screening opweegt tegen de belasting van de medische 
onderzoeken voor de individuele patiënt. 
Karyotypering bij het syndroom van Turner 
In de eerdere richtlijnen wordt aangegeven dat bij klinische verdenking op het SvT, het 
syndroom gediagnosticeerd wordt met standaard karyotypering van 30 bloed lymfocyten.10,37,38 
De richtlijnen adviseerden om alleen aanvullende cellijnen te onderzoeken als er sprake 
is van klinische virilisatie of een marker chromosoom.39-42 De vraag is echter of standaard 
karyotypering een adequate weerspiegeling geeft van het genotype. Een laag-gradig 
mozaïcisme in het bloed wordt op deze manier niet uitgesloten en er wordt met deze methode 
ook geen rekening gehouden met weefselmozaïcisme: het vóórkomen van andere karyotypen 
in andere weefsels in het lichaam. Meerdere studies bij patiënten met het SvT bevestigen het 
bestaan van weefselmozaïcisme.39-41 Het onderkennen van weefselmozaïcisme is niet alleen 
belangrijk om meer inzicht te krijgen in de genotype fenotype correlatie, maar met name 
ook als er sprake is van een Y-chromosoom. De aanwezigheid van een Y-chromosoom is 
geassocieerd met de ontwikkeling van gonadoblastomen in de ovaria en over het algemeen 
wordt geadviseerd om een preventieve gonadectomie  te verrichten om de ontwikkeling naar 
een maligne dysgerminoom te voorkomen.43 In hoofdstuk 3 beschrijven we onze studie 
waarin we bij vrouwen met het SvT naast de standaard karyotypering ook ‘polymerase chain 
reaction’ (PCR) en ‘fluorescence in situ hybridization’(FISH) verrichtten. Naast lymfocyten in 
het bloed onderzochten we ook een tweede cellijn: wangslijmvlies. Het doel van deze studie 
was om te onderzoeken welke additionele waarde deze aanvullende technieken hebben. Aan 
deze studie deden 162 vrouwen met het SvT mee (gemiddelde leeftijd 29,9±10,3 jaar). Ongeveer 
de helft van hen, 75 patiënten, had middels standaard karyotypering een monosomie 45,X. Van 
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deze 75 patiënten, ondergingen er 63 aanvullende onderzoeken met FISH op wangslijmvlies en 
PCR-Y op bloed. FISH op wangslijmvlies liet zien dan 19 van de 63 (30,2%) een mozaïek bleek 
te hebben. Bij het grootste deel van de patiënten bleek het te gaan om mozaïcisme met 46,XX, 
maar bij 5 patiënten ging het om een mozaïek met een Y-chromosoom. Conventionele PCR-Y 
op bloed was negatief in alle gevallen. Een sensitievere ‘real-time’ PCR kon de aanwezigheid 
van Y-chromosomaal weefsel bevestigen in 3 van de 5 patiënten. Vier patiënten hebben naar 
aanleiding van het vaststellen van de aanwezigheid van een Y-chromosoom een gonadectomie 
ondergaan. Bij pathologisch onderzoek bleek er in geen van de gevallen sprake te zijn van een 
gonadoblastoom. Bij twee patiënten is FISH onderzoek op het ovariumweefsel uitgevoerd, 
waarbij in beide gevallen Y-chromosomen werden aangetoond. Onze resultaten bevestigen dat 
standaard karyotypering in vrouwen met 45,X onvoldoende is om een volledig beeld te krijgen 
van het genotype. Het vinden van een additioneel Y-chromosoom lijkt van belang, al is het 
exacte risico op het ontwikkelen van een gonadoblastoom bij een Y-chromosoom gevonden 
met deze additionele technieken niet bekend. Het is echter aannemelijk dat een Y-chromosoom 
gevonden met deze additionele technieken een vergelijkbaar risico op gonadoblastoom met 
zich meebrengt als een Y-chromosoom vastgesteld met standaard karyotypering. Het risico op 
een gonadoblastoom bij vrouwen met het SvT en een Y-chromosoom lijkt relatief laag, zeker 
wanneer virilisatie ontbreekt.44 Desalniettemin, lijkt ook een laag risico op het ontwikkelen 
van een gonadoblastoom een gonadectomie te rechtvaardigen, zeker wanneer de ovaria reeds in 
regressie zijn. Het advies is dan ook om bij vrouwen met het SvT en monosomie 45,X een tweede 
cellijn te onderzoeken. Wangslijmvlies is hiervoor, gezien de gemakkelijke verkrijgwijze, 
uitermate geschikt. Een dergelijk advies is opgenomen in de Vlaams-Nederlandse klinische 
richtlijn Turner syndroom.45
Lange termijn effecten van oxandrolon behandeling in de 
kinderjaren
Hoewel meisjes met het SvT niet groeihormoondeficiënt zijn, wordt groeihormoon (GH) 
routinematig voorgeschreven om de eindlengte van meisjes met het SvT te verbeteren. In de 
zoektocht naar betere behandelmogelijkheden zijn niet alleen  hogere doseringen GH, maar ook 
de toevoeging van androgenen als oxandrolon (Ox) aan GH onderzocht. Bij eerste studies naar 
het effect van Ox, waarin doseringen tot 0,1 mg/kg/dag werden gebruikt, moest de dosering vaak 
naar beneden worden aangepast in verband met virilisatie en versnelde botrijping.46-48 Recent 
zijn drie gerandomiseerde studies naar het groeibevorderende effect van lagere doseringen Ox 
naast GH gepubliceerd.49-51 Hieronder valt ook de Nederlandse Turner Oxandrolon Studie, een 
samenwerking van 10 kinderendocrinologische centra in Nederland. Inclusie van deze studie 
vond plaats tussen 1991 en 2003.49 In totaal zijn 133 meisjes geïncludeerd en gerandomiseerd om 
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naast GH behandeling (1,33mg/m2/dag) vanaf achtjarige leeftijd òf Ox in een dosering van 0,03 
mg/kg/dag (GH+Ox 0,03), òf Ox in een dosering van 0,06 mg/kg/dag (GH+Ox 0,06), òf een 
placebo (GH+Pl) te krijgen. Daarnaast werden de meisjes, als spontane puberteit afwezig was, 
behandeld met oestrogenen vanaf 12 jarige leeftijd. 
De belangrijkste uitkomstmaat was de lengtewinst op volwassen leeftijd, gedefinieerd als 
volwassen lengte minus de voorspelde lengte. Vergeleken met GH+Pl gaf GH+Ox 0,03 een 
significante lengtewinst (9,5 vs. 7,2 cm in GH+Pl). Deze lengtewinst ging gepaard met een 
vertraagde borstontwikkeling in de GH+Ox 0,03 groep. In de groep met de hogere dosering 
Ox (GH+Ox 0,06) was er geen sprake van significante lengtewinst (8,3 vs. 7,2 cm in GH+Pl). 
Mogelijke verklaringen hiervoor zijn een snellere botrijping en eerder staken van Ox door 
virilisatie in de GH+Ox 0,06 groep. In deze groep gaven meer meisjes aan last te hebben van 
virilisatie. In beide met  Ox behandelde groepen was er sprake van een afname van de vetmassa 
en een toename van de spiermassa. Er trad een verlaging van de stemfrequentie op, in de meeste 
gevallen naar een normale stemhoogte. 52,53 Er werd geen effect van Ox op gedrag, agressie, 
seksuele ontwikkeling, stemming en ‘gender role’ gevonden.54 Ook waren er geen effecten van 
Ox op het glucose metabolisme.55
De genoemde resultaten betreffen de korte termijn effecten bij kinderen en adolescenten. In 
hoofdstuk 4, 5 en 6 van dit proefschrift bespreken we de resultaten van de follow-up studie 
van de Nederlandse Turner Oxandrolon Studie. Het doel van de follow-up studie was om 
de lange termijn resultaten van de drie genoemde regimes in kaart te brengen. De vraag is of 
de resultaten van de kinderstudie op volwassen leeftijd blijven bestaan en of het positieve 
effect op de volwassen eindlengte opweegt tegen de potentieel negatieve bijwerkingen.  Alle 
deelneemsters aan de kinderstudie werden gevraagd deel te nemen aan de follow-up studie. 
Achtenzestig volwassen vrouwen (GH+Pl, n=23; GH+Ox 0,03, n=27; and GH+Ox 0,06, n=18) 
participeerden in de dubbelblinde follow-up studie (gemiddelde leeftijd 24 jaar oud, gemiddelde 
tijd sinds stop GH 8,7 jaren; gemiddelde duur van GH/Ox behandeling 4,9 jaren).
In hoofdstuk 4 wordt het effect van Ox op lengte, lichaamsproporties, borstgrootte, virilisatie 
en lichaamssamenstelling op volwassen leeftijd beschreven. De lengtewinst zoals gevonden 
in de kinderstudie blijft op volwassen leeftijd bestaan (GH+Ox 0,03 10,2±4,9 cm,GH+Ox 
0,06 9,7±4,4 cm vergeleken met GH+Pl 8,0±4,6 cm). Borstgrootte, Tanner stadium en 
lichaamssamenstelling op volwassen leeftijd verschilden niet tussen de drie groepen. De 
vrouwen die in het verleden met Ox behandeld waren gaven meer klachten aan van virilisatie 
dan de vrouwen behandeld met Pl.  Objectieve virilisatie persisteerde slechts in enkele gevallen. 
Wel werd er een lagere stemfrequentie gevonden  bij met Ox behandelde vrouwen.  
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In hoofdstuk 5 wordt het effect van Ox op neurocognitie, kwaliteit van leven en sociaal-
emotioneel functioneren beschreven. We vonden geen effect op het neurocognitief 
functioneren. De vrouwen die in het verleden behandeld waren met Ox scoorden hoger op de 
angst vragenlijst (STAI; 37,4±8,4 vs 31,8±5,0, p0,002) en hadden hogere scores op de subschaal 
depressie van de SCL-90-R (25,7±10,7 vs 20,5±4,7, p0,01), echter er was geen effect op de totale 
kwaliteit van leven. Wat betreft sociaal-emotioneel functioneren, vonden we alleen een klein 
effect van Ox op emotie perceptie: vrouwen met Ox behandeling in het verleden herkenden de 
emotie angst minder goed in lage intensiteit. Overigens leidde dit niet tot andere scores op de 
sociale interactie vragenlijsten. Over het algemeen lijken de effecten van Ox op later (neuro)
psychologisch functioneren beperkt.
In hoofdstuk 6 beschrijven we het gehoor bij jong volwassenen met het SvT en de effecten 
van Ox behandeling in het verleden hierop. We verrichtten conventionele audiometrie met 
het meten van lucht- en botgeleiding in decibel gehoorsniveau. Tweederde van de vrouwen 
had een voorgeschiedenis van otitis media. De onderzoeken laten zien dat er bij 66% van deze 
jongvolwassen patiënten sprake is van gehoorsverlies. Dit betreft puur perceptief gehoorsverlies 
bij 32% van de vrouwen. De gehoorsdrempels waren ongeveer 10 decibel slechter bij de patiënten 
met een complete monosomie van de korte arm van het X chromosoom (monosomie 45,X en 
isochromosoom) vergeleken met de groep met slechts een partiële monosomie van de korte 
arm van het X-chromosoom (mozaiek en deleties). We vonden geen effect op oor en gehoor van 
Ox behandeling in het verleden. 
Uit de studies beschreven in hoofdstuk 4, 5 en 6 kunnen we concluderen dat Ox in een 
lage dosering van 0,03 mg/kg/dag een gunstig effect heeft op de volwassen eindlengte. 
Ondanks het feit dat er tijdens de kinderstudie sprake was van een vertraagde ontwikkeling 
van de borsten, is de borstgrootte op volwassen leeftijd gelijk. Terwijl subjectieve beleving 
van viriliserende kenmerken veelvuldig voorkomt, persisteert objectieve virilisatie slechts in 
een kleine minderheid van de patiënten. Uit onze onderzoeken kunnen we concluderen dat 
hirsutisme en acne met de tijd verdwijnen, terwijl stemverlaging en clitoromegalie persisteren. 
Op het gebied van de psychologische effecten op de volwassen leeftijd zijn de verschillen 
tussen de Ox groepen en de Pl groep slechts klein. In de kinderstudie werd reeds gemeld dat 
de positieve effecten van Ox in een dosering van 0,06 mg/kg/dag niet in balans zijn met de 
negatieve effecten. Wij onderschrijven de conclusie dat Ox in een dosering van 0,03 mg/kg/
dag ook op de lange termijn effectief en veilig is. Het gebruik van Ox in een dosering van 0,06 
mg/kg/dag wordt ontraden.
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Onze studies naar het effect van Ox werden vrijwel gelijktijdig gepubliceerd met twee andere 
gerandomiseerde studies naar het groeibevorderende effect van Ox bij het SvT. De eerste is een 
studie uit de Verenigde Staten waarin het effect van Ox 0,06 mg/kg/dag onderzocht wordt 
en de tweede is een studie uit Groot-Brittannië waarin de effecten van Ox 0,05 mg/kg/dag 
worden beschreven.50,51 Als we onze data samenvoegen lijkt het gemiddelde additionele effect 
van Ox toegevoegd aan GH tussen de 2,3 en 4,6 cm te zijn.56 Alle drie studies laten zien dat lage 
doseringen van Ox effectief zijn. Het blijft een interessante vraag of zelfs nog lagere doseringen 
eveneens effectief zijn met een mogelijk nog gunstiger bijwerkingenprofiel. Wellicht is het 
zelfs fysiologischer, en daarmee mogelijk effectiever, als doseringen individueel aangepast 
worden aan de androgeenspiegels voor behandeling en een stijgende dosering toegepast wordt 
met het ouder worden. Wat betreft de timing van behandeling lijkt Ox effectief te zijn in de 
leeftijdsrange van 8 tot 16 jaar. In onze kinderstudie hebben we laten zien dat er geen verschillen 
in effectiviteit zijn tussen de verschillende leeftijdsgroepen (leeftijdsgroep 1 begon op 8 jarige 
leeftijd, leeftijdsgroep 2 begon op 8-11 jarige leeftijd, leeftijdsgroep 3 startte op 12-16 jarige 
leeftijd). Dit maakt het aannemelijk dat het niet van toegevoegde waarde is om vóór het 8ste 
levensjaar te starten. De behandeling uitstellen tot bijvoorbeeld na het begin van de puberteit 
of één tot twee jaar na  start van oestrogeen behandeling zou eventueel nog een optie kunnen 
zijn om de negatieve gevolgen voor borstontwikkeling te omzeilen, al is het de vraag of de 
behandelduur dan niet teveel bekort wordt door het al deels sluiten van de epifysairschijven.  
Concluderend is Ox een groeibevorderend medicijn dat van toegevoegde waarde kan zijn 
bij meisjes met het SvT. Ox is effectief en veilig en geeft weinig bijwerkingen als het in een 
lage dosering wordt gebruikt. Op dit moment is het advies om Ox vanaf het 8ste levensjaar te 
gebruiken in een dosis van 0,03-0,05 mg/kg/dag met een pragmatische maximale dosering van 
2,5 mg per dag om overdosering te voorkomen. Bij gebruik van Ox dient er aandacht te zijn voor 
subjectieve en objectieve virilisatie, borstontwikkeling en lipiden. We hopen dat onze studies, 
samen met de andere twee gerandomiseerde trials, bijdragen aan het opnieuw beschikbaar 
komen van Ox op de markt aangezien het een belangrijke optie kan zijn voor meisjes met het 
SvT, vooral bij diegene met een opvallend lage voorspelde eindlengte of een tegenvallende groei 
ondanks adequaat GH gebruik. 
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Dankwoord
Allereerst wil ik alle vrouwen met het syndroom van Turner, die op wat voor manier dan ook 
aan de totstandkoming van dit boekje hebben bijgedragen, hartelijk bedanken! Jullie hebben me 
echt geleerd wat het syndroom van Turner is en laten zien dat alle vrouwen met het syndroom 
van Turner uniek zijn.
Beste prof. dr. Hermus, beste Ad, onze paden kruisten elkaar toen ik, net terug uit Tanzania, op 
zoek ging naar een geschikte plek voor een wetenschappelijke stage. Je (ja, ik heb het geleerd…) 
bleek een ontzettend prettige begeleider en met veel enthousiasme ben ik dan ook met dit 
promotieonderzoek aan de slag gegaan. Je bent een zeer motiverende en benaderbare promotor 
gebleken. Naast dat je de grote lijnen goed hebt bewaakt, was je er ook voor de (soms letterlijke) 
puntjes op de ‘i’. 
 Beste dr. Timmers, beste Henri, je had vaak medelijden met me, omdat ik het grootste 
gedeelte van mijn onderzoekstijd in een hoekje op je kamer heb doorgebracht. Toch was dat 
nergens voor nodig, ik kijk positief terug op mijn promotie jaren! Ik heb veel van je geleerd als 
onderzoeker, maar ook zeker als arts. Bedankt voor je begeleiding, je weet als geen ander wat 
positieve feedback is en ik heb nog geen enkele andere onderzoeker gesproken die sneller zijn 
correcties terug krijgt! 
 Beste dr. Sas, beste Theo, je hebt samen met Leonie de overdracht van de kinderdata in 
perfecte banen geleid. Je zorgde altijd voor continuïteit en jouw frisse blik op de zaken leidde 
telkens weer tot nieuwe inzichten waar ik mee aan de slag kon. Bedankt!
De leden van de manuscriptcommissie prof. dr. C. Noordam, prof. dr. D.D.M. Braat en prof. dr. 
V.V.A.M. Knoers wil ik bedanken voor de bereidheid om mijn manuscript te beoordelen en om 
in mijn promotiecommissie plaats te nemen. Ook de overige leden van de promotiecommissie 
wil ik bij deze hartelijk danken.
Promoveren op het syndroom van Turner betekent werken in een multidisciplinaire omgeving. 
Ik wil alle afdelingen bedanken voor hun diverse ‘kijkjes in de keuken’ en samenwerking. Alle 
co-auteurs en anderen die indirect hebben bijgedragen aan de artikelen in dit boekje wil ik 
hiervoor hartelijk danken. Hierbij wil ik er enkelen graag bij naam noemen. 
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 Allereerst de kinderendocrinologen, de grondleggers van de Turner Oxandrolon Studie. 
Beste dr. Otten, beste Barto, fantastisch om met je te hebben mogen samenwerken. Je 
enthousiasme voor het vak en originele kijk op het geheel waren heel motiverend! Beste prof. 
dr. Jan Maarten Wit en dr. Sabine de Muinck Keizer-Schrama, ik had me geen betere co-auteurs 
kunnen wensen. Jullie kennis van zaken en razendsnelle antwoorden zijn van onschatbare 
waarde geweest. Leonie Menke, bedankt voor de goede start. Je hebt me perfect wegwijs 
gemaakt in de data van de Turner Oxandrolon Studie en was altijd weer bereid ‘even’ een vraag 
over de database te beantwoorden. Ook wil ik de Stichting Kind en Groei en met name Gladys 
Zandwijken bedanken voor alle ondersteuning.
 Ook dank aan alle analisten van de afdeling genetica, die vele uren in alle analyses hebben 
gestoken. Beste Dominique, jou ben ik extra dank verschuldigd. Bedankt voor het geduld waarmee 
je de genetische technieken en achterliggende gedachten met me hebt willen delen. 
 Van de afdeling gynaecologie wil ik alle gynaecologen die betrokken zijn geweest bij mijn 
onderzoek, maar met name Ina Beerendonk en Maaike Traas, hartelijk bedanken. 
 Ook aan de participerende KNO-artsen ben ik veel dank verschuldigd. Beste Dirk Kunst en 
Eva Verver bedankt voor jullie vele uurtjes en bijdragen aan de artikelen. Prof. dr. DeJonckere, 
bedankt voor uw hulp bij de stemanalyses. 
 Beste Chris Verhaak, ontzettend bedankt voor je tijd en energie om me (enigszins) te scholen 
in de psychologie. Beste Roy Kessels, ook de kennismaking met de neuropsychologie heb ik als 
zeer prettig ervaren. Beiden bedankt voor jullie geduldige uitleg! Beste Yvon en Robin-Elisa, ik 
had me geen betere psychologiestudenten kunnen wensen! Bedankt voor jullie flexibiliteit bij 
het uitvoeren van het psychologisch onderzoek. 
 De betrokken medewerkers van de afdeling nucleaire geneeskunde: bedankt voor het 
uitvoeren en beoordelen van alle scans!
 Janneke Timmermans, bedankt voor je samenwerking op het gebied van de cardiologie! 
 
Uiteraard wil ik graag de afdeling Endocriene ziekten hartelijk bedanken voor de prettige en 
collegiale werksfeer tijdens mijn promotieonderzoek en ook nu tijdens mijn opleiding. Romana 
Netea-Maier, bedankt voor je kritische blik op mijn artikelen. Martin den Heijer, bedankt 
voor je wijze statistieklessen! Secretaresses van de endo, bedankt voor jullie luisterend oor en 
perfecte ondersteuning. Marieke, bedankt voor je nauwkeurige hulp bij de database. Daarnaast 
wil ik alle AIOS Interne geneeskunde en opleiders in zowel het Jeroen Bosch Ziekenhuis als 
het Radboudumc bedanken voor de goede werksfeer en flexibiliteit om dit proefschrift af te 
kunnen maken! 
Lieve vrienden en vriendinnen,  bedankt voor jullie luisterend oor en natuurlijk voor alle leuke 
dingen buiten dit promotieboekje! Linda, ik ben heel erg blij dat je vandaag naast me staat als 
Dankwoord
159
paranimf. Sinds de introductie van de studie geneeskunde volgen we een zeer vergelijkbaar pad. 
Samen studeren, samen co-schappen lopen met als hoogtepunt een gezamenlijk co-schap in 
Tanzania. Uiteindelijk zelfs samen AIOS Interne in Den Bosch. Nu we allebei druk zijn met 
opleiding en gezin, zien we elkaar minder dan ik zou willen, maar dat maakt de vriendschap niet 
minder waardevol! Marry, ook mijn keuze voor jou als paranimf is voor mij een heel logische. 
We kennen elkaar al vanaf het begin van de studie en bij jou kan ik altijd terecht voor raad en 
daad. Ik kijk met veel plezier terug op onze studietijd die naast het samen studeren, met name 
gekenmerkt werd door het roeien en alle gezelligheid daaromheen. Ook nu, in een nieuwe fase 
met gezin en werk, weten we elkaar toch altijd weer op te zoeken. Ik ben enorm trots dat jullie 
vandaag naast me staan!
Lieve (schoon) familie, bedankt! Opa, ik ben heel erg blij en trots dat je weer zo’n bijzondere 
mijlpaal uit mijn leven meemaakt! Lieve Rob, we zien elkaar niet zoveel als we zouden willen, 
maar ik weet dat we er altijd voor elkaar zijn. Esmee, lief zusje, ik geloof dat ik voor de afronding 
van dit boekje een beetje bij je heb afgekeken. Jouw enorme daadkracht en de wijze waarop je 
aan nieuwe uitdagingen begint, dwingen veel respect af! Lieve pap en mam, dit boekje draag ik 
op aan jullie. Ik ben heel blij dat ik in zo’n fijn gezin heb mogen opgroeien. Bedankt dat jullie 
altijd voor ons klaar staan!
Bedankt lief thuisfront! Lieve Pepijn en Kasper, het is echt ontzettend fijn om na een dag werken 
thuis te komen en opgewacht te worden door jullie gelach! Jullie fotoboeken worden mijn 
nieuwe klus. Lieve Frank, je bent echt mijn grootste steun geweest! Bedankt voor je hulp en 
luisterend oor. Al die mooie dingen die we de laatste jaren hebben meegemaakt zijn me heel erg 
dierbaar. Ik hoop op een hele mooie toekomst met jou. En nu… ben jij aan de beurt! 
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VWO diploma aan de ‘Driemark’. In 1998 heeft zij een jaar Hoger Laboratorium Onderwijs 
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zij als arts-onderzoeker op de afdeling Endocriene Ziekten (prof. dr. A.R.M.M. Hermus) 
gewerkt. In 2007 startte zij met de opleiding tot internist. De eerste twee jaar werkte zij 
in het Jeroen Bosch Ziekenhuis te Den Bosch (opleider dr. P.M. Netten). Het vervolg van de 
opleiding vond plaats in het Radboud universitair medisch centrum (hoofdopleiders prof.dr. 
J. de Graaf, prof. dr. J.W.M. van der Meer). Tijdens haar promotieonderzoek participeerde zij in 
de multidisciplinaire Turnerpolikliniek voor volwassen vrouwen in het Radboud universitair 
medisch centrum. Daarnaast schreef zij mee aan de klinische richtlijn Turner syndroom van 
het  Nederlands-Vlaamse Multidisciplinair Netwerk Turner syndroom en aan een uitgebreide 
patiëntenfolder voor meisjes en vrouwen met het syndroom van Turner. Momenteel werkt zij 
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